date generated: 2023-11-14

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

The profiling data being passed to mitch
bl gu
A1BG -0.2102058 -0.1319328
A1BG-AS1 0.2349686 -0.7637720
A1CF -0.4174745 -0.4654375
A2BP1 -0.2978746 -0.1608440
A2LD1 -0.2519359 -0.3229581
A2M -0.9043933 -0.3200584

Here are some metrics about the input data profile:

Profiling data metrics
Profile metrics
num_genes_in_profile 25716
duplicated_genes_present 0
num_profile_genes_in_sets 10331
num_profile_genes_not_in_sets 15385
profile_pearson_correl 0.17753
profile_spearman_correl 0.19618

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used:

GMT file of genesets: ReactomePathways.gmt
Gene set metrics
Gene sets metrics
num_genesets 2630
num_genesets_excluded 1044
num_genesets_included 1586

Gene sets by quadrant


Number of significant gene sets (FDR<0.05)= 417

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results


A plot of effect size versus significance


Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 50 gene sets

## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.
set setSize pMANOVA p.adjustMANOVA s.dist s.bl s.gu p.bl p.gu
Class C/3 (Metabotropic glutamate/pheromone receptors) 39 1.81e-10 5.51e-09 0.677 -0.49000 -0.468 1.16e-07 4.29e-07
TICAM1-dependent activation of IRF3/IRF7 12 1.24e-03 7.62e-03 0.667 0.45000 0.492 6.92e-03 3.16e-03
Scavenging of heme from plasma 12 1.97e-03 1.14e-02 0.643 -0.47300 -0.436 4.52e-03 8.98e-03
Eicosanoids 12 2.96e-04 2.16e-03 0.640 0.63100 -0.102 1.52e-04 5.41e-01
Pexophagy 11 4.13e-03 2.04e-02 0.626 0.51500 0.356 3.11e-03 4.08e-02
SARS-CoV-1 modulates host translation machinery 34 1.09e-07 1.47e-06 0.604 0.52200 0.305 1.40e-07 2.11e-03
Sensory perception of sweet, bitter, and umami (glutamate) taste 41 1.17e-08 2.18e-07 0.594 -0.46500 -0.370 2.48e-07 4.17e-05
TICAM1,TRAF6-dependent induction of TAK1 complex 10 1.46e-02 5.47e-02 0.580 0.43100 0.388 1.82e-02 3.36e-02
Competing endogenous RNAs (ceRNAs) regulate PTEN translation 16 1.27e-04 1.02e-03 0.555 -0.48200 0.274 8.37e-04 5.77e-02
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling 11 1.48e-02 5.51e-02 0.550 0.44000 0.331 1.16e-02 5.76e-02
Glucuronidation 25 8.06e-05 6.63e-04 0.548 -0.37800 -0.397 1.06e-03 5.87e-04
SCF(Skp2)-mediated degradation of p27/p21 58 3.60e-10 9.91e-09 0.547 0.41200 0.359 5.52e-08 2.26e-06
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 50 9.13e-09 1.75e-07 0.543 0.41100 0.355 4.82e-07 1.43e-05
APC/C:Cdc20 mediated degradation of Cyclin B 24 1.35e-04 1.07e-03 0.539 0.30000 0.448 1.08e-02 1.44e-04
Peptide chain elongation 84 2.22e-14 1.41e-12 0.538 0.46600 0.269 1.47e-13 2.00e-05
PINK1-PRKN Mediated Mitophagy 21 4.63e-04 3.22e-03 0.534 0.28700 0.450 2.27e-02 3.53e-04
Eukaryotic Translation Termination 87 1.17e-14 7.75e-13 0.534 0.46400 0.263 6.84e-14 2.17e-05
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 50 2.24e-08 3.78e-07 0.527 0.42500 0.313 1.99e-07 1.31e-04
p53-Independent DNA Damage Response 50 2.24e-08 3.78e-07 0.527 0.42500 0.313 1.99e-07 1.31e-04
p53-Independent G1/S DNA damage checkpoint 50 2.24e-08 3.78e-07 0.527 0.42500 0.313 1.99e-07 1.31e-04
Sensory perception of taste 47 9.25e-08 1.28e-06 0.525 -0.36500 -0.377 1.49e-05 7.81e-06
Autodegradation of Cdh1 by Cdh1:APC/C 62 5.36e-10 1.42e-08 0.524 0.37200 0.370 4.13e-07 4.61e-07
Hh mutants are degraded by ERAD 54 8.26e-09 1.60e-07 0.523 0.40800 0.328 2.13e-07 3.10e-05
Eukaryotic Translation Elongation 88 2.89e-14 1.70e-12 0.522 0.45800 0.251 1.07e-13 4.71e-05
Autodegradation of the E3 ubiquitin ligase COP1 50 3.12e-08 5.04e-07 0.521 0.43300 0.289 1.17e-07 4.03e-04
Ubiquitin-dependent degradation of Cyclin D 50 3.46e-08 5.38e-07 0.520 0.42500 0.300 1.98e-07 2.43e-04
Viral mRNA Translation 84 2.28e-13 1.03e-11 0.519 0.44500 0.267 1.75e-12 2.29e-05
Selenocysteine synthesis 87 8.57e-14 4.39e-12 0.517 0.44800 0.258 4.60e-13 3.23e-05
Vpu mediated degradation of CD4 50 5.45e-08 7.93e-07 0.515 0.40500 0.318 7.14e-07 9.93e-05
TICAM1, RIP1-mediated IKK complex recruitment 18 2.53e-03 1.39e-02 0.514 0.33600 0.389 1.35e-02 4.27e-03
Stabilization of p53 55 1.09e-08 2.05e-07 0.514 0.41000 0.310 1.47e-07 6.91e-05
Formation of the posterior neural plate 10 1.65e-02 6.01e-02 0.512 -0.00479 0.512 9.79e-01 5.05e-03
AUF1 (hnRNP D0) binds and destabilizes mRNA 53 2.15e-08 3.75e-07 0.512 0.42200 0.289 1.04e-07 2.75e-04
Negative regulation of NOTCH4 signaling 52 3.98e-08 6.01e-07 0.510 0.39400 0.324 8.64e-07 5.24e-05
SCF-beta-TrCP mediated degradation of Emi1 53 3.18e-08 5.09e-07 0.509 0.39200 0.325 7.97e-07 4.25e-05
Regulation of activated PAK-2p34 by proteasome mediated degradation 48 1.59e-07 2.02e-06 0.507 0.41100 0.296 8.06e-07 3.78e-04
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis 53 3.31e-08 5.25e-07 0.506 0.41200 0.295 2.15e-07 2.07e-04
Condensation of Prometaphase Chromosomes 11 1.98e-02 7.05e-02 0.506 0.14200 0.485 4.15e-01 5.33e-03
APC/C:Cdc20 mediated degradation of Securin 66 7.78e-10 1.90e-08 0.503 0.38100 0.329 8.61e-08 3.79e-06
Mitochondrial iron-sulfur cluster biogenesis 12 2.09e-02 7.39e-02 0.503 0.28100 0.417 9.19e-02 1.24e-02
Mitophagy 27 1.68e-04 1.32e-03 0.500 0.25600 0.429 2.12e-02 1.14e-04
Aspirin ADME 44 7.56e-07 8.62e-06 0.498 -0.25500 -0.428 3.44e-03 8.73e-07
Response of EIF2AK4 (GCN2) to amino acid deficiency 95 6.80e-14 3.72e-12 0.498 0.42700 0.256 5.90e-13 1.62e-05
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 89 5.01e-13 2.15e-11 0.497 0.42700 0.254 3.05e-12 3.51e-05
Digestion 18 3.42e-03 1.77e-02 0.497 -0.27300 -0.415 4.53e-02 2.28e-03
CASP8 activity is inhibited 11 2.59e-02 8.71e-02 0.496 0.46100 0.184 8.10e-03 2.91e-01
Dimerization of procaspase-8 11 2.59e-02 8.71e-02 0.496 0.46100 0.184 8.10e-03 2.91e-01
Regulation by c-FLIP 11 2.59e-02 8.71e-02 0.496 0.46100 0.184 8.10e-03 2.91e-01
Vif-mediated degradation of APOBEC3G 50 1.72e-07 2.16e-06 0.495 0.40400 0.286 7.52e-07 4.60e-04
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 72 2.43e-10 7.08e-09 0.495 0.36800 0.331 6.42e-08 1.16e-06


Results (complete table)


Click HERE to show results for all gene sets

Complete results
set setSize pMANOVA p.adjustMANOVA s.dist s.bl s.gu p.bl p.gu
Class C/3 (Metabotropic glutamate/pheromone receptors) 39 1.81e-10 5.51e-09 0.67700 -4.90e-01 -4.68e-01 1.16e-07 4.29e-07
TICAM1-dependent activation of IRF3/IRF7 12 1.24e-03 7.62e-03 0.66700 4.50e-01 4.92e-01 6.92e-03 3.16e-03
Scavenging of heme from plasma 12 1.97e-03 1.14e-02 0.64300 -4.73e-01 -4.36e-01 4.52e-03 8.98e-03
Eicosanoids 12 2.96e-04 2.16e-03 0.64000 6.31e-01 -1.02e-01 1.52e-04 5.41e-01
Pexophagy 11 4.13e-03 2.04e-02 0.62600 5.15e-01 3.56e-01 3.11e-03 4.08e-02
SARS-CoV-1 modulates host translation machinery 34 1.09e-07 1.47e-06 0.60400 5.22e-01 3.05e-01 1.40e-07 2.11e-03
Sensory perception of sweet, bitter, and umami (glutamate) taste 41 1.17e-08 2.18e-07 0.59400 -4.65e-01 -3.70e-01 2.48e-07 4.17e-05
TICAM1,TRAF6-dependent induction of TAK1 complex 10 1.46e-02 5.47e-02 0.58000 4.31e-01 3.88e-01 1.82e-02 3.36e-02
Competing endogenous RNAs (ceRNAs) regulate PTEN translation 16 1.27e-04 1.02e-03 0.55500 -4.82e-01 2.74e-01 8.37e-04 5.77e-02
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling 11 1.48e-02 5.51e-02 0.55000 4.40e-01 3.31e-01 1.16e-02 5.76e-02
Glucuronidation 25 8.06e-05 6.63e-04 0.54800 -3.78e-01 -3.97e-01 1.06e-03 5.87e-04
SCF(Skp2)-mediated degradation of p27/p21 58 3.60e-10 9.91e-09 0.54700 4.12e-01 3.59e-01 5.52e-08 2.26e-06
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 50 9.13e-09 1.75e-07 0.54300 4.11e-01 3.55e-01 4.82e-07 1.43e-05
APC/C:Cdc20 mediated degradation of Cyclin B 24 1.35e-04 1.07e-03 0.53900 3.00e-01 4.48e-01 1.08e-02 1.44e-04
Peptide chain elongation 84 2.22e-14 1.41e-12 0.53800 4.66e-01 2.69e-01 1.47e-13 2.00e-05
PINK1-PRKN Mediated Mitophagy 21 4.63e-04 3.22e-03 0.53400 2.87e-01 4.50e-01 2.27e-02 3.53e-04
Eukaryotic Translation Termination 87 1.17e-14 7.75e-13 0.53400 4.64e-01 2.63e-01 6.84e-14 2.17e-05
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 50 2.24e-08 3.78e-07 0.52700 4.25e-01 3.13e-01 1.99e-07 1.31e-04
p53-Independent DNA Damage Response 50 2.24e-08 3.78e-07 0.52700 4.25e-01 3.13e-01 1.99e-07 1.31e-04
p53-Independent G1/S DNA damage checkpoint 50 2.24e-08 3.78e-07 0.52700 4.25e-01 3.13e-01 1.99e-07 1.31e-04
Sensory perception of taste 47 9.25e-08 1.28e-06 0.52500 -3.65e-01 -3.77e-01 1.49e-05 7.81e-06
Autodegradation of Cdh1 by Cdh1:APC/C 62 5.36e-10 1.42e-08 0.52400 3.72e-01 3.70e-01 4.13e-07 4.61e-07
Hh mutants are degraded by ERAD 54 8.26e-09 1.60e-07 0.52300 4.08e-01 3.28e-01 2.13e-07 3.10e-05
Eukaryotic Translation Elongation 88 2.89e-14 1.70e-12 0.52200 4.58e-01 2.51e-01 1.07e-13 4.71e-05
Autodegradation of the E3 ubiquitin ligase COP1 50 3.12e-08 5.04e-07 0.52100 4.33e-01 2.89e-01 1.17e-07 4.03e-04
Ubiquitin-dependent degradation of Cyclin D 50 3.46e-08 5.38e-07 0.52000 4.25e-01 3.00e-01 1.98e-07 2.43e-04
Viral mRNA Translation 84 2.28e-13 1.03e-11 0.51900 4.45e-01 2.67e-01 1.75e-12 2.29e-05
Selenocysteine synthesis 87 8.57e-14 4.39e-12 0.51700 4.48e-01 2.58e-01 4.60e-13 3.23e-05
Vpu mediated degradation of CD4 50 5.45e-08 7.93e-07 0.51500 4.05e-01 3.18e-01 7.14e-07 9.93e-05
TICAM1, RIP1-mediated IKK complex recruitment 18 2.53e-03 1.39e-02 0.51400 3.36e-01 3.89e-01 1.35e-02 4.27e-03
Stabilization of p53 55 1.09e-08 2.05e-07 0.51400 4.10e-01 3.10e-01 1.47e-07 6.91e-05
Formation of the posterior neural plate 10 1.65e-02 6.01e-02 0.51200 -4.79e-03 5.12e-01 9.79e-01 5.05e-03
AUF1 (hnRNP D0) binds and destabilizes mRNA 53 2.15e-08 3.75e-07 0.51200 4.22e-01 2.89e-01 1.04e-07 2.75e-04
Negative regulation of NOTCH4 signaling 52 3.98e-08 6.01e-07 0.51000 3.94e-01 3.24e-01 8.64e-07 5.24e-05
SCF-beta-TrCP mediated degradation of Emi1 53 3.18e-08 5.09e-07 0.50900 3.92e-01 3.25e-01 7.97e-07 4.25e-05
Regulation of activated PAK-2p34 by proteasome mediated degradation 48 1.59e-07 2.02e-06 0.50700 4.11e-01 2.96e-01 8.06e-07 3.78e-04
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis 53 3.31e-08 5.25e-07 0.50600 4.12e-01 2.95e-01 2.15e-07 2.07e-04
Condensation of Prometaphase Chromosomes 11 1.98e-02 7.05e-02 0.50600 1.42e-01 4.85e-01 4.15e-01 5.33e-03
APC/C:Cdc20 mediated degradation of Securin 66 7.78e-10 1.90e-08 0.50300 3.81e-01 3.29e-01 8.61e-08 3.79e-06
Mitochondrial iron-sulfur cluster biogenesis 12 2.09e-02 7.39e-02 0.50300 2.81e-01 4.17e-01 9.19e-02 1.24e-02
Mitophagy 27 1.68e-04 1.32e-03 0.50000 2.56e-01 4.29e-01 2.12e-02 1.14e-04
Aspirin ADME 44 7.56e-07 8.62e-06 0.49800 -2.55e-01 -4.28e-01 3.44e-03 8.73e-07
Response of EIF2AK4 (GCN2) to amino acid deficiency 95 6.80e-14 3.72e-12 0.49800 4.27e-01 2.56e-01 5.90e-13 1.62e-05
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 89 5.01e-13 2.15e-11 0.49700 4.27e-01 2.54e-01 3.05e-12 3.51e-05
Digestion 18 3.42e-03 1.77e-02 0.49700 -2.73e-01 -4.15e-01 4.53e-02 2.28e-03
CASP8 activity is inhibited 11 2.59e-02 8.71e-02 0.49600 4.61e-01 1.84e-01 8.10e-03 2.91e-01
Dimerization of procaspase-8 11 2.59e-02 8.71e-02 0.49600 4.61e-01 1.84e-01 8.10e-03 2.91e-01
Regulation by c-FLIP 11 2.59e-02 8.71e-02 0.49600 4.61e-01 1.84e-01 8.10e-03 2.91e-01
Vif-mediated degradation of APOBEC3G 50 1.72e-07 2.16e-06 0.49500 4.04e-01 2.86e-01 7.52e-07 4.60e-04
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 72 2.43e-10 7.08e-09 0.49500 3.68e-01 3.31e-01 6.42e-08 1.16e-06
Cross-presentation of soluble exogenous antigens (endosomes) 46 6.30e-07 7.30e-06 0.49000 4.23e-01 2.48e-01 6.80e-07 3.66e-03
Regulation of RUNX3 expression and activity 53 1.13e-07 1.49e-06 0.49000 3.77e-01 3.13e-01 2.03e-06 8.05e-05
Hh mutants abrogate ligand secretion 57 3.79e-08 5.79e-07 0.48800 3.79e-01 3.08e-01 7.52e-07 5.75e-05
Expression and translocation of olfactory receptors 356 8.57e-47 6.79e-44 0.48500 -2.68e-01 -4.04e-01 3.01e-18 1.84e-39
Early Phase of HIV Life Cycle 14 1.10e-02 4.41e-02 0.48200 1.43e-01 4.60e-01 3.54e-01 2.86e-03
p53-Dependent G1 DNA Damage Response 64 8.02e-09 1.58e-07 0.48200 3.63e-01 3.17e-01 4.94e-07 1.18e-05
p53-Dependent G1/S DNA damage checkpoint 64 8.02e-09 1.58e-07 0.48200 3.63e-01 3.17e-01 4.94e-07 1.18e-05
SRP-dependent cotranslational protein targeting to membrane 105 2.33e-14 1.42e-12 0.48100 4.19e-01 2.36e-01 1.21e-13 2.82e-05
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 71 1.29e-09 2.92e-08 0.48000 3.56e-01 3.21e-01 2.08e-07 2.82e-06
Formation of a pool of free 40S subunits 94 6.59e-13 2.68e-11 0.47800 4.23e-01 2.24e-01 1.34e-12 1.73e-04
G1/S DNA Damage Checkpoints 66 6.21e-09 1.30e-07 0.47800 3.60e-01 3.14e-01 4.25e-07 9.98e-06
Olfactory Signaling Pathway 363 3.27e-46 1.73e-43 0.47700 -2.59e-01 -4.00e-01 1.77e-17 1.95e-39
CDK-mediated phosphorylation and removal of Cdc6 71 1.65e-09 3.58e-08 0.47700 3.39e-01 3.36e-01 7.94e-07 9.67e-07
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint 72 1.52e-09 3.36e-08 0.47400 3.50e-01 3.20e-01 2.76e-07 2.60e-06
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins 75 7.03e-10 1.77e-08 0.47400 3.41e-01 3.29e-01 3.35e-07 7.98e-07
Defective C1GALT1C1 causes TNPS 18 6.39e-03 2.94e-02 0.47300 -3.36e-01 -3.33e-01 1.35e-02 1.44e-02
APC/C:Cdc20 mediated degradation of mitotic proteins 74 1.04e-09 2.38e-08 0.47300 3.40e-01 3.28e-01 4.14e-07 1.05e-06
GLI3 is processed to GLI3R by the proteasome 58 7.82e-08 1.11e-06 0.47200 3.78e-01 2.83e-01 6.21e-07 1.92e-04
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation 10 1.89e-02 6.79e-02 0.47100 -1.90e-01 4.31e-01 2.97e-01 1.82e-02
APC-Cdc20 mediated degradation of Nek2A 26 6.02e-04 3.91e-03 0.47100 2.48e-01 4.01e-01 2.89e-02 4.03e-04
Defective CFTR causes cystic fibrosis 59 7.91e-08 1.11e-06 0.46800 3.79e-01 2.75e-01 4.87e-07 2.61e-04
Degradation of GLI2 by the proteasome 58 1.04e-07 1.41e-06 0.46800 3.80e-01 2.73e-01 5.55e-07 3.28e-04
Synthesis of active ubiquitin: roles of E1 and E2 enzymes 27 5.00e-04 3.40e-03 0.46800 2.42e-01 4.00e-01 2.98e-02 3.18e-04
Degradation of DVL 55 2.75e-07 3.41e-06 0.46600 3.73e-01 2.80e-01 1.71e-06 3.31e-04
Josephin domain DUBs 11 4.85e-02 1.40e-01 0.46500 2.70e-01 3.79e-01 1.20e-01 2.95e-02
SARS-CoV-2 modulates host translation machinery 46 2.84e-06 2.85e-05 0.46500 3.94e-01 2.47e-01 3.66e-06 3.79e-03
TNFR1-induced proapoptotic signaling 24 1.51e-03 9.03e-03 0.46500 3.36e-01 3.21e-01 4.42e-03 6.40e-03
Phosphorylation of the APC/C 20 3.53e-03 1.81e-02 0.46400 2.12e-01 4.13e-01 1.00e-01 1.39e-03
RIPK1-mediated regulated necrosis 30 3.12e-04 2.24e-03 0.46300 3.28e-01 3.27e-01 1.84e-03 1.93e-03
Regulation of necroptotic cell death 30 3.12e-04 2.24e-03 0.46300 3.28e-01 3.27e-01 1.84e-03 1.93e-03
Regulation of APC/C activators between G1/S and early anaphase 79 6.01e-10 1.54e-08 0.46300 3.15e-01 3.40e-01 1.26e-06 1.77e-07
Selenoamino acid metabolism 103 5.65e-13 2.36e-11 0.46200 3.93e-01 2.43e-01 5.35e-12 1.98e-05
GTP hydrolysis and joining of the 60S ribosomal subunit 104 3.11e-13 1.37e-11 0.46100 4.06e-01 2.19e-01 7.83e-13 1.14e-04
Regulation of ornithine decarboxylase (ODC) 49 2.11e-06 2.18e-05 0.46000 3.63e-01 2.83e-01 1.11e-05 6.16e-04
Senescence-Associated Secretory Phenotype (SASP) 53 8.18e-07 9.22e-06 0.45700 2.68e-01 3.70e-01 7.50e-04 3.09e-06
STAT5 activation downstream of FLT3 ITD mutants 10 6.57e-02 1.74e-01 0.45700 2.15e-01 4.03e-01 2.40e-01 2.73e-02
Defective GALNT12 causes CRCS1 18 9.06e-03 3.90e-02 0.45700 -3.30e-01 -3.15e-01 1.53e-02 2.06e-02
L13a-mediated translational silencing of Ceruloplasmin expression 103 6.90e-13 2.74e-11 0.45600 4.05e-01 2.10e-01 1.18e-12 2.25e-04
Activation of RAC1 11 3.53e-02 1.13e-01 0.45500 -4.50e-01 -7.06e-02 9.78e-03 6.85e-01
APC/C-mediated degradation of cell cycle proteins 86 2.45e-10 7.08e-09 0.45300 3.11e-01 3.30e-01 6.08e-07 1.21e-07
Regulation of mitotic cell cycle 86 2.45e-10 7.08e-09 0.45300 3.11e-01 3.30e-01 6.08e-07 1.21e-07
Degradation of GLI1 by the proteasome 58 3.21e-07 3.88e-06 0.45300 3.51e-01 2.87e-01 3.85e-06 1.60e-04
Interaction With Cumulus Cells And The Zona Pellucida 11 2.55e-02 8.64e-02 0.45300 5.11e-02 -4.50e-01 7.69e-01 9.79e-03
Suppression of phagosomal maturation 13 3.56e-02 1.14e-01 0.45200 3.36e-01 3.03e-01 3.59e-02 5.88e-02
Defective GALNT3 causes HFTC 18 1.00e-02 4.18e-02 0.45100 -3.34e-01 -3.04e-01 1.42e-02 2.57e-02
Cap-dependent Translation Initiation 111 1.84e-13 8.59e-12 0.45100 3.97e-01 2.13e-01 4.65e-13 1.06e-04
Eukaryotic Translation Initiation 111 1.84e-13 8.59e-12 0.45100 3.97e-01 2.13e-01 4.65e-13 1.06e-04
NIK–>noncanonical NF-kB signaling 57 4.85e-07 5.70e-06 0.45000 3.49e-01 2.84e-01 4.97e-06 2.09e-04
Metabolism of polyamines 55 8.30e-07 9.27e-06 0.44800 3.66e-01 2.58e-01 2.60e-06 9.49e-04
Respiratory electron transport 90 1.43e-10 4.54e-09 0.44800 2.82e-01 3.47e-01 3.65e-06 1.20e-08
Formation of the ternary complex, and subsequently, the 43S complex 46 5.65e-06 5.46e-05 0.44700 4.00e-01 1.99e-01 2.61e-06 1.94e-02
Regulation of Apoptosis 51 2.59e-06 2.63e-05 0.44700 3.58e-01 2.67e-01 9.59e-06 9.76e-04
cGMP effects 15 1.24e-02 4.77e-02 0.44600 -6.24e-02 -4.41e-01 6.76e-01 3.09e-03
Dectin-1 mediated noncanonical NF-kB signaling 60 3.16e-07 3.85e-06 0.44500 3.49e-01 2.76e-01 2.86e-06 2.19e-04
Activation of IRF3, IRF7 mediated by TBK1, IKBKE 17 1.10e-02 4.41e-02 0.44400 1.68e-01 4.11e-01 2.30e-01 3.34e-03
Prednisone ADME 10 8.67e-02 2.17e-01 0.44200 -2.99e-01 -3.25e-01 1.02e-01 7.50e-02
Constitutive Signaling by Overexpressed ERBB2 10 6.43e-02 1.72e-01 0.44100 1.10e-01 4.27e-01 5.46e-01 1.94e-02
Apoptotic cleavage of cell adhesion proteins 11 6.23e-02 1.70e-01 0.44100 -3.84e-01 -2.16e-01 2.73e-02 2.14e-01
Assembly of the ORC complex at the origin of replication 10 2.98e-02 9.79e-02 0.44000 -3.85e-01 2.12e-01 3.49e-02 2.46e-01
Aberrant regulation of mitotic exit in cancer due to RB1 defects 20 6.09e-03 2.84e-02 0.43800 1.83e-01 3.98e-01 1.56e-01 2.04e-03
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) 108 3.61e-12 1.30e-10 0.43600 3.71e-01 2.30e-01 2.75e-11 3.51e-05
Nonsense-Mediated Decay (NMD) 108 3.61e-12 1.30e-10 0.43600 3.71e-01 2.30e-01 2.75e-11 3.51e-05
Assembly Of The HIV Virion 16 1.12e-02 4.45e-02 0.43600 5.95e-02 4.32e-01 6.80e-01 2.76e-03
MET activates RAS signaling 11 2.14e-02 7.48e-02 0.43500 -2.51e-01 3.55e-01 1.49e-01 4.15e-02
Somitogenesis 53 3.22e-06 3.22e-05 0.43500 3.47e-01 2.62e-01 1.24e-05 9.78e-04
Membrane binding and targetting of GAG proteins 14 2.12e-02 7.44e-02 0.43400 7.01e-02 4.28e-01 6.50e-01 5.52e-03
Synthesis And Processing Of GAG, GAGPOL Polyproteins 14 2.12e-02 7.44e-02 0.43400 7.01e-02 4.28e-01 6.50e-01 5.52e-03
Major pathway of rRNA processing in the nucleolus and cytosol 171 1.52e-18 2.05e-16 0.43400 3.64e-01 2.36e-01 1.88e-16 1.02e-07
PRC2 methylates histones and DNA 13 1.17e-02 4.57e-02 0.43100 -2.34e-01 3.62e-01 1.44e-01 2.37e-02
Influenza Viral RNA Transcription and Replication 129 7.55e-14 3.99e-12 0.43100 3.43e-01 2.62e-01 1.73e-11 2.80e-07
Regulation of expression of SLITs and ROBOs 159 7.86e-17 6.56e-15 0.42800 3.57e-01 2.37e-01 7.67e-15 2.52e-07
SARS-CoV-1 activates/modulates innate immune responses 36 1.82e-04 1.42e-03 0.42800 1.99e-01 3.79e-01 3.84e-02 8.41e-05
NF-kB is activated and signals survival 12 5.55e-02 1.55e-01 0.42700 3.86e-01 1.81e-01 2.05e-02 2.76e-01
Regulation of innate immune responses to cytosolic DNA 14 4.08e-02 1.25e-01 0.42600 3.34e-01 2.64e-01 3.06e-02 8.69e-02
Assembly of the pre-replicative complex 82 6.78e-09 1.40e-07 0.42600 2.49e-01 3.45e-01 9.56e-05 6.48e-08
Aberrant regulation of mitotic cell cycle due to RB1 defects 36 1.41e-04 1.12e-03 0.42500 1.45e-01 4.00e-01 1.33e-01 3.30e-05
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase 20 8.38e-03 3.69e-02 0.42500 1.80e-01 3.85e-01 1.64e-01 2.87e-03
rRNA processing in the nucleus and cytosol 180 1.55e-18 2.05e-16 0.42400 3.47e-01 2.45e-01 9.86e-16 1.35e-08
Spry regulation of FGF signaling 16 2.49e-02 8.49e-02 0.42400 2.21e-01 3.61e-01 1.26e-01 1.23e-02
Degradation of AXIN 53 5.70e-06 5.48e-05 0.42300 3.47e-01 2.42e-01 1.22e-05 2.27e-03
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 62 8.64e-07 9.58e-06 0.42300 3.25e-01 2.71e-01 9.50e-06 2.20e-04
Digestion and absorption 23 5.63e-03 2.67e-02 0.42300 -2.63e-01 -3.31e-01 2.92e-02 5.97e-03
Dectin-2 family 28 1.62e-03 9.58e-03 0.42200 -3.61e-01 -2.18e-01 9.34e-04 4.55e-02
Influenza Infection 148 5.17e-15 3.56e-13 0.42100 3.20e-01 2.74e-01 1.63e-11 8.96e-09
p75NTR recruits signalling complexes 12 6.48e-02 1.73e-01 0.42000 3.64e-01 2.09e-01 2.90e-02 2.11e-01
The role of GTSE1 in G2/M progression after G2 checkpoint 76 4.70e-08 6.94e-07 0.41900 3.34e-01 2.54e-01 4.90e-07 1.26e-04
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 95 9.39e-10 2.22e-08 0.41600 2.50e-01 3.33e-01 2.52e-05 2.01e-08
Cyclin E associated events during G1/S transition 81 2.64e-08 4.41e-07 0.41500 2.91e-01 2.96e-01 6.12e-06 3.97e-06
Signaling by NOTCH4 79 3.74e-08 5.76e-07 0.41400 3.28e-01 2.53e-01 4.62e-07 9.84e-05
Activation of the TFAP2 (AP-2) family of transcription factors 11 8.96e-02 2.23e-01 0.41400 3.47e-01 2.25e-01 4.61e-02 1.96e-01
TNFR1-induced NF-kappa-B signaling pathway 29 2.02e-03 1.15e-02 0.41300 2.93e-01 2.91e-01 6.23e-03 6.66e-03
DNA Replication Pre-Initiation 97 8.51e-10 2.04e-08 0.41300 2.49e-01 3.29e-01 2.20e-05 2.01e-08
ATF6 (ATF6-alpha) activates chaperone genes 10 1.15e-01 2.64e-01 0.41200 2.40e-01 3.35e-01 1.88e-01 6.65e-02
p75NTR signals via NF-kB 15 3.56e-02 1.14e-01 0.41200 3.65e-01 1.92e-01 1.43e-02 1.98e-01
Thyroxine biosynthesis 10 1.14e-01 2.60e-01 0.41200 -3.45e-01 -2.26e-01 5.87e-02 2.16e-01
Carnitine metabolism 13 1.81e-02 6.54e-02 0.41200 -3.63e-01 1.95e-01 2.34e-02 2.22e-01
Diseases of mitotic cell cycle 37 2.29e-04 1.74e-03 0.41000 1.50e-01 3.81e-01 1.13e-01 6.01e-05
Cyclin A:Cdk2-associated events at S phase entry 83 2.95e-08 4.82e-07 0.40900 2.86e-01 2.92e-01 6.43e-06 4.33e-06
RUNX1 regulates transcription of genes involved in differentiation of HSCs 68 6.69e-07 7.69e-06 0.40900 2.77e-01 3.01e-01 7.82e-05 1.81e-05
Asymmetric localization of PCP proteins 62 2.19e-06 2.25e-05 0.40800 3.23e-01 2.49e-01 1.07e-05 6.80e-04
Ribosomal scanning and start codon recognition 53 8.96e-06 8.36e-05 0.40800 3.67e-01 1.78e-01 3.72e-06 2.52e-02
Golgi Cisternae Pericentriolar Stack Reorganization 14 4.26e-02 1.29e-01 0.40800 1.46e-01 3.81e-01 3.44e-01 1.36e-02
Defective pyroptosis 11 5.32e-02 1.50e-01 0.40800 -3.02e-02 4.07e-01 8.62e-01 1.95e-02
rRNA processing 186 1.24e-17 1.31e-15 0.40700 3.29e-01 2.40e-01 8.99e-15 1.62e-08
Switching of origins to a post-replicative state 90 7.39e-09 1.50e-07 0.40700 2.52e-01 3.19e-01 3.52e-05 1.67e-07
Hedgehog ligand biogenesis 63 2.25e-06 2.30e-05 0.40500 3.14e-01 2.56e-01 1.64e-05 4.34e-04
Androgen biosynthesis 11 6.79e-02 1.78e-01 0.40500 -4.45e-02 -4.02e-01 7.98e-01 2.09e-02
Diseases of programmed cell death 43 1.20e-04 9.63e-04 0.40300 2.04e-01 3.48e-01 2.08e-02 7.81e-05
Activation of NF-kappaB in B cells 64 2.10e-06 2.18e-05 0.40300 3.11e-01 2.56e-01 1.65e-05 3.91e-04
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 54 9.17e-06 8.51e-05 0.40300 3.65e-01 1.70e-01 3.40e-06 3.07e-02
Response of Mtb to phagocytosis 22 1.07e-02 4.37e-02 0.40300 3.30e-01 2.31e-01 7.40e-03 6.05e-02
CYP2E1 reactions 11 9.86e-02 2.38e-01 0.40200 -3.52e-01 -1.95e-01 4.31e-02 2.63e-01
mRNA decay by 3’ to 5’ exoribonuclease 13 3.43e-02 1.11e-01 0.40200 4.01e-01 -2.81e-02 1.22e-02 8.61e-01
Infection with Mycobacterium tuberculosis 25 6.23e-03 2.88e-02 0.40100 3.20e-01 2.41e-01 5.60e-03 3.68e-02
Inactivation of APC/C via direct inhibition of the APC/C complex 21 1.15e-02 4.50e-02 0.40100 1.69e-01 3.63e-01 1.81e-01 3.93e-03
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components 21 1.15e-02 4.50e-02 0.40100 1.69e-01 3.63e-01 1.81e-01 3.93e-03
SARS-CoV-1-host interactions 90 1.44e-08 2.56e-07 0.40000 2.69e-01 2.96e-01 1.00e-05 1.16e-06
Translation initiation complex formation 53 1.46e-05 1.33e-04 0.39800 3.62e-01 1.66e-01 5.17e-06 3.65e-02
Mitochondrial RNA degradation 10 1.29e-01 2.81e-01 0.39400 1.71e-01 3.55e-01 3.48e-01 5.20e-02
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects 17 2.26e-02 7.76e-02 0.39300 7.68e-02 3.86e-01 5.83e-01 5.89e-03
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) 17 2.26e-02 7.76e-02 0.39300 7.68e-02 3.86e-01 5.83e-01 5.89e-03
Diseases associated with glycosylation precursor biosynthesis 15 5.04e-02 1.44e-01 0.39300 2.04e-01 3.36e-01 1.72e-01 2.41e-02
Cellular response to hypoxia 71 1.23e-06 1.35e-05 0.39100 2.86e-01 2.67e-01 3.09e-05 9.86e-05
Mitochondrial translation termination 87 5.84e-08 8.34e-07 0.39100 2.68e-01 2.85e-01 1.59e-05 4.14e-06
Orc1 removal from chromatin 69 1.89e-06 2.01e-05 0.39100 2.70e-01 2.82e-01 1.02e-04 5.09e-05
Sensory Perception 569 5.82e-48 9.23e-45 0.39000 -2.09e-01 -3.29e-01 1.43e-17 2.70e-41
Negative regulation of activity of TFAP2 (AP-2) family transcription factors 10 1.29e-01 2.81e-01 0.38900 3.63e-01 1.40e-01 4.69e-02 4.43e-01
Receptor Mediated Mitophagy 10 1.06e-01 2.48e-01 0.38700 4.28e-02 3.85e-01 8.15e-01 3.50e-02
Formation of paraxial mesoderm 65 4.67e-06 4.60e-05 0.38700 3.03e-01 2.41e-01 2.37e-05 7.71e-04
Translation 262 5.15e-22 1.17e-19 0.38700 3.04e-01 2.39e-01 2.18e-17 2.67e-11
Regulation of RAS by GAPs 65 5.12e-06 4.98e-05 0.38600 2.95e-01 2.49e-01 3.83e-05 5.08e-04
Transcriptional regulation of granulopoiesis 31 5.33e-04 3.57e-03 0.38600 -4.87e-02 3.83e-01 6.39e-01 2.27e-04
Mitochondrial translation 93 3.40e-08 5.33e-07 0.38500 2.66e-01 2.78e-01 9.11e-06 3.66e-06
Methylation 14 4.74e-02 1.38e-01 0.38400 3.81e-01 5.35e-02 1.37e-02 7.29e-01
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 34 1.24e-03 7.63e-03 0.38300 1.46e-01 3.54e-01 1.41e-01 3.53e-04
Defective Intrinsic Pathway for Apoptosis 25 1.02e-02 4.23e-02 0.38200 2.73e-01 2.68e-01 1.80e-02 2.05e-02
Mitochondrial translation elongation 87 1.48e-07 1.91e-06 0.38000 2.62e-01 2.76e-01 2.44e-05 8.67e-06
Mitochondrial translation initiation 87 1.57e-07 2.01e-06 0.37900 2.63e-01 2.73e-01 2.15e-05 1.06e-05
TNFR2 non-canonical NF-kB pathway 94 4.07e-08 6.08e-07 0.37900 2.98e-01 2.35e-01 6.03e-07 8.12e-05
DNA Damage Recognition in GG-NER 36 1.51e-03 9.03e-03 0.37900 2.56e-01 2.80e-01 7.81e-03 3.67e-03
Nuclear events mediated by NFE2L2 94 4.73e-08 6.94e-07 0.37800 2.41e-01 2.91e-01 5.41e-05 1.03e-06
Regulation of TNFR1 signaling 45 3.27e-04 2.34e-03 0.37700 2.54e-01 2.79e-01 3.15e-03 1.22e-03
Transcriptional regulation of testis differentiation 12 9.03e-02 2.23e-01 0.37600 8.75e-02 3.65e-01 6.00e-01 2.85e-02
Polo-like kinase mediated events 16 4.11e-02 1.26e-01 0.37500 8.70e-02 3.64e-01 5.47e-01 1.16e-02
Pyrimidine salvage 10 8.18e-02 2.09e-01 0.37400 -1.52e-01 3.42e-01 4.07e-01 6.08e-02
Telomere C-strand synthesis initiation 11 1.17e-01 2.66e-01 0.37400 1.06e-01 3.59e-01 5.43e-01 3.95e-02
Termination of O-glycan biosynthesis 25 1.24e-02 4.77e-02 0.37300 -2.97e-01 -2.25e-01 1.01e-02 5.12e-02
Folding of actin by CCT/TriC 10 1.29e-01 2.82e-01 0.37200 3.69e-01 4.88e-02 4.35e-02 7.89e-01
ER-Phagosome pathway 87 2.96e-07 3.64e-06 0.37200 2.70e-01 2.56e-01 1.34e-05 3.76e-05
Pausing and recovery of Tat-mediated HIV elongation 27 9.13e-03 3.91e-02 0.37000 3.04e-01 2.11e-01 6.26e-03 5.83e-02
Tat-mediated HIV elongation arrest and recovery 27 9.13e-03 3.91e-02 0.37000 3.04e-01 2.11e-01 6.26e-03 5.83e-02
ATF4 activates genes in response to endoplasmic reticulum stress 28 4.12e-03 2.04e-02 0.36900 3.62e-01 7.44e-02 9.19e-04 4.96e-01
IRAK1 recruits IKK complex 12 1.26e-01 2.79e-01 0.36900 2.19e-01 2.97e-01 1.88e-01 7.53e-02
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation 12 1.26e-01 2.79e-01 0.36900 2.19e-01 2.97e-01 1.88e-01 7.53e-02
Erythrocytes take up carbon dioxide and release oxygen 12 1.31e-01 2.85e-01 0.36700 -2.34e-01 -2.82e-01 1.60e-01 9.05e-02
O2/CO2 exchange in erythrocytes 12 1.31e-01 2.85e-01 0.36700 -2.34e-01 -2.82e-01 1.60e-01 9.05e-02
Purine ribonucleoside monophosphate biosynthesis 11 1.05e-01 2.47e-01 0.36700 2.21e-02 3.66e-01 8.99e-01 3.56e-02
IKK complex recruitment mediated by RIP1 22 1.95e-02 6.94e-02 0.36600 1.47e-01 3.36e-01 2.32e-01 6.44e-03
RHO GTPases activate KTN1 11 6.87e-02 1.80e-01 0.36600 -1.77e-01 3.20e-01 3.08e-01 6.61e-02
Regulation of mRNA stability by proteins that bind AU-rich elements 87 3.68e-07 4.39e-06 0.36600 3.04e-01 2.03e-01 9.30e-07 1.06e-03
NRIF signals cell death from the nucleus 16 6.18e-02 1.69e-01 0.36400 3.24e-01 1.66e-01 2.47e-02 2.51e-01
Regulation of PTEN mRNA translation 25 2.49e-03 1.39e-02 0.36400 -3.24e-01 1.67e-01 5.05e-03 1.49e-01
PERK regulates gene expression 32 2.53e-03 1.39e-02 0.36400 3.52e-01 9.18e-02 5.58e-04 3.69e-01
Class I peroxisomal membrane protein import 19 3.97e-02 1.23e-01 0.36400 3.07e-01 1.96e-01 2.05e-02 1.40e-01
Processing and activation of SUMO 10 1.41e-01 2.99e-01 0.36300 4.54e-02 3.61e-01 8.04e-01 4.84e-02
Anchoring fibril formation 13 4.77e-02 1.39e-01 0.36300 1.39e-01 -3.35e-01 3.84e-01 3.63e-02
UCH proteinases 81 1.42e-06 1.54e-05 0.36300 2.89e-01 2.19e-01 6.64e-06 6.49e-04
Calnexin/calreticulin cycle 25 1.33e-02 5.05e-02 0.36300 1.64e-01 3.24e-01 1.56e-01 5.07e-03
G1/S Transition 126 7.44e-10 1.84e-08 0.36300 2.07e-01 2.98e-01 5.79e-05 7.69e-09
Mitochondrial protein import 54 8.60e-05 7.03e-04 0.36100 1.48e-01 3.29e-01 5.94e-02 2.80e-05
Metabolism of amine-derived hormones 17 6.12e-02 1.68e-01 0.36100 -2.84e-01 -2.22e-01 4.25e-02 1.12e-01
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest 18 4.77e-02 1.39e-01 0.36000 1.68e-01 3.18e-01 2.16e-01 1.95e-02
TNF signaling 53 1.82e-04 1.42e-03 0.36000 2.30e-01 2.76e-01 3.79e-03 4.96e-04
DNA Replication 125 1.50e-09 3.36e-08 0.36000 2.22e-01 2.83e-01 1.80e-05 4.64e-08
ATF6 (ATF6-alpha) activates chaperones 11 1.67e-01 3.35e-01 0.35900 2.23e-01 2.81e-01 2.00e-01 1.06e-01
RUNX3 regulates p14-ARF 10 1.68e-01 3.36e-01 0.35800 1.05e-01 3.43e-01 5.65e-01 6.07e-02
ER Quality Control Compartment (ERQC) 20 3.89e-02 1.21e-01 0.35700 2.04e-01 2.93e-01 1.14e-01 2.32e-02
Complex I biogenesis 49 4.07e-04 2.85e-03 0.35600 2.38e-01 2.66e-01 4.00e-03 1.29e-03
Nuclear import of Rev protein 32 3.36e-03 1.75e-02 0.35600 9.21e-02 3.44e-01 3.67e-01 7.63e-04
Synthesis of bile acids and bile salts via 27-hydroxycholesterol 15 9.18e-02 2.26e-01 0.35600 -2.73e-01 -2.28e-01 6.71e-02 1.26e-01
Unwinding of DNA 12 1.44e-01 3.03e-01 0.35500 1.92e-01 2.99e-01 2.50e-01 7.33e-02
RNA Polymerase III Transcription Initiation From Type 3 Promoter 28 1.13e-02 4.50e-02 0.35400 1.94e-01 2.96e-01 7.61e-02 6.68e-03
RNA Polymerase III Transcription Initiation 36 2.89e-03 1.56e-02 0.35300 1.70e-01 3.10e-01 7.70e-02 1.29e-03
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex 13 9.42e-02 2.29e-01 0.35300 5.92e-02 3.48e-01 7.12e-01 2.98e-02
Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 14 7.24e-02 1.89e-01 0.35300 2.92e-02 3.51e-01 8.50e-01 2.28e-02
activated TAK1 mediates p38 MAPK activation 20 3.86e-02 1.21e-01 0.35100 1.55e-01 3.16e-01 2.31e-01 1.46e-02
tRNA processing in the nucleus 55 1.86e-04 1.44e-03 0.35100 2.04e-01 2.86e-01 8.86e-03 2.47e-04
HIV elongation arrest and recovery 29 9.69e-03 4.08e-02 0.35100 3.07e-01 1.71e-01 4.27e-03 1.11e-01
Pausing and recovery of HIV elongation 29 9.69e-03 4.08e-02 0.35100 3.07e-01 1.71e-01 4.27e-03 1.11e-01
Mitotic G1 phase and G1/S transition 144 1.47e-10 4.57e-09 0.35100 1.86e-01 2.97e-01 1.14e-04 7.19e-10
Translesion Synthesis by POLH 19 4.89e-02 1.41e-01 0.35000 1.75e-01 3.04e-01 1.87e-01 2.19e-02
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway 16 8.36e-02 2.11e-01 0.34900 2.86e-01 2.01e-01 4.77e-02 1.64e-01
Hormone ligand-binding receptors 13 1.03e-01 2.45e-01 0.34900 -7.37e-02 -3.41e-01 6.46e-01 3.31e-02
Base-Excision Repair, AP Site Formation 18 3.49e-02 1.12e-01 0.34900 1.64e-02 3.49e-01 9.04e-01 1.04e-02
Synthesis of DNA 118 1.41e-08 2.54e-07 0.34900 2.14e-01 2.75e-01 5.68e-05 2.36e-07
RNA Polymerase III Transcription Initiation From Type 1 Promoter 28 1.35e-02 5.08e-02 0.34900 2.11e-01 2.78e-01 5.36e-02 1.09e-02
Downstream signaling events of B Cell Receptor (BCR) 78 6.92e-06 6.57e-05 0.34900 2.62e-01 2.30e-01 6.13e-05 4.53e-04
Beta defensins 28 2.01e-03 1.15e-02 0.34800 2.96e-01 -1.83e-01 6.66e-03 9.44e-02
RNA Polymerase III Transcription Initiation From Type 2 Promoter 27 1.62e-02 5.95e-02 0.34800 2.15e-01 2.74e-01 5.33e-02 1.39e-02
Hedgehog ‘on’ state 83 3.59e-06 3.56e-05 0.34700 2.60e-01 2.30e-01 4.13e-05 2.91e-04
Inhibition of DNA recombination at telomere 20 4.56e-02 1.35e-01 0.34700 2.93e-01 1.87e-01 2.34e-02 1.49e-01
Nitric oxide stimulates guanylate cyclase 22 2.08e-02 7.36e-02 0.34700 -5.56e-02 -3.43e-01 6.52e-01 5.41e-03
Bicarbonate transporters 10 2.04e-01 3.84e-01 0.34700 -1.47e-01 -3.14e-01 4.20e-01 8.59e-02
Metalloprotease DUBs 19 3.12e-02 1.02e-01 0.34500 1.67e-02 3.45e-01 9.00e-01 9.20e-03
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 19 5.82e-02 1.61e-01 0.34500 2.59e-01 2.28e-01 5.07e-02 8.46e-02
Signaling by Ligand-Responsive EGFR Variants in Cancer 19 5.82e-02 1.61e-01 0.34500 2.59e-01 2.28e-01 5.07e-02 8.46e-02
Cellular response to starvation 147 3.04e-10 8.62e-09 0.34400 2.72e-01 2.12e-01 1.26e-08 9.45e-06
mRNA Splicing - Minor Pathway 51 3.69e-04 2.60e-03 0.34400 3.06e-01 1.56e-01 1.52e-04 5.37e-02
Collagen chain trimerization 42 8.62e-04 5.46e-03 0.34400 -7.76e-02 -3.35e-01 3.84e-01 1.74e-04
Antigen processing-Cross presentation 100 3.85e-07 4.56e-06 0.34400 2.56e-01 2.29e-01 9.86e-06 7.27e-05
Cleavage of the damaged pyrimidine 16 6.58e-02 1.74e-01 0.34300 6.57e-02 3.37e-01 6.49e-01 1.97e-02
Depyrimidination 16 6.58e-02 1.74e-01 0.34300 6.57e-02 3.37e-01 6.49e-01 1.97e-02
Recognition and association of DNA glycosylase with site containing an affected pyrimidine 16 6.58e-02 1.74e-01 0.34300 6.57e-02 3.37e-01 6.49e-01 1.97e-02
Lysosome Vesicle Biogenesis 33 2.93e-03 1.56e-02 0.34300 3.15e-02 3.42e-01 7.54e-01 6.82e-04
MyD88 deficiency (TLR2/4) 16 3.73e-02 1.18e-01 0.34300 -1.12e-01 3.24e-01 4.40e-01 2.47e-02
SUMOylation of transcription factors 20 4.96e-02 1.42e-01 0.34200 1.81e-01 2.90e-01 1.61e-01 2.47e-02
MET activates PTK2 signaling 30 1.21e-02 4.69e-02 0.34200 -2.12e-01 -2.67e-01 4.39e-02 1.12e-02
Fatty acids 15 5.43e-02 1.52e-01 0.34100 3.34e-01 -6.49e-02 2.49e-02 6.64e-01
TRAF6-mediated induction of TAK1 complex within TLR4 complex 15 9.33e-02 2.28e-01 0.34100 1.16e-01 3.20e-01 4.37e-01 3.17e-02
rRNA modification in the nucleus and cytosol 55 2.97e-04 2.16e-03 0.34000 1.87e-01 2.84e-01 1.66e-02 2.65e-04
Glucocorticoid biosynthesis 10 1.47e-01 3.07e-01 0.33900 6.06e-02 -3.34e-01 7.40e-01 6.74e-02
Formation of the anterior neural plate 11 1.13e-01 2.59e-01 0.33900 -9.93e-02 3.24e-01 5.69e-01 6.29e-02
Signaling by ROBO receptors 203 1.73e-13 8.59e-12 0.33800 2.78e-01 1.93e-01 8.03e-12 2.18e-06
G2/M Checkpoints 129 8.08e-09 1.58e-07 0.33800 1.94e-01 2.77e-01 1.44e-04 5.67e-08
Alpha-protein kinase 1 signaling pathway 10 2.40e-01 4.27e-01 0.33700 2.53e-01 2.23e-01 1.66e-01 2.23e-01
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation 14 1.24e-01 2.77e-01 0.33700 1.54e-01 3.00e-01 3.17e-01 5.22e-02
Cyclin D associated events in G1 46 1.20e-03 7.43e-03 0.33700 1.74e-01 2.89e-01 4.16e-02 6.98e-04
G1 Phase 46 1.20e-03 7.43e-03 0.33700 1.74e-01 2.89e-01 4.16e-02 6.98e-04
SUMOylation of immune response proteins 11 2.09e-01 3.90e-01 0.33700 2.30e-01 2.46e-01 1.87e-01 1.57e-01
Transcriptional regulation by RUNX3 93 1.93e-06 2.04e-05 0.33600 2.59e-01 2.14e-01 1.57e-05 3.69e-04
Regulation of TP53 Activity through Methylation 18 7.81e-02 2.01e-01 0.33500 2.10e-01 2.61e-01 1.23e-01 5.49e-02
FCERI mediated NF-kB activation 77 1.98e-05 1.77e-04 0.33500 2.53e-01 2.20e-01 1.24e-04 8.59e-04
Response of EIF2AK1 (HRI) to heme deficiency 14 1.40e-01 2.97e-01 0.33500 2.31e-01 2.43e-01 1.35e-01 1.16e-01
Nuclear events stimulated by ALK signaling in cancer 18 6.94e-02 1.82e-01 0.33500 1.42e-01 3.03e-01 2.97e-01 2.61e-02
Degradation of beta-catenin by the destruction complex 81 1.24e-05 1.13e-04 0.33400 2.49e-01 2.23e-01 1.09e-04 5.27e-04
Diseases associated with N-glycosylation of proteins 19 4.92e-02 1.42e-01 0.33400 7.58e-02 3.25e-01 5.68e-01 1.42e-02
NEP/NS2 Interacts with the Cellular Export Machinery 30 9.05e-03 3.90e-02 0.33300 8.24e-02 3.23e-01 4.34e-01 2.20e-03
Aspartate and asparagine metabolism 11 2.12e-01 3.95e-01 0.33300 -2.74e-01 -1.89e-01 1.16e-01 2.77e-01
Regulation of signaling by NODAL 10 1.28e-01 2.81e-01 0.33200 2.44e-01 -2.25e-01 1.81e-01 2.18e-01
Reactions specific to the complex N-glycan synthesis pathway 10 2.49e-01 4.39e-01 0.33200 -2.61e-01 -2.04e-01 1.52e-01 2.63e-01
Regulation of BACH1 activity 15 1.25e-01 2.78e-01 0.33200 2.11e-01 2.56e-01 1.58e-01 8.57e-02
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression 16 6.15e-02 1.68e-01 0.33200 -1.32e-02 3.31e-01 9.27e-01 2.17e-02
Downstream TCR signaling 92 1.82e-06 1.95e-05 0.33200 2.95e-01 1.52e-01 1.00e-06 1.19e-02
Export of Viral Ribonucleoproteins from Nucleus 31 9.52e-03 4.03e-02 0.33100 1.08e-01 3.13e-01 3.00e-01 2.55e-03
Processing of Intronless Pre-mRNAs 19 4.91e-02 1.42e-01 0.32900 5.20e-02 3.25e-01 6.94e-01 1.41e-02
NGF-stimulated transcription 39 4.56e-03 2.22e-02 0.32900 1.81e-01 2.75e-01 5.09e-02 2.96e-03
Interactions of Rev with host cellular proteins 35 4.72e-03 2.27e-02 0.32900 7.91e-02 3.19e-01 4.18e-01 1.08e-03
Regulation of RUNX2 expression and activity 71 6.64e-05 5.55e-04 0.32900 2.51e-01 2.13e-01 2.60e-04 1.95e-03
Processing of Capped Intron-Containing Pre-mRNA 263 4.97e-16 3.75e-14 0.32800 2.27e-01 2.37e-01 2.08e-10 3.54e-11
Keratinization 213 4.28e-14 2.43e-12 0.32800 -1.20e-01 -3.05e-01 2.52e-03 1.44e-14
Transport of Mature mRNAs Derived from Intronless Transcripts 41 1.79e-03 1.05e-02 0.32800 6.51e-02 3.21e-01 4.71e-01 3.75e-04
G1/S-Specific Transcription 28 1.48e-02 5.51e-02 0.32800 8.65e-02 3.16e-01 4.28e-01 3.81e-03
mRNA Splicing 199 2.60e-12 9.81e-11 0.32700 2.51e-01 2.10e-01 9.51e-10 3.20e-07
Activation of the phototransduction cascade 11 2.21e-01 4.04e-01 0.32700 -2.77e-01 -1.74e-01 1.12e-01 3.19e-01
Budding and maturation of HIV virion 28 1.28e-02 4.90e-02 0.32700 5.43e-02 3.22e-01 6.19e-01 3.17e-03
NS1 Mediated Effects on Host Pathways 39 3.75e-03 1.90e-02 0.32600 1.21e-01 3.03e-01 1.92e-01 1.06e-03
Transport of Mature mRNA Derived from an Intronless Transcript 40 2.21e-03 1.25e-02 0.32600 6.44e-02 3.19e-01 4.81e-01 4.71e-04
Transcriptional Regulation by E2F6 32 3.20e-03 1.69e-02 0.32500 -7.47e-02 3.17e-01 4.65e-01 1.92e-03
Signaling by FLT3 ITD and TKD mutants 16 1.04e-01 2.46e-01 0.32500 1.29e-01 2.98e-01 3.70e-01 3.88e-02
Abortive elongation of HIV-1 transcript in the absence of Tat 23 4.58e-02 1.35e-01 0.32500 2.66e-01 1.86e-01 2.71e-02 1.23e-01
Host Interactions of HIV factors 122 9.88e-08 1.35e-06 0.32400 1.99e-01 2.56e-01 1.50e-04 1.01e-06
PCP/CE pathway 90 7.35e-06 6.94e-05 0.32400 2.31e-01 2.27e-01 1.52e-04 1.91e-04
Regulation of RUNX1 Expression and Activity 25 9.31e-03 3.96e-02 0.32400 -2.97e-01 1.30e-01 1.02e-02 2.62e-01
TRAF3-dependent IRF activation pathway 14 1.53e-01 3.16e-01 0.32400 1.75e-01 2.72e-01 2.56e-01 7.76e-02
ERKs are inactivated 13 1.81e-01 3.54e-01 0.32400 2.39e-01 2.18e-01 1.36e-01 1.73e-01
Endosomal/Vacuolar pathway 12 1.58e-01 3.23e-01 0.32300 3.20e-01 4.72e-02 5.51e-02 7.77e-01
Regulation of PTEN stability and activity 66 1.87e-04 1.44e-03 0.32200 2.33e-01 2.23e-01 1.08e-03 1.71e-03
Caspase activation via Death Receptors in the presence of ligand 16 1.21e-01 2.73e-01 0.32200 2.61e-01 1.88e-01 7.02e-02 1.92e-01
Degradation of cysteine and homocysteine 15 1.17e-01 2.65e-01 0.32100 9.34e-02 3.07e-01 5.31e-01 3.93e-02
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 11 2.19e-01 4.01e-01 0.32100 1.25e-01 2.96e-01 4.73e-01 8.93e-02
NoRC negatively regulates rRNA expression 43 3.09e-03 1.65e-02 0.32100 1.51e-01 2.83e-01 8.74e-02 1.29e-03
RNA Polymerase III Chain Elongation 18 9.87e-02 2.38e-01 0.32000 2.41e-01 2.11e-01 7.72e-02 1.21e-01
Regulation of NF-kappa B signaling 17 1.08e-01 2.50e-01 0.32000 2.67e-01 1.77e-01 5.71e-02 2.07e-01
Nucleotide salvage 21 2.78e-02 9.23e-02 0.32000 -5.96e-02 3.14e-01 6.36e-01 1.27e-02
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) 16 8.35e-02 2.11e-01 0.31900 2.00e-02 3.19e-01 8.90e-01 2.72e-02
Butyrophilin (BTN) family interactions 12 1.37e-01 2.93e-01 0.31900 3.17e-01 -3.61e-02 5.72e-02 8.29e-01
Metabolism of RNA 678 2.50e-37 9.91e-35 0.31900 2.31e-01 2.19e-01 7.57e-25 1.60e-22
ABC transporter disorders 75 5.82e-05 4.91e-04 0.31800 2.71e-01 1.68e-01 5.06e-05 1.19e-02
Signaling by CSF3 (G-CSF) 28 2.62e-02 8.76e-02 0.31800 1.65e-01 2.72e-01 1.30e-01 1.28e-02
E3 ubiquitin ligases ubiquitinate target proteins 42 4.83e-03 2.32e-02 0.31700 1.88e-01 2.55e-01 3.49e-02 4.26e-03
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models 22 6.30e-02 1.71e-01 0.31700 2.17e-01 2.30e-01 7.74e-02 6.16e-02
Neurodegenerative Diseases 22 6.30e-02 1.71e-01 0.31700 2.17e-01 2.30e-01 7.74e-02 6.16e-02
SUMOylation of SUMOylation proteins 33 1.06e-02 4.35e-02 0.31600 9.87e-02 3.01e-01 3.26e-01 2.81e-03
FLT3 signaling in disease 28 2.22e-02 7.68e-02 0.31600 1.10e-01 2.97e-01 3.14e-01 6.59e-03
SARS-CoV-2 modulates autophagy 11 1.88e-01 3.63e-01 0.31600 1.97e-02 3.15e-01 9.10e-01 7.01e-02
Protein ubiquitination 60 4.95e-04 3.38e-03 0.31500 1.70e-01 2.65e-01 2.23e-02 3.86e-04
RNA Pol II CTD phosphorylation and interaction with CE 26 3.81e-02 1.19e-01 0.31500 2.55e-01 1.85e-01 2.46e-02 1.02e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection 26 3.81e-02 1.19e-01 0.31500 2.55e-01 1.85e-01 2.46e-02 1.02e-01
B-WICH complex positively regulates rRNA expression 29 2.73e-02 9.10e-02 0.31500 2.24e-01 2.21e-01 3.67e-02 3.92e-02
Transport of the SLBP Dependant Mature mRNA 34 9.75e-03 4.09e-02 0.31400 9.32e-02 2.99e-01 3.47e-01 2.51e-03
Platelet Adhesion to exposed collagen 15 1.34e-01 2.89e-01 0.31300 -2.95e-01 -1.04e-01 4.76e-02 4.84e-01
E2F mediated regulation of DNA replication 20 2.62e-02 8.76e-02 0.31200 -2.18e-01 2.24e-01 9.20e-02 8.26e-02
IRAK4 deficiency (TLR2/4) 17 5.40e-02 1.51e-01 0.31200 -1.10e-01 2.92e-01 4.30e-01 3.71e-02
Transport of Ribonucleoproteins into the Host Nucleus 30 1.64e-02 6.01e-02 0.31200 8.07e-02 3.02e-01 4.44e-01 4.25e-03
KEAP1-NFE2L2 pathway 126 2.11e-07 2.63e-06 0.31200 1.94e-01 2.44e-01 1.69e-04 2.22e-06
Vpr-mediated nuclear import of PICs 32 8.93e-03 3.87e-02 0.31100 1.95e-02 3.11e-01 8.48e-01 2.33e-03
Transport of the SLBP independent Mature mRNA 33 1.20e-02 4.66e-02 0.31100 9.32e-02 2.97e-01 3.54e-01 3.15e-03
mRNA Splicing - Major Pathway 189 1.19e-10 3.85e-09 0.31100 2.37e-01 2.01e-01 1.81e-08 1.81e-06
Cleavage of the damaged purine 11 1.44e-01 3.03e-01 0.31000 -1.62e-01 2.64e-01 3.51e-01 1.29e-01
Depurination 11 1.44e-01 3.03e-01 0.31000 -1.62e-01 2.64e-01 3.51e-01 1.29e-01
Recognition and association of DNA glycosylase with site containing an affected purine 11 1.44e-01 3.03e-01 0.31000 -1.62e-01 2.64e-01 3.51e-01 1.29e-01
Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 13 1.34e-01 2.89e-01 0.30900 -3.20e-02 3.07e-01 8.42e-01 5.51e-02
Rev-mediated nuclear export of HIV RNA 33 1.09e-02 4.40e-02 0.30900 6.36e-02 3.02e-01 5.27e-01 2.65e-03
Postmitotic nuclear pore complex (NPC) reformation 26 4.04e-02 1.25e-01 0.30900 1.54e-01 2.68e-01 1.74e-01 1.81e-02
SUMOylation of DNA replication proteins 44 3.26e-03 1.72e-02 0.30900 1.02e-01 2.91e-01 2.40e-01 8.30e-04
CLEC7A (Dectin-1) signaling 96 1.10e-05 1.02e-04 0.30800 2.14e-01 2.22e-01 2.94e-04 1.66e-04
Interactions of Vpr with host cellular proteins 33 9.21e-03 3.93e-02 0.30800 3.13e-02 3.06e-01 7.56e-01 2.31e-03
Formation of HIV-1 elongation complex containing HIV-1 Tat 38 1.10e-02 4.40e-02 0.30800 2.18e-01 2.17e-01 1.99e-02 2.05e-02
HIV Transcription Elongation 38 1.10e-02 4.40e-02 0.30800 2.18e-01 2.17e-01 1.99e-02 2.05e-02
Tat-mediated elongation of the HIV-1 transcript 38 1.10e-02 4.40e-02 0.30800 2.18e-01 2.17e-01 1.99e-02 2.05e-02
SARS-CoV-1 Infection 134 1.12e-07 1.49e-06 0.30800 1.82e-01 2.48e-01 2.69e-04 7.07e-07
Signaling by activated point mutants of FGFR1 11 2.71e-01 4.64e-01 0.30800 2.22e-01 2.13e-01 2.03e-01 2.21e-01
NFE2L2 regulating tumorigenic genes 11 2.33e-01 4.19e-01 0.30800 8.39e-02 2.96e-01 6.30e-01 8.93e-02
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA 17 1.08e-01 2.50e-01 0.30700 2.94e-01 9.12e-02 3.61e-02 5.15e-01
Nuclear Pore Complex (NPC) Disassembly 34 8.37e-03 3.69e-02 0.30700 3.47e-02 3.05e-01 7.26e-01 2.06e-03
Negative epigenetic regulation of rRNA expression 45 3.97e-03 1.99e-02 0.30700 1.46e-01 2.70e-01 9.03e-02 1.70e-03
Energy dependent regulation of mTOR by LKB1-AMPK 28 1.24e-02 4.77e-02 0.30700 -5.41e-02 3.02e-01 6.20e-01 5.67e-03
Viral Messenger RNA Synthesis 42 6.64e-03 2.99e-02 0.30700 1.77e-01 2.50e-01 4.70e-02 4.98e-03
Formation of apoptosome 10 1.81e-01 3.54e-01 0.30600 2.66e-01 -1.51e-01 1.45e-01 4.08e-01
Regulation of the apoptosome activity 10 1.81e-01 3.54e-01 0.30600 2.66e-01 -1.51e-01 1.45e-01 4.08e-01
HIV Transcription Initiation 43 6.64e-03 2.99e-02 0.30500 2.19e-01 2.13e-01 1.31e-02 1.57e-02
RNA Polymerase II HIV Promoter Escape 43 6.64e-03 2.99e-02 0.30500 2.19e-01 2.13e-01 1.31e-02 1.57e-02
RNA Polymerase II Promoter Escape 43 6.64e-03 2.99e-02 0.30500 2.19e-01 2.13e-01 1.31e-02 1.57e-02
RNA Polymerase II Transcription Initiation 43 6.64e-03 2.99e-02 0.30500 2.19e-01 2.13e-01 1.31e-02 1.57e-02
RNA Polymerase II Transcription Initiation And Promoter Clearance 43 6.64e-03 2.99e-02 0.30500 2.19e-01 2.13e-01 1.31e-02 1.57e-02
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening 43 6.64e-03 2.99e-02 0.30500 2.19e-01 2.13e-01 1.31e-02 1.57e-02
Formation of TC-NER Pre-Incision Complex 51 2.61e-03 1.42e-02 0.30500 2.28e-01 2.02e-01 4.79e-03 1.25e-02
Assembly of active LPL and LIPC lipase complexes 17 5.28e-02 1.49e-01 0.30500 2.26e-01 -2.04e-01 1.06e-01 1.45e-01
Negative regulation of FGFR1 signaling 32 2.45e-02 8.40e-02 0.30400 2.14e-01 2.16e-01 3.59e-02 3.45e-02
S Phase 157 1.20e-08 2.21e-07 0.30400 1.85e-01 2.41e-01 6.42e-05 1.75e-07
SUMOylation of ubiquitinylation proteins 37 7.92e-03 3.51e-02 0.30400 7.09e-02 2.95e-01 4.55e-01 1.89e-03
The citric acid (TCA) cycle and respiratory electron transport 143 5.58e-08 8.05e-07 0.30300 1.64e-01 2.54e-01 7.08e-04 1.47e-07
NOTCH3 Activation and Transmission of Signal to the Nucleus 25 3.68e-02 1.16e-01 0.30100 2.97e-01 5.29e-02 1.02e-02 6.47e-01
Transport of Mature mRNA derived from an Intron-Containing Transcript 67 4.89e-04 3.35e-03 0.30100 1.93e-01 2.31e-01 6.34e-03 1.06e-03
Nucleotide biosynthesis 14 1.54e-01 3.19e-01 0.30000 3.95e-02 2.98e-01 7.98e-01 5.36e-02
TP53 Regulates Transcription of Death Receptors and Ligands 12 2.56e-01 4.46e-01 0.30000 1.86e-01 2.35e-01 2.64e-01 1.58e-01
VLDLR internalisation and degradation 16 1.65e-01 3.32e-01 0.30000 2.01e-01 2.22e-01 1.64e-01 1.24e-01
tRNA Aminoacylation 24 4.39e-02 1.32e-01 0.30000 5.38e-02 2.95e-01 6.48e-01 1.24e-02
Positive epigenetic regulation of rRNA expression 43 7.06e-03 3.17e-02 0.30000 1.59e-01 2.54e-01 7.14e-02 3.94e-03
Glutamate and glutamine metabolism 12 1.77e-01 3.50e-01 0.29900 -2.86e-02 2.97e-01 8.64e-01 7.45e-02
Negative regulation of FGFR3 signaling 28 4.21e-02 1.28e-01 0.29800 1.70e-01 2.45e-01 1.20e-01 2.48e-02
HIV Infection 216 3.08e-11 1.06e-09 0.29800 1.75e-01 2.42e-01 9.35e-06 8.93e-10
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells 15 1.85e-01 3.59e-01 0.29800 1.77e-01 2.40e-01 2.34e-01 1.08e-01
Formation of Senescence-Associated Heterochromatin Foci (SAHF) 11 1.77e-01 3.50e-01 0.29800 -1.15e-01 2.75e-01 5.10e-01 1.15e-01
Initiation of Nuclear Envelope (NE) Reformation 18 9.45e-02 2.29e-01 0.29700 3.70e-02 2.95e-01 7.86e-01 3.03e-02
Interaction between L1 and Ankyrins 30 1.17e-02 4.56e-02 0.29700 6.28e-02 -2.90e-01 5.52e-01 5.96e-03
RNA Polymerase I Transcription Termination 27 5.13e-02 1.46e-01 0.29600 2.14e-01 2.05e-01 5.44e-02 6.52e-02
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 16 1.52e-01 3.15e-01 0.29500 1.09e-01 2.75e-01 4.51e-01 5.72e-02
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 19 1.02e-01 2.43e-01 0.29500 8.85e-02 2.81e-01 5.04e-01 3.38e-02
Ketone body metabolism 10 3.35e-01 5.42e-01 0.29500 -2.26e-01 -1.89e-01 2.16e-01 3.01e-01
mRNA 3’-end processing 53 3.15e-03 1.67e-02 0.29500 2.01e-01 2.16e-01 1.15e-02 6.60e-03
IRE1alpha activates chaperones 49 2.76e-03 1.50e-02 0.29400 8.60e-02 2.82e-01 2.97e-01 6.46e-04
NOTCH4 Activation and Transmission of Signal to the Nucleus 11 2.14e-01 3.96e-01 0.29400 2.93e-01 -2.87e-02 9.24e-02 8.69e-01
Transport of Mature Transcript to Cytoplasm 76 2.36e-04 1.77e-03 0.29400 1.69e-01 2.41e-01 1.09e-02 2.78e-04
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) 12 2.65e-01 4.57e-01 0.29400 2.47e-01 1.59e-01 1.38e-01 3.41e-01
HIV Life Cycle 139 1.29e-07 1.68e-06 0.29400 1.23e-01 2.67e-01 1.20e-02 5.46e-08
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) 30 2.97e-02 9.78e-02 0.29400 1.03e-01 2.75e-01 3.31e-01 9.06e-03
Regulation of Glucokinase by Glucokinase Regulatory Protein 30 2.97e-02 9.78e-02 0.29400 1.03e-01 2.75e-01 3.31e-01 9.06e-03
Heme degradation 16 1.31e-01 2.85e-01 0.29400 -4.10e-02 -2.91e-01 7.77e-01 4.40e-02
KSRP (KHSRP) binds and destabilizes mRNA 17 8.68e-02 2.17e-01 0.29300 2.88e-01 -5.46e-02 3.96e-02 6.97e-01
Formation of Incision Complex in GG-NER 40 9.96e-03 4.17e-02 0.29300 1.13e-01 2.70e-01 2.15e-01 3.07e-03
TP53 Regulates Transcription of DNA Repair Genes 57 1.93e-03 1.13e-02 0.29300 2.45e-01 1.62e-01 1.40e-03 3.46e-02
Xenobiotics 24 7.56e-02 1.96e-01 0.29300 -2.00e-01 -2.14e-01 9.04e-02 6.91e-02
Transcriptional regulation by small RNAs 46 5.99e-03 2.81e-02 0.29300 1.43e-01 2.55e-01 9.24e-02 2.72e-03
Formation of HIV elongation complex in the absence of HIV Tat 40 1.34e-02 5.07e-02 0.29300 2.24e-01 1.88e-01 1.40e-02 3.95e-02
Passive transport by Aquaporins 13 2.33e-01 4.18e-01 0.29300 -1.36e-01 -2.59e-01 3.95e-01 1.06e-01
XBP1(S) activates chaperone genes 47 3.75e-03 1.90e-02 0.29200 8.07e-02 2.80e-01 3.38e-01 8.76e-04
Attenuation phase 25 6.39e-02 1.72e-01 0.29100 2.53e-01 1.44e-01 2.84e-02 2.12e-01
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest 14 1.58e-01 3.23e-01 0.29100 3.03e-03 2.91e-01 9.84e-01 5.91e-02
STING mediated induction of host immune responses 13 2.46e-01 4.35e-01 0.29100 2.39e-01 1.67e-01 1.36e-01 2.98e-01
Negative regulation of MAPK pathway 41 9.54e-03 4.03e-02 0.29100 1.12e-01 2.68e-01 2.13e-01 2.93e-03
RNA Polymerase II Pre-transcription Events 72 4.87e-04 3.35e-03 0.29100 2.13e-01 1.98e-01 1.73e-03 3.73e-03
mRNA Capping 28 5.16e-02 1.47e-01 0.29000 2.18e-01 1.93e-01 4.63e-02 7.78e-02
Eicosanoid ligand-binding receptors 14 1.16e-01 2.64e-01 0.28900 -1.59e-01 2.42e-01 3.02e-01 1.17e-01
Transcription of the HIV genome 62 1.55e-03 9.21e-03 0.28900 2.05e-01 2.03e-01 5.14e-03 5.68e-03
Formation of the Early Elongation Complex 32 3.61e-02 1.15e-01 0.28800 2.11e-01 1.96e-01 3.92e-02 5.48e-02
Formation of the HIV-1 Early Elongation Complex 32 3.61e-02 1.15e-01 0.28800 2.11e-01 1.96e-01 3.92e-02 5.48e-02
TBC/RABGAPs 42 7.16e-03 3.20e-02 0.28700 6.20e-02 2.80e-01 4.87e-01 1.68e-03
ISG15 antiviral mechanism 71 5.87e-04 3.85e-03 0.28700 1.58e-01 2.39e-01 2.13e-02 4.90e-04
Transcription of E2F targets under negative control by DREAM complex 19 1.32e-01 2.87e-01 0.28700 1.41e-01 2.49e-01 2.86e-01 5.99e-02
Formation of RNA Pol II elongation complex 52 4.58e-03 2.22e-02 0.28700 2.26e-01 1.76e-01 4.72e-03 2.84e-02
RNA Polymerase II Transcription Elongation 52 4.58e-03 2.22e-02 0.28700 2.26e-01 1.76e-01 4.72e-03 2.84e-02
Purine catabolism 17 1.38e-01 2.95e-01 0.28600 2.78e-01 6.43e-02 4.68e-02 6.46e-01
MAPK6/MAPK4 signaling 89 1.11e-04 8.97e-04 0.28500 2.28e-01 1.70e-01 1.93e-04 5.62e-03
Negative regulation of FLT3 15 2.18e-01 4.01e-01 0.28400 2.18e-01 1.82e-01 1.44e-01 2.22e-01
Role of LAT2/NTAL/LAB on calcium mobilization 16 1.48e-01 3.08e-01 0.28400 -2.82e-01 -3.50e-02 5.12e-02 8.09e-01
RNA Polymerase III Abortive And Retractive Initiation 41 1.31e-02 5.00e-02 0.28300 1.26e-01 2.54e-01 1.63e-01 4.87e-03
RNA Polymerase III Transcription 41 1.31e-02 5.00e-02 0.28300 1.26e-01 2.54e-01 1.63e-01 4.87e-03
G0 and Early G1 27 5.22e-02 1.48e-01 0.28300 9.54e-02 2.67e-01 3.91e-01 1.65e-02
Purine salvage 12 2.69e-01 4.60e-01 0.28300 9.32e-02 2.67e-01 5.76e-01 1.09e-01
TRAF6 mediated NF-kB activation 23 9.34e-02 2.28e-01 0.28300 1.45e-01 2.43e-01 2.28e-01 4.39e-02
TP53 Regulates Metabolic Genes 83 9.69e-05 7.88e-04 0.28200 7.67e-02 2.72e-01 2.27e-01 1.85e-05
Cytosolic sensors of pathogen-associated DNA 60 2.51e-03 1.39e-02 0.28200 2.03e-01 1.96e-01 6.45e-03 8.63e-03
Downregulation of ERBB2:ERBB3 signaling 13 2.55e-01 4.45e-01 0.28200 1.19e-01 2.55e-01 4.56e-01 1.11e-01
Processing of Capped Intronless Pre-mRNA 28 4.14e-02 1.27e-01 0.28200 5.90e-02 2.75e-01 5.89e-01 1.16e-02
Interleukin-1 signaling 109 2.07e-05 1.84e-04 0.28100 2.05e-01 1.93e-01 2.16e-04 5.05e-04
TCR signaling 112 7.91e-06 7.43e-05 0.28100 2.56e-01 1.16e-01 2.74e-06 3.39e-02
Cell Cycle Checkpoints 248 1.47e-11 5.18e-10 0.28100 1.49e-01 2.38e-01 5.04e-05 1.01e-10
Inactivation of CSF3 (G-CSF) signaling 23 1.04e-01 2.45e-01 0.28000 1.85e-01 2.11e-01 1.25e-01 8.02e-02
Nuclear Events (kinase and transcription factor activation) 60 2.14e-03 1.21e-02 0.28000 1.30e-01 2.48e-01 8.13e-02 8.85e-04
Processing of DNA double-strand break ends 61 2.01e-03 1.15e-02 0.28000 1.35e-01 2.45e-01 6.82e-02 9.18e-04
Regulation of CDH11 mRNA translation by microRNAs 10 2.74e-01 4.66e-01 0.27900 -2.76e-01 4.51e-02 1.31e-01 8.05e-01
Mitotic Metaphase and Anaphase 222 3.62e-10 9.91e-09 0.27900 1.66e-01 2.25e-01 2.09e-05 7.79e-09
Elevation of cytosolic Ca2+ levels 16 9.92e-02 2.39e-01 0.27900 -2.13e-01 1.80e-01 1.40e-01 2.14e-01
Diseases associated with the TLR signaling cascade 29 2.21e-02 7.65e-02 0.27900 -6.38e-02 2.71e-01 5.52e-01 1.15e-02
Diseases of Immune System 29 2.21e-02 7.65e-02 0.27900 -6.38e-02 2.71e-01 5.52e-01 1.15e-02
HCMV Late Events 54 2.36e-03 1.32e-02 0.27900 5.24e-02 2.74e-01 5.05e-01 5.05e-04
Activation of SMO 17 1.83e-01 3.57e-01 0.27800 1.45e-01 2.38e-01 3.01e-01 8.97e-02
Late Phase of HIV Life Cycle 126 2.82e-06 2.85e-05 0.27800 1.24e-01 2.49e-01 1.58e-02 1.37e-06
Unfolded Protein Response (UPR) 91 1.53e-04 1.21e-03 0.27800 1.87e-01 2.05e-01 1.99e-03 7.21e-04
Metabolism of non-coding RNA 50 4.91e-03 2.34e-02 0.27800 8.45e-02 2.64e-01 3.01e-01 1.21e-03
snRNP Assembly 50 4.91e-03 2.34e-02 0.27800 8.45e-02 2.64e-01 3.01e-01 1.21e-03
Collagen biosynthesis and modifying enzymes 65 1.47e-03 8.88e-03 0.27800 -1.31e-01 -2.45e-01 6.79e-02 6.42e-04
Cellular response to chemical stress 207 2.05e-09 4.34e-08 0.27700 1.69e-01 2.20e-01 2.85e-05 4.49e-08
RNA Polymerase II Transcription Termination 62 2.52e-03 1.39e-02 0.27700 1.82e-01 2.09e-01 1.30e-02 4.39e-03
Regulated Necrosis 56 4.06e-03 2.02e-02 0.27700 1.45e-01 2.36e-01 6.05e-02 2.28e-03
Mitotic Anaphase 221 5.85e-10 1.52e-08 0.27700 1.63e-01 2.23e-01 2.79e-05 1.06e-08
IRF3-mediated induction of type I IFN 11 3.37e-01 5.44e-01 0.27600 2.41e-01 1.35e-01 1.67e-01 4.37e-01
Signaling by FGFR2 IIIa TM 19 1.58e-01 3.23e-01 0.27600 2.29e-01 1.54e-01 8.40e-02 2.45e-01
Na+/Cl- dependent neurotransmitter transporters 18 8.02e-02 2.05e-01 0.27600 2.28e-01 -1.55e-01 9.40e-02 2.54e-01
Chemokine receptors bind chemokines 56 4.83e-04 3.35e-03 0.27500 2.46e-01 -1.23e-01 1.46e-03 1.10e-01
mTORC1-mediated signalling 23 7.61e-02 1.97e-01 0.27500 3.50e-02 2.73e-01 7.71e-01 2.36e-02
DNA Double Strand Break Response 42 1.83e-02 6.58e-02 0.27500 1.69e-01 2.17e-01 5.87e-02 1.49e-02
RNA polymerase II transcribes snRNA genes 77 5.50e-04 3.66e-03 0.27500 1.36e-01 2.38e-01 3.83e-02 2.98e-04
Nucleotide-like (purinergic) receptors 13 2.62e-01 4.54e-01 0.27400 -2.59e-01 -8.97e-02 1.05e-01 5.76e-01
WNT5A-dependent internalization of FZD4 15 2.44e-01 4.33e-01 0.27400 1.92e-01 1.95e-01 1.98e-01 1.90e-01
Regulation of TP53 Activity through Phosphorylation 88 2.35e-04 1.76e-03 0.27400 1.60e-01 2.22e-01 9.49e-03 3.09e-04
FGFR2 alternative splicing 26 8.58e-02 2.16e-01 0.27300 2.17e-01 1.67e-01 5.56e-02 1.41e-01
Interleukin-10 signaling 45 1.24e-02 4.77e-02 0.27300 2.42e-01 1.28e-01 5.03e-03 1.38e-01
p38MAPK events 13 1.82e-01 3.55e-01 0.27300 -9.28e-02 2.57e-01 5.63e-01 1.08e-01
Fanconi Anemia Pathway 36 3.19e-02 1.04e-01 0.27300 1.44e-01 2.32e-01 1.35e-01 1.60e-02
Acetylcholine regulates insulin secretion 10 2.55e-01 4.45e-01 0.27200 -2.18e-01 1.62e-01 2.32e-01 3.75e-01
Regulation of IFNA/IFNB signaling 22 1.06e-01 2.48e-01 0.27100 -7.98e-02 -2.59e-01 5.17e-01 3.53e-02
FOXO-mediated transcription of cell death genes 15 2.31e-01 4.18e-01 0.27100 2.48e-01 1.09e-01 9.64e-02 4.65e-01
Phospholipase C-mediated cascade: FGFR1 16 2.11e-01 3.93e-01 0.27100 2.46e-01 1.12e-01 8.82e-02 4.36e-01
MTOR signalling 40 8.49e-03 3.73e-02 0.27100 -3.16e-02 2.69e-01 7.30e-01 3.27e-03
Gastrulation 113 3.31e-05 2.90e-04 0.27000 1.74e-01 2.06e-01 1.40e-03 1.49e-04
Nuclear Envelope Breakdown 50 3.52e-03 1.81e-02 0.27000 1.82e-03 2.70e-01 9.82e-01 9.65e-04
Oncogene Induced Senescence 35 3.49e-02 1.12e-01 0.26900 1.16e-01 2.43e-01 2.36e-01 1.27e-02
RAF-independent MAPK1/3 activation 22 1.28e-01 2.81e-01 0.26900 2.30e-01 1.40e-01 6.19e-02 2.54e-01
Tryptophan catabolism 12 3.12e-01 5.15e-01 0.26900 -2.48e-01 -1.04e-01 1.37e-01 5.33e-01
Collagen degradation 61 2.90e-03 1.56e-02 0.26800 -1.09e-01 -2.45e-01 1.41e-01 9.16e-04
Formation of definitive endoderm 15 1.46e-01 3.07e-01 0.26800 -1.06e-01 2.46e-01 4.79e-01 9.83e-02
Separation of Sister Chromatids 179 1.15e-07 1.51e-06 0.26800 1.88e-01 1.90e-01 1.35e-05 1.14e-05
Cargo concentration in the ER 32 2.13e-02 7.47e-02 0.26700 -5.47e-02 2.62e-01 5.92e-01 1.03e-02
VEGFR2 mediated vascular permeability 26 4.24e-02 1.28e-01 0.26700 -2.59e-01 6.53e-02 2.22e-02 5.65e-01
Protein localization 147 1.74e-06 1.87e-05 0.26700 1.54e-01 2.18e-01 1.27e-03 4.85e-06
Regulation of TP53 Activity through Association with Co-factors 14 1.87e-01 3.62e-01 0.26600 -2.59e-01 6.02e-02 9.34e-02 6.97e-01
RNA Polymerase I Promoter Escape 28 8.36e-02 2.11e-01 0.26600 1.99e-01 1.77e-01 6.89e-02 1.06e-01
Selective autophagy 78 9.87e-04 6.21e-03 0.26600 1.67e-01 2.07e-01 1.09e-02 1.58e-03
SUMOylation of chromatin organization proteins 54 2.34e-03 1.31e-02 0.26500 -1.90e-02 2.64e-01 8.09e-01 7.86e-04
RUNX3 regulates NOTCH signaling 13 3.07e-01 5.09e-01 0.26500 2.30e-01 1.31e-01 1.51e-01 4.12e-01
Trafficking and processing of endosomal TLR 11 3.55e-01 5.61e-01 0.26500 1.00e-01 2.45e-01 5.65e-01 1.60e-01
NOTCH2 intracellular domain regulates transcription 11 3.82e-01 5.88e-01 0.26400 1.81e-01 1.93e-01 2.99e-01 2.68e-01
Cytochrome c-mediated apoptotic response 12 2.13e-01 3.96e-01 0.26400 2.16e-01 -1.51e-01 1.94e-01 3.64e-01
HSF1 activation 27 9.34e-02 2.28e-01 0.26400 2.06e-01 1.65e-01 6.34e-02 1.39e-01
SUMOylation of RNA binding proteins 45 1.05e-02 4.30e-02 0.26400 4.49e-02 2.60e-01 6.02e-01 2.53e-03
Signaling by NOTCH3 48 1.04e-02 4.28e-02 0.26300 2.50e-01 8.36e-02 2.77e-03 3.16e-01
Zygotic genome activation (ZGA) 15 1.90e-01 3.65e-01 0.26300 1.95e-02 -2.62e-01 8.96e-01 7.89e-02
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks 41 2.88e-02 9.53e-02 0.26200 1.70e-01 2.00e-01 6.00e-02 2.66e-02
Constitutive Signaling by NOTCH1 HD Domain Mutants 15 2.18e-01 4.01e-01 0.26200 2.60e-01 3.61e-02 8.16e-02 8.08e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer 15 2.18e-01 4.01e-01 0.26200 2.60e-01 3.61e-02 8.16e-02 8.08e-01
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 53 7.70e-03 3.43e-02 0.26200 1.02e-01 2.41e-01 1.99e-01 2.36e-03
Ub-specific processing proteases 152 2.07e-06 2.17e-05 0.26200 1.63e-01 2.05e-01 5.13e-04 1.28e-05
Signaling by WNT in cancer 32 1.72e-02 6.23e-02 0.26200 -1.59e-01 2.08e-01 1.21e-01 4.14e-02
MET activates RAP1 and RAC1 11 2.50e-01 4.39e-01 0.26200 -2.19e-01 1.43e-01 2.07e-01 4.13e-01
HDL remodeling 10 3.97e-01 6.02e-01 0.26200 -9.68e-02 -2.43e-01 5.96e-01 1.83e-01
Endosomal Sorting Complex Required For Transport (ESCRT) 31 4.43e-02 1.32e-01 0.26200 3.86e-02 2.59e-01 7.10e-01 1.26e-02
SHC-mediated cascade:FGFR3 17 1.97e-01 3.77e-01 0.26100 6.99e-02 2.52e-01 6.18e-01 7.25e-02
NFE2L2 regulating anti-oxidant/detoxification enzymes 19 1.03e-01 2.45e-01 0.26100 -8.83e-02 2.46e-01 5.05e-01 6.38e-02
NOD1/2 Signaling Pathway 33 4.43e-02 1.32e-01 0.26000 7.29e-02 2.50e-01 4.68e-01 1.30e-02
Chaperone Mediated Autophagy 20 1.49e-01 3.10e-01 0.26000 2.52e-01 6.48e-02 5.13e-02 6.16e-01
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA 17 1.69e-01 3.37e-01 0.26000 2.60e-01 3.41e-03 6.37e-02 9.81e-01
MET promotes cell motility 41 3.12e-02 1.02e-01 0.26000 -1.75e-01 -1.92e-01 5.22e-02 3.36e-02
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation 35 4.65e-02 1.37e-01 0.25900 1.24e-01 2.28e-01 2.05e-01 1.95e-02
tRNA processing 98 2.39e-04 1.78e-03 0.25900 1.47e-01 2.13e-01 1.20e-02 2.62e-04
SHC-mediated cascade:FGFR1 21 1.70e-01 3.38e-01 0.25900 1.56e-01 2.06e-01 2.15e-01 1.02e-01
Hedgehog ‘off’ state 110 7.72e-05 6.38e-04 0.25800 2.24e-01 1.29e-01 4.90e-05 1.98e-02
FGFR2c ligand binding and activation 12 3.66e-01 5.74e-01 0.25800 1.60e-01 2.02e-01 3.38e-01 2.25e-01
Signaling by FGFR2 72 2.55e-03 1.39e-02 0.25800 1.85e-01 1.79e-01 6.62e-03 8.57e-03
Transcriptional regulation of pluripotent stem cells 30 2.52e-02 8.57e-02 0.25700 -1.62e-01 2.00e-01 1.25e-01 5.82e-02
DNA Damage/Telomere Stress Induced Senescence 28 6.39e-02 1.72e-01 0.25700 3.01e-02 2.55e-01 7.83e-01 1.94e-02
Transcriptional Regulation by VENTX 41 1.57e-02 5.76e-02 0.25600 2.67e-03 2.56e-01 9.76e-01 4.61e-03
ZBP1(DAI) mediated induction of type I IFNs 20 1.95e-01 3.74e-01 0.25500 1.92e-01 1.68e-01 1.38e-01 1.92e-01
Organic anion transporters 10 3.02e-01 5.03e-01 0.25500 1.38e-01 -2.15e-01 4.50e-01 2.40e-01
FGFR1c ligand binding and activation 13 3.47e-01 5.56e-01 0.25400 1.66e-01 1.93e-01 2.99e-01 2.29e-01
TAK1-dependent IKK and NF-kappa-B activation 41 3.59e-02 1.14e-01 0.25300 1.54e-01 2.01e-01 8.80e-02 2.57e-02
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol 24 1.24e-01 2.77e-01 0.25300 -2.37e-01 -9.04e-02 4.48e-02 4.43e-01
NOTCH3 Intracellular Domain Regulates Transcription 24 1.41e-01 2.99e-01 0.25300 2.08e-01 1.45e-01 7.82e-02 2.20e-01
Detoxification of Reactive Oxygen Species 35 6.05e-02 1.67e-01 0.25300 1.81e-01 1.77e-01 6.35e-02 7.06e-02
Phase 0 - rapid depolarisation 31 3.48e-02 1.12e-01 0.25300 5.71e-02 -2.46e-01 5.82e-01 1.76e-02
Negative regulation of FGFR4 signaling 30 8.83e-02 2.20e-01 0.25300 1.48e-01 2.05e-01 1.60e-01 5.23e-02
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism 11 3.51e-01 5.58e-01 0.25300 2.78e-02 2.51e-01 8.73e-01 1.49e-01
HDR through MMEJ (alt-NHEJ) 11 3.63e-01 5.71e-01 0.25200 4.79e-02 2.48e-01 7.83e-01 1.55e-01
Branched-chain amino acid catabolism 20 1.55e-01 3.20e-01 0.25200 3.82e-02 2.49e-01 7.67e-01 5.37e-02
Deposition of new CENPA-containing nucleosomes at the centromere 26 1.04e-01 2.45e-01 0.25200 8.07e-02 2.39e-01 4.76e-01 3.52e-02
Nucleosome assembly 26 1.04e-01 2.45e-01 0.25200 8.07e-02 2.39e-01 4.76e-01 3.52e-02
Fertilization 26 7.98e-02 2.05e-01 0.25200 -9.25e-03 -2.51e-01 9.35e-01 2.65e-02
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation 12 2.58e-01 4.49e-01 0.25200 -2.30e-01 1.02e-01 1.68e-01 5.42e-01
Signaling by EGFR in Cancer 25 1.28e-01 2.81e-01 0.25100 1.17e-01 2.22e-01 3.12e-01 5.47e-02
Synthesis of PIPs at the late endosome membrane 10 3.11e-01 5.14e-01 0.25000 -1.87e-01 1.66e-01 3.06e-01 3.62e-01
G2/M DNA damage checkpoint 58 7.17e-03 3.20e-02 0.25000 8.37e-02 2.35e-01 2.70e-01 1.92e-03
Mitotic G2-G2/M phases 191 3.47e-07 4.17e-06 0.24900 1.58e-01 1.93e-01 1.70e-04 4.00e-06
Activation of PPARGC1A (PGC-1alpha) by phosphorylation 10 4.22e-01 6.25e-01 0.24900 7.34e-02 2.38e-01 6.88e-01 1.92e-01
DNA Damage Bypass 46 1.92e-02 6.85e-02 0.24900 7.13e-02 2.38e-01 4.03e-01 5.16e-03
Acyl chain remodelling of PI 16 1.75e-01 3.48e-01 0.24800 8.89e-02 -2.32e-01 5.38e-01 1.08e-01
Mitochondrial tRNA aminoacylation 18 2.22e-01 4.04e-01 0.24800 8.50e-02 2.33e-01 5.32e-01 8.72e-02
The NLRP3 inflammasome 16 2.49e-01 4.39e-01 0.24800 6.07e-02 2.40e-01 6.74e-01 9.62e-02
Biosynthesis of specialized proresolving mediators (SPMs) 19 1.16e-01 2.64e-01 0.24800 -1.45e-01 2.00e-01 2.73e-01 1.30e-01
Induction of Cell-Cell Fusion 12 3.88e-01 5.94e-01 0.24800 -1.29e-01 -2.12e-01 4.41e-01 2.04e-01
NOTCH4 Intracellular Domain Regulates Transcription 19 2.32e-01 4.18e-01 0.24800 1.64e-01 1.86e-01 2.16e-01 1.61e-01
G2/M Transition 189 5.07e-07 5.92e-06 0.24800 1.56e-01 1.92e-01 2.15e-04 5.12e-06
Inhibition of replication initiation of damaged DNA by RB1/E2F1 11 3.67e-01 5.74e-01 0.24700 2.73e-02 2.46e-01 8.75e-01 1.58e-01
RHOJ GTPase cycle 51 8.98e-03 3.88e-02 0.24700 -2.46e-01 -1.58e-02 2.34e-03 8.45e-01
Toll Like Receptor 3 (TLR3) Cascade 99 3.73e-04 2.62e-03 0.24600 1.07e-01 2.22e-01 6.58e-02 1.37e-04
Apoptotic factor-mediated response 17 2.38e-01 4.26e-01 0.24600 2.36e-01 6.90e-02 9.16e-02 6.22e-01
Signaling by FGFR3 39 4.73e-02 1.38e-01 0.24600 1.23e-01 2.13e-01 1.84e-01 2.13e-02
Free fatty acids regulate insulin secretion 10 3.85e-01 5.92e-01 0.24600 -2.46e-01 7.55e-03 1.78e-01 9.67e-01
Recognition of DNA damage by PCNA-containing replication complex 29 9.95e-02 2.39e-01 0.24500 1.04e-01 2.22e-01 3.31e-01 3.85e-02
Negative regulators of DDX58/IFIH1 signaling 33 7.02e-02 1.83e-01 0.24500 9.59e-02 2.26e-01 3.40e-01 2.48e-02
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases 14 2.17e-01 4.01e-01 0.24400 -2.09e-01 1.26e-01 1.76e-01 4.13e-01
Diseases associated with visual transduction 11 4.40e-01 6.40e-01 0.24400 -1.76e-01 -1.69e-01 3.13e-01 3.31e-01
Diseases of the neuronal system 11 4.40e-01 6.40e-01 0.24400 -1.76e-01 -1.69e-01 3.13e-01 3.31e-01
Retinoid cycle disease events 11 4.40e-01 6.40e-01 0.24400 -1.76e-01 -1.69e-01 3.13e-01 3.31e-01
Recycling of bile acids and salts 18 2.60e-01 4.52e-01 0.24300 -1.43e-01 -1.97e-01 2.94e-01 1.49e-01
Negative regulation of FGFR2 signaling 33 8.62e-02 2.16e-01 0.24300 1.53e-01 1.88e-01 1.27e-01 6.11e-02
HSF1-dependent transactivation 35 6.52e-02 1.73e-01 0.24200 2.21e-01 9.95e-02 2.37e-02 3.08e-01
FCGR activation 12 2.75e-01 4.66e-01 0.24200 1.29e-01 -2.05e-01 4.38e-01 2.19e-01
TP53 Regulates Transcription of Cell Death Genes 42 2.78e-02 9.23e-02 0.24200 4.15e-02 2.39e-01 6.42e-01 7.45e-03
Cellular Senescence 130 1.58e-05 1.42e-04 0.24200 3.93e-02 2.39e-01 4.39e-01 2.60e-06
Paracetamol ADME 27 1.21e-01 2.73e-01 0.24100 -2.22e-01 -9.38e-02 4.54e-02 3.99e-01
Cyclin A/B1/B2 associated events during G2/M transition 24 1.51e-01 3.13e-01 0.24100 8.43e-02 2.26e-01 4.75e-01 5.55e-02
Laminin interactions 28 1.26e-01 2.78e-01 0.24100 -1.33e-01 -2.01e-01 2.23e-01 6.58e-02
Chylomicron remodeling 10 4.23e-01 6.25e-01 0.24000 -2.52e-02 -2.39e-01 8.90e-01 1.91e-01
RHO GTPases Activate WASPs and WAVEs 34 8.46e-02 2.13e-01 0.23900 1.94e-01 1.40e-01 5.03e-02 1.57e-01
Cell recruitment (pro-inflammatory response) 26 1.23e-01 2.75e-01 0.23900 5.92e-02 2.32e-01 6.01e-01 4.09e-02
Purinergic signaling in leishmaniasis infection 26 1.23e-01 2.75e-01 0.23900 5.92e-02 2.32e-01 6.01e-01 4.09e-02
Metabolism of cofactors 19 2.17e-01 4.01e-01 0.23800 5.58e-02 2.31e-01 6.74e-01 8.07e-02
Formation of axial mesoderm 13 2.66e-01 4.58e-01 0.23800 2.15e-01 -1.03e-01 1.80e-01 5.22e-01
RNA Polymerase I Transcription 47 2.99e-02 9.81e-02 0.23800 1.03e-01 2.14e-01 2.21e-01 1.10e-02
ALK mutants bind TKIs 12 3.33e-01 5.40e-01 0.23800 -2.37e-01 2.38e-02 1.56e-01 8.86e-01
HDACs deacetylate histones 29 9.01e-02 2.23e-01 0.23700 3.30e-02 2.35e-01 7.59e-01 2.85e-02
Mitotic Telophase/Cytokinesis 10 3.76e-01 5.83e-01 0.23700 -7.56e-02 2.24e-01 6.79e-01 2.20e-01
RNA Polymerase I Promoter Clearance 46 3.42e-02 1.11e-01 0.23700 1.06e-01 2.11e-01 2.12e-01 1.31e-02
Regulation of FZD by ubiquitination 21 1.95e-01 3.74e-01 0.23600 6.50e-02 2.27e-01 6.06e-01 7.18e-02
Regulation of PTEN gene transcription 59 6.15e-03 2.86e-02 0.23600 2.83e-03 2.36e-01 9.70e-01 1.71e-03
Mitotic Prophase 78 1.29e-03 7.86e-03 0.23600 7.41e-03 2.36e-01 9.10e-01 3.21e-04
Ovarian tumor domain proteases 35 6.50e-02 1.73e-01 0.23500 5.96e-02 2.28e-01 5.42e-01 1.97e-02
Cell Cycle, Mitotic 476 1.52e-15 1.09e-13 0.23500 1.04e-01 2.11e-01 9.16e-05 2.76e-15
Signaling by NOTCH2 32 1.01e-01 2.40e-01 0.23500 2.04e-01 1.17e-01 4.53e-02 2.53e-01
M Phase 335 4.01e-11 1.33e-09 0.23500 1.07e-01 2.09e-01 7.23e-04 4.62e-11
Defensins 36 2.79e-02 9.25e-02 0.23500 2.10e-01 -1.06e-01 2.95e-02 2.72e-01
Thromboxane signalling through TP receptor 24 1.02e-01 2.43e-01 0.23500 -6.77e-02 2.25e-01 5.66e-01 5.68e-02
Neutrophil degranulation 456 2.02e-17 2.00e-15 0.23400 -2.78e-03 2.34e-01 9.19e-01 9.74e-18
Global Genome Nucleotide Excision Repair (GG-NER) 81 3.44e-03 1.78e-02 0.23400 1.22e-01 1.99e-01 5.69e-02 1.95e-03
Antiviral mechanism by IFN-stimulated genes 143 5.72e-05 4.88e-04 0.23300 1.45e-01 1.83e-01 2.74e-03 1.61e-04
Translocation of ZAP-70 to Immunological synapse 17 1.78e-01 3.52e-01 0.23300 1.72e-01 -1.58e-01 2.20e-01 2.60e-01
MyD88-independent TLR4 cascade 103 5.27e-04 3.54e-03 0.23300 8.22e-02 2.18e-01 1.50e-01 1.33e-04
TRIF(TICAM1)-mediated TLR4 signaling 103 5.27e-04 3.54e-03 0.23300 8.22e-02 2.18e-01 1.50e-01 1.33e-04
FGFR2 mutant receptor activation 32 1.06e-01 2.48e-01 0.23300 2.02e-01 1.15e-01 4.75e-02 2.60e-01
Pre-NOTCH Processing in Golgi 18 1.65e-01 3.32e-01 0.23300 -1.33e-01 1.91e-01 3.28e-01 1.61e-01
ABC-family proteins mediated transport 98 1.19e-03 7.43e-03 0.23300 1.92e-01 1.32e-01 1.05e-03 2.38e-02
Signaling by FGFR4 40 6.31e-02 1.71e-01 0.23200 1.26e-01 1.95e-01 1.67e-01 3.27e-02
Plasma lipoprotein remodeling 32 6.11e-02 1.68e-01 0.23200 2.30e-02 -2.31e-01 8.22e-01 2.36e-02
Diseases associated with O-glycosylation of proteins 66 1.17e-02 4.56e-02 0.23200 -1.57e-01 -1.71e-01 2.74e-02 1.63e-02
Signal amplification 33 3.94e-02 1.22e-01 0.23100 -1.21e-01 1.97e-01 2.28e-01 5.02e-02
Cytosolic sulfonation of small molecules 21 1.26e-01 2.78e-01 0.23000 -1.74e-01 1.50e-01 1.66e-01 2.33e-01
Maturation of nucleoprotein 9683610 11 3.47e-01 5.55e-01 0.23000 1.13e-01 -2.00e-01 5.18e-01 2.50e-01
COPII-mediated vesicle transport 66 4.46e-03 2.18e-02 0.23000 -8.74e-05 2.30e-01 9.99e-01 1.26e-03
Nucleotide Excision Repair 107 8.65e-04 5.46e-03 0.22900 1.50e-01 1.73e-01 7.21e-03 1.93e-03
Cellular responses to stress 714 7.75e-21 1.54e-18 0.22900 1.36e-01 1.84e-01 4.74e-10 4.02e-17
Cytoprotection by HMOX1 58 1.53e-02 5.66e-02 0.22900 7.24e-02 2.17e-01 3.40e-01 4.18e-03
Nuclear Envelope (NE) Reassembly 73 6.09e-03 2.84e-02 0.22900 9.16e-02 2.10e-01 1.76e-01 1.92e-03
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein 74 4.77e-03 2.29e-02 0.22900 7.02e-02 2.18e-01 2.97e-01 1.18e-03
Telomere Extension By Telomerase 22 2.17e-01 4.01e-01 0.22900 9.44e-02 2.08e-01 4.43e-01 9.10e-02
Transcriptional Regulation by TP53 346 3.78e-11 1.28e-09 0.22800 8.58e-02 2.12e-01 6.06e-03 1.24e-11
Chromosome Maintenance 86 3.31e-03 1.74e-02 0.22800 1.22e-01 1.93e-01 5.09e-02 2.02e-03
SUMOylation of intracellular receptors 29 6.16e-02 1.68e-01 0.22800 -1.41e-01 1.79e-01 1.89e-01 9.59e-02
RIP-mediated NFkB activation via ZBP1 16 3.53e-01 5.59e-01 0.22700 1.41e-01 1.78e-01 3.28e-01 2.17e-01
Biosynthesis of DHA-derived SPMs 17 2.03e-01 3.82e-01 0.22700 -1.13e-01 1.97e-01 4.19e-01 1.60e-01
Transcriptional regulation by RUNX2 116 5.84e-04 3.85e-03 0.22700 1.57e-01 1.63e-01 3.43e-03 2.36e-03
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) 93 1.66e-03 9.78e-03 0.22600 8.47e-02 2.10e-01 1.58e-01 4.64e-04
Cellular responses to stimuli 728 1.12e-20 1.97e-18 0.22600 1.36e-01 1.81e-01 4.22e-10 6.73e-17
RHOV GTPase cycle 36 5.72e-02 1.59e-01 0.22600 -2.26e-01 -1.68e-03 1.88e-02 9.86e-01
FRS-mediated FGFR1 signaling 23 2.30e-01 4.17e-01 0.22600 1.58e-01 1.61e-01 1.89e-01 1.81e-01
Dual Incision in GG-NER 39 6.71e-02 1.76e-01 0.22600 7.85e-02 2.12e-01 3.96e-01 2.21e-02
Miscellaneous transport and binding events 23 2.21e-01 4.03e-01 0.22600 -1.17e-01 -1.93e-01 3.31e-01 1.09e-01
mitochondrial fatty acid beta-oxidation of saturated fatty acids 11 3.84e-01 5.91e-01 0.22600 -5.56e-02 2.19e-01 7.49e-01 2.09e-01
MET receptor recycling 10 3.87e-01 5.93e-01 0.22600 -1.55e-01 1.64e-01 3.97e-01 3.68e-01
Cell Cycle 601 6.69e-18 8.17e-16 0.22500 9.60e-02 2.04e-01 5.63e-05 1.09e-17
Homology Directed Repair 99 1.27e-03 7.77e-03 0.22500 9.19e-02 2.06e-01 1.14e-01 4.02e-04
Cardiogenesis 25 1.63e-01 3.28e-01 0.22500 4.77e-02 2.20e-01 6.80e-01 5.67e-02
Activation of the pre-replicative complex 31 9.37e-02 2.28e-01 0.22500 1.92e-02 2.24e-01 8.53e-01 3.06e-02
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation 10 5.14e-01 7.05e-01 0.22500 1.01e-01 2.01e-01 5.81e-01 2.70e-01
RHOBTB1 GTPase cycle 22 2.40e-01 4.27e-01 0.22500 1.20e-01 1.90e-01 3.29e-01 1.23e-01
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template 38 7.26e-02 1.89e-01 0.22500 7.59e-02 2.12e-01 4.18e-01 2.38e-02
FGFR1 ligand binding and activation 17 3.29e-01 5.35e-01 0.22500 1.95e-01 1.11e-01 1.63e-01 4.29e-01
Transcriptional regulation of white adipocyte differentiation 81 3.68e-03 1.87e-02 0.22400 7.03e-02 2.13e-01 2.74e-01 9.08e-04
Condensation of Prophase Chromosomes 12 3.73e-01 5.78e-01 0.22400 -2.73e-02 2.23e-01 8.70e-01 1.82e-01
Translesion synthesis by POLI 17 3.42e-01 5.50e-01 0.22400 1.70e-01 1.47e-01 2.26e-01 2.95e-01
Specification of primordial germ cells 12 4.05e-01 6.08e-01 0.22400 2.12e-02 2.23e-01 8.99e-01 1.81e-01
Signaling by the B Cell Receptor (BCR) 105 1.38e-03 8.40e-03 0.22400 1.59e-01 1.58e-01 4.81e-03 5.22e-03
Activation of ATR in response to replication stress 37 7.87e-02 2.02e-01 0.22400 7.25e-02 2.12e-01 4.45e-01 2.57e-02
Activation of HOX genes during differentiation 62 1.35e-02 5.08e-02 0.22300 6.26e-02 2.14e-01 3.94e-01 3.50e-03
Activation of anterior HOX genes in hindbrain development during early embryogenesis 62 1.35e-02 5.08e-02 0.22300 6.26e-02 2.14e-01 3.94e-01 3.50e-03
DNA Repair 276 1.62e-08 2.86e-07 0.22300 9.87e-02 2.00e-01 4.74e-03 9.87e-09
Telomere Maintenance 62 2.10e-02 7.41e-02 0.22300 1.45e-01 1.69e-01 4.78e-02 2.13e-02
ERBB2 Activates PTK6 Signaling 13 3.02e-01 5.02e-01 0.22300 1.42e-01 -1.72e-01 3.77e-01 2.84e-01
Metabolism of amino acids and derivatives 345 5.18e-10 1.39e-08 0.22200 1.79e-01 1.32e-01 9.93e-09 2.56e-05
Cellular response to heat stress 95 2.71e-03 1.47e-02 0.22200 1.38e-01 1.74e-01 2.00e-02 3.31e-03
MAP3K8 (TPL2)-dependent MAPK1/3 activation 15 3.92e-01 5.98e-01 0.22200 1.35e-01 1.76e-01 3.65e-01 2.37e-01
Signaling by BMP 30 1.08e-01 2.50e-01 0.22200 -1.77e-02 -2.21e-01 8.67e-01 3.61e-02
RAB geranylgeranylation 57 2.48e-02 8.48e-02 0.22200 9.43e-02 2.00e-01 2.18e-01 8.84e-03
NOTCH1 Intracellular Domain Regulates Transcription 44 4.15e-02 1.27e-01 0.22100 2.71e-02 2.19e-01 7.56e-01 1.19e-02
Signaling by FLT3 fusion proteins 19 2.00e-01 3.79e-01 0.22000 -7.15e-02 2.08e-01 5.90e-01 1.16e-01
PTEN Regulation 150 2.93e-05 2.58e-04 0.22000 4.36e-02 2.16e-01 3.56e-01 4.90e-06
Activated NTRK2 signals through FRS2 and FRS3 11 4.96e-01 6.94e-01 0.22000 9.78e-02 1.97e-01 5.74e-01 2.57e-01
Epigenetic regulation of gene expression 118 2.46e-04 1.83e-03 0.22000 3.60e-02 2.17e-01 5.00e-01 4.61e-05
Uptake and function of anthrax toxins 11 3.98e-01 6.02e-01 0.22000 -2.10e-01 6.48e-02 2.27e-01 7.10e-01
Impaired BRCA2 binding to RAD51 33 1.27e-01 2.80e-01 0.22000 1.10e-01 1.90e-01 2.72e-01 5.86e-02
Miscellaneous substrates 12 3.49e-01 5.56e-01 0.22000 1.94e-01 -1.04e-01 2.45e-01 5.33e-01
Neddylation 232 8.20e-07 9.22e-06 0.22000 1.34e-01 1.74e-01 4.26e-04 4.99e-06
Chondroitin sulfate biosynthesis 18 2.03e-01 3.82e-01 0.22000 -1.21e-01 1.83e-01 3.74e-01 1.78e-01
Tie2 Signaling 18 1.99e-01 3.79e-01 0.21900 -1.64e-01 1.46e-01 2.29e-01 2.84e-01
Assembly of collagen fibrils and other multimeric structures 59 1.55e-02 5.73e-02 0.21900 -3.11e-02 -2.17e-01 6.80e-01 3.96e-03
Inflammasomes 21 2.73e-01 4.66e-01 0.21900 1.14e-01 1.87e-01 3.67e-01 1.38e-01
Regulation of HSF1-mediated heat shock response 78 8.90e-03 3.87e-02 0.21900 1.30e-01 1.76e-01 4.70e-02 7.17e-03
FGFR2 ligand binding and activation 19 2.98e-01 4.97e-01 0.21900 2.00e-01 8.93e-02 1.32e-01 5.00e-01
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux 43 3.66e-02 1.16e-01 0.21800 -2.17e-01 2.01e-02 1.36e-02 8.20e-01
Deubiquitination 225 1.14e-06 1.25e-05 0.21800 1.11e-01 1.87e-01 3.92e-03 1.26e-06
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism 12 3.87e-01 5.93e-01 0.21800 -3.95e-02 2.14e-01 8.13e-01 1.99e-01
alpha-linolenic acid (ALA) metabolism 12 3.87e-01 5.93e-01 0.21800 -3.95e-02 2.14e-01 8.13e-01 1.99e-01
Drug ADME 106 1.69e-03 9.90e-03 0.21800 -1.22e-01 -1.81e-01 3.04e-02 1.32e-03
Collagen formation 88 4.41e-03 2.17e-02 0.21800 -1.02e-01 -1.92e-01 9.82e-02 1.82e-03
Viral Infection Pathways 662 1.01e-17 1.15e-15 0.21700 1.18e-01 1.83e-01 2.00e-07 9.31e-16
CD28 dependent Vav1 pathway 11 4.68e-01 6.69e-01 0.21700 2.14e-01 3.62e-02 2.18e-01 8.35e-01
Synthesis of bile acids and bile salts 34 1.16e-01 2.64e-01 0.21700 -2.01e-01 -8.20e-02 4.25e-02 4.08e-01
Initial triggering of complement 21 1.61e-01 3.26e-01 0.21700 1.28e-01 -1.75e-01 3.11e-01 1.64e-01
RORA activates gene expression 17 2.25e-01 4.10e-01 0.21700 -1.64e-01 1.42e-01 2.42e-01 3.10e-01
HDR through Single Strand Annealing (SSA) 36 1.08e-01 2.50e-01 0.21700 9.53e-02 1.95e-01 3.23e-01 4.31e-02
Interleukin-2 signaling 11 4.36e-01 6.37e-01 0.21700 2.16e-01 -1.78e-02 2.15e-01 9.19e-01
Interleukin-12 signaling 43 6.68e-02 1.76e-01 0.21600 8.22e-02 2.00e-01 3.51e-01 2.31e-02
RNA Polymerase I Transcription Initiation 42 7.75e-02 2.00e-01 0.21600 1.01e-01 1.91e-01 2.58e-01 3.22e-02
Regulation of TP53 Expression and Degradation 37 1.07e-01 2.49e-01 0.21600 1.05e-01 1.88e-01 2.67e-01 4.74e-02
Thrombin signalling through proteinase activated receptors (PARs) 32 8.64e-02 2.16e-01 0.21500 -3.43e-02 2.12e-01 7.37e-01 3.76e-02
Binding and Uptake of Ligands by Scavenger Receptors 41 8.92e-02 2.22e-01 0.21500 -1.19e-01 -1.79e-01 1.88e-01 4.71e-02
NOTCH2 Activation and Transmission of Signal to the Nucleus 22 2.55e-01 4.46e-01 0.21500 1.99e-01 8.19e-02 1.07e-01 5.06e-01
Interconversion of nucleotide di- and triphosphates 29 1.18e-01 2.67e-01 0.21500 -1.40e-02 2.14e-01 8.96e-01 4.57e-02
Translesion synthesis by REV1 16 3.95e-01 5.99e-01 0.21400 1.29e-01 1.71e-01 3.72e-01 2.35e-01
Regulation of CDH11 gene transcription 10 5.62e-01 7.38e-01 0.21400 1.57e-01 1.45e-01 3.89e-01 4.26e-01
Non-integrin membrane-ECM interactions 55 4.20e-02 1.28e-01 0.21400 -1.36e-01 -1.65e-01 8.12e-02 3.37e-02
Cell-extracellular matrix interactions 16 3.52e-01 5.59e-01 0.21400 2.08e-01 4.90e-02 1.49e-01 7.34e-01
RHO GTPases Activate NADPH Oxidases 22 1.57e-01 3.22e-01 0.21300 -1.33e-01 1.66e-01 2.79e-01 1.78e-01
Glycogen storage diseases 14 4.48e-01 6.48e-01 0.21200 1.22e-01 1.74e-01 4.29e-01 2.60e-01
FGFR1 mutant receptor activation 30 1.65e-01 3.32e-01 0.21200 8.56e-02 1.94e-01 4.17e-01 6.55e-02
Polymerase switching on the C-strand of the telomere 24 2.07e-01 3.88e-01 0.21200 3.60e-02 2.09e-01 7.60e-01 7.61e-02
Prefoldin mediated transfer of substrate to CCT/TriC 27 1.62e-01 3.28e-01 0.21200 2.11e-01 2.08e-02 5.77e-02 8.51e-01
Phospholipase C-mediated cascade; FGFR3 12 5.09e-01 7.01e-01 0.21200 1.54e-01 1.46e-01 3.56e-01 3.81e-01
Degradation of the extracellular matrix 135 3.65e-04 2.58e-03 0.21100 -9.31e-02 -1.90e-01 6.16e-02 1.39e-04
Regulation of commissural axon pathfinding by SLIT and ROBO 10 5.45e-01 7.27e-01 0.21100 -7.24e-02 -1.98e-01 6.92e-01 2.77e-01
Translesion synthesis by POLK 17 3.76e-01 5.83e-01 0.21100 1.06e-01 1.82e-01 4.48e-01 1.94e-01
Depolymerization of the Nuclear Lamina 14 3.49e-01 5.56e-01 0.21100 -4.80e-02 2.05e-01 7.56e-01 1.84e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function 23 2.79e-01 4.70e-01 0.21000 1.38e-01 1.58e-01 2.51e-01 1.88e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function 23 2.79e-01 4.70e-01 0.21000 1.38e-01 1.58e-01 2.51e-01 1.88e-01
Defective homologous recombination repair (HRR) due to BRCA1 loss of function 23 2.79e-01 4.70e-01 0.21000 1.38e-01 1.58e-01 2.51e-01 1.88e-01
Defective homologous recombination repair (HRR) due to PALB2 loss of function 23 2.79e-01 4.70e-01 0.21000 1.38e-01 1.58e-01 2.51e-01 1.88e-01
Impaired BRCA2 binding to PALB2 23 2.79e-01 4.70e-01 0.21000 1.38e-01 1.58e-01 2.51e-01 1.88e-01
Signaling by Hedgehog 146 3.04e-04 2.20e-03 0.21000 1.64e-01 1.32e-01 6.22e-04 6.01e-03
TP53 Regulates Transcription of Cell Cycle Genes 49 4.40e-02 1.32e-01 0.21000 3.87e-02 2.06e-01 6.39e-01 1.24e-02
Regulation of TP53 Degradation 36 1.21e-01 2.72e-01 0.21000 8.49e-02 1.92e-01 3.78e-01 4.63e-02
PD-1 signaling 21 1.79e-01 3.53e-01 0.21000 1.63e-01 -1.33e-01 1.97e-01 2.93e-01
Intrinsic Pathway of Fibrin Clot Formation 21 3.06e-01 5.08e-01 0.20900 -1.11e-01 -1.78e-01 3.78e-01 1.59e-01
RHOBTB2 GTPase cycle 22 2.66e-01 4.58e-01 0.20900 1.99e-01 6.50e-02 1.07e-01 5.97e-01
FRS-mediated FGFR3 signaling 19 3.28e-01 5.35e-01 0.20900 8.12e-02 1.93e-01 5.40e-01 1.46e-01
Ribavirin ADME 11 5.05e-01 6.99e-01 0.20900 4.88e-02 2.03e-01 7.79e-01 2.43e-01
SHC1 events in EGFR signaling 14 3.28e-01 5.35e-01 0.20900 -1.04e-01 1.81e-01 5.02e-01 2.40e-01
O-linked glycosylation of mucins 62 1.89e-02 6.79e-02 0.20800 -2.06e-01 -2.87e-02 4.92e-03 6.96e-01
DNA Double-Strand Break Repair 129 6.90e-04 4.43e-03 0.20700 8.98e-02 1.87e-01 7.79e-02 2.48e-04
Transcription-Coupled Nucleotide Excision Repair (TC-NER) 76 1.69e-02 6.14e-02 0.20700 1.37e-01 1.55e-01 3.89e-02 1.93e-02
Early SARS-CoV-2 Infection Events 34 1.18e-01 2.67e-01 0.20700 2.96e-02 2.05e-01 7.65e-01 3.90e-02
Generation of second messenger molecules 30 9.34e-02 2.28e-01 0.20700 1.23e-01 -1.66e-01 2.42e-01 1.16e-01
Glutathione conjugation 36 1.36e-01 2.93e-01 0.20600 1.01e-01 1.80e-01 2.96e-01 6.12e-02
SUMOylation of DNA methylation proteins 16 2.82e-01 4.73e-01 0.20600 -1.57e-01 1.34e-01 2.78e-01 3.54e-01
Negative regulation of TCF-dependent signaling by WNT ligand antagonists 15 3.13e-01 5.15e-01 0.20600 -1.04e-01 1.78e-01 4.84e-01 2.34e-01
Macroautophagy 130 5.85e-04 3.85e-03 0.20600 7.27e-02 1.93e-01 1.52e-01 1.48e-04
Lysine catabolism 12 5.27e-01 7.12e-01 0.20600 -1.27e-01 -1.62e-01 4.48e-01 3.31e-01
Signalling to RAS 20 2.44e-01 4.33e-01 0.20600 -3.79e-02 2.02e-01 7.69e-01 1.18e-01
Autophagy 144 2.31e-04 1.74e-03 0.20600 6.21e-02 1.96e-01 1.98e-01 4.87e-05
SARS-CoV-2-host interactions 185 4.93e-05 4.23e-04 0.20600 1.14e-01 1.71e-01 7.45e-03 5.93e-05
O-glycosylation of TSR domain-containing proteins 37 1.04e-01 2.46e-01 0.20500 -3.75e-02 -2.02e-01 6.93e-01 3.34e-02
Regulation of gene expression by Hypoxia-inducible Factor 11 5.15e-01 7.05e-01 0.20500 4.22e-02 2.01e-01 8.08e-01 2.49e-01
FGFR3 mutant receptor activation 11 5.61e-01 7.38e-01 0.20500 1.36e-01 1.53e-01 4.33e-01 3.81e-01
Signaling by activated point mutants of FGFR3 11 5.61e-01 7.38e-01 0.20500 1.36e-01 1.53e-01 4.33e-01 3.81e-01
Oxidative Stress Induced Senescence 66 1.01e-02 4.19e-02 0.20400 -3.82e-02 2.01e-01 5.91e-01 4.80e-03
Phosphorylation of CD3 and TCR zeta chains 20 2.31e-01 4.18e-01 0.20300 1.89e-01 -7.52e-02 1.43e-01 5.61e-01
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 34 1.55e-01 3.19e-01 0.20300 8.32e-02 1.85e-01 4.01e-01 6.13e-02
Defective B3GALTL causes PpS 36 1.25e-01 2.77e-01 0.20300 -5.07e-02 -1.96e-01 5.99e-01 4.17e-02
SUMOylation of DNA damage response and repair proteins 71 1.07e-02 4.38e-02 0.20300 -7.85e-05 2.03e-01 9.99e-01 3.15e-03
WNT ligand biogenesis and trafficking 25 2.77e-01 4.69e-01 0.20200 1.46e-01 1.40e-01 2.07e-01 2.25e-01
MAP kinase activation 58 3.79e-02 1.19e-01 0.20200 6.18e-02 1.93e-01 4.15e-01 1.11e-02
Citric acid cycle (TCA cycle) 21 3.41e-01 5.50e-01 0.20200 1.41e-01 1.45e-01 2.62e-01 2.51e-01
Bile acid and bile salt metabolism 45 1.00e-01 2.39e-01 0.20200 -1.40e-01 -1.46e-01 1.04e-01 9.08e-02
Signaling by CSF1 (M-CSF) in myeloid cells 30 2.05e-01 3.86e-01 0.20100 9.71e-02 1.77e-01 3.57e-01 9.42e-02
Ethanol oxidation 12 4.33e-01 6.35e-01 0.20100 5.45e-02 -1.94e-01 7.44e-01 2.45e-01
Mitotic Spindle Checkpoint 106 3.88e-03 1.95e-02 0.20100 9.89e-02 1.75e-01 7.84e-02 1.81e-03
Synthesis of Leukotrienes (LT) and Eoxins (EX) 21 2.99e-01 4.98e-01 0.20100 1.96e-01 4.68e-02 1.21e-01 7.11e-01
Cytosolic iron-sulfur cluster assembly 10 5.58e-01 7.37e-01 0.20100 1.97e-01 3.87e-02 2.80e-01 8.32e-01
Interleukin-1 family signaling 145 6.64e-04 4.30e-03 0.20100 1.50e-01 1.34e-01 1.84e-03 5.31e-03
ECM proteoglycans 73 2.00e-02 7.10e-02 0.20100 -8.29e-02 -1.83e-01 2.21e-01 6.81e-03
Peptide hormone biosynthesis 11 5.55e-01 7.36e-01 0.20100 -1.83e-01 -8.40e-02 2.95e-01 6.30e-01
Gap-filling DNA repair synthesis and ligation in TC-NER 62 4.36e-02 1.31e-01 0.20100 1.50e-01 1.33e-01 4.04e-02 7.04e-02
Killing mechanisms 11 5.71e-01 7.46e-01 0.20100 1.21e-01 1.60e-01 4.86e-01 3.59e-01
WNT5:FZD7-mediated leishmania damping 11 5.71e-01 7.46e-01 0.20100 1.21e-01 1.60e-01 4.86e-01 3.59e-01
HDR through Homologous Recombination (HRR) 64 3.50e-02 1.12e-01 0.20100 9.44e-02 1.77e-01 1.92e-01 1.43e-02
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain 13 4.36e-01 6.37e-01 0.20000 -1.06e-02 2.00e-01 9.47e-01 2.12e-01
ADP signalling through P2Y purinoceptor 1 25 1.59e-01 3.25e-01 0.20000 -1.07e-01 1.69e-01 3.54e-01 1.43e-01
RHOU GTPase cycle 37 9.97e-02 2.39e-01 0.20000 -2.00e-01 4.00e-05 3.53e-02 1.00e+00
Insulin processing 24 2.50e-01 4.39e-01 0.20000 -1.96e-01 -3.72e-02 9.57e-02 7.52e-01
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) 25 2.80e-01 4.71e-01 0.20000 1.11e-01 1.66e-01 3.36e-01 1.51e-01
Erythropoietin activates RAS 14 4.17e-01 6.21e-01 0.20000 -1.74e-03 2.00e-01 9.91e-01 1.96e-01
Apoptosis 164 2.80e-04 2.06e-03 0.20000 1.26e-01 1.55e-01 5.51e-03 6.06e-04
Activation of Matrix Metalloproteinases 31 2.08e-01 3.89e-01 0.20000 -1.14e-01 -1.64e-01 2.73e-01 1.14e-01
Germ layer formation at gastrulation 16 4.16e-01 6.20e-01 0.19900 -1.90e-01 -6.12e-02 1.89e-01 6.72e-01
Fc epsilon receptor (FCERI) signaling 126 1.97e-03 1.14e-02 0.19900 1.39e-01 1.43e-01 7.10e-03 5.68e-03
Toll Like Receptor 9 (TLR9) Cascade 100 4.61e-03 2.23e-02 0.19900 6.77e-02 1.87e-01 2.42e-01 1.22e-03
NR1H2 and NR1H3-mediated signaling 53 4.49e-02 1.33e-01 0.19900 -1.97e-01 -2.50e-02 1.30e-02 7.53e-01
Peroxisomal protein import 62 4.66e-02 1.37e-01 0.19800 1.54e-01 1.25e-01 3.57e-02 8.94e-02
RHOBTB GTPase Cycle 34 1.87e-01 3.62e-01 0.19800 1.49e-01 1.30e-01 1.32e-01 1.89e-01
Calcitonin-like ligand receptors 10 6.10e-01 7.73e-01 0.19800 -1.24e-01 -1.54e-01 4.97e-01 3.98e-01
Beta-catenin phosphorylation cascade 16 3.55e-01 5.61e-01 0.19800 -3.10e-02 1.96e-01 8.30e-01 1.76e-01
DCC mediated attractive signaling 14 4.94e-01 6.94e-01 0.19800 -1.01e-01 -1.70e-01 5.15e-01 2.70e-01
RNA Polymerase III Transcription Termination 23 3.24e-01 5.29e-01 0.19800 1.46e-01 1.33e-01 2.25e-01 2.69e-01
Protein hydroxylation 18 3.94e-01 5.98e-01 0.19800 1.79e-01 8.28e-02 1.88e-01 5.43e-01
Synthesis of PIPs at the plasma membrane 48 4.56e-02 1.35e-01 0.19800 -1.95e-01 3.00e-02 1.92e-02 7.19e-01
Programmed Cell Death 195 6.15e-05 5.16e-04 0.19700 1.03e-01 1.68e-01 1.32e-02 4.99e-05
N-glycan antennae elongation in the medial/trans-Golgi 26 2.00e-01 3.80e-01 0.19700 -1.97e-01 1.04e-02 8.22e-02 9.27e-01
Zinc influx into cells by the SLC39 gene family 10 6.11e-01 7.73e-01 0.19700 1.61e-01 1.13e-01 3.77e-01 5.35e-01
Formation of Fibrin Clot (Clotting Cascade) 37 1.66e-01 3.32e-01 0.19700 -1.49e-01 -1.29e-01 1.17e-01 1.75e-01
Downregulation of ERBB2 signaling 28 2.54e-01 4.45e-01 0.19700 1.57e-01 1.18e-01 1.50e-01 2.78e-01
PI-3K cascade:FGFR1 21 3.24e-01 5.29e-01 0.19600 1.88e-01 5.54e-02 1.35e-01 6.61e-01
Signaling by FGFR1 51 8.57e-02 2.16e-01 0.19600 1.32e-01 1.45e-01 1.03e-01 7.29e-02
CREB1 phosphorylation through the activation of Adenylate Cyclase 11 4.77e-01 6.78e-01 0.19600 -6.50e-02 1.85e-01 7.09e-01 2.88e-01
LGI-ADAM interactions 14 5.11e-01 7.03e-01 0.19500 1.25e-01 1.50e-01 4.18e-01 3.31e-01
Signaling by PDGFR in disease 20 2.44e-01 4.33e-01 0.19500 -1.55e-01 1.18e-01 2.30e-01 3.60e-01
TNFs bind their physiological receptors 25 2.79e-01 4.70e-01 0.19500 1.81e-01 7.23e-02 1.18e-01 5.32e-01
HCMV Infection 97 4.99e-03 2.37e-02 0.19400 3.44e-02 1.91e-01 5.58e-01 1.13e-03
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand 55 5.56e-02 1.55e-01 0.19400 1.87e-01 5.37e-02 1.67e-02 4.90e-01
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) 14 4.96e-01 6.94e-01 0.19400 7.85e-02 1.77e-01 6.11e-01 2.50e-01
Signaling by FGFR 87 1.65e-02 6.01e-02 0.19400 1.52e-01 1.21e-01 1.45e-02 5.17e-02
Regulation of CDH11 function 10 5.79e-01 7.52e-01 0.19300 -1.91e-01 -3.00e-02 2.96e-01 8.70e-01
Regulation of NPAS4 gene expression 13 5.01e-01 6.96e-01 0.19300 -1.88e-01 -4.27e-02 2.40e-01 7.90e-01
Dual incision in TC-NER 63 5.32e-02 1.50e-01 0.19300 1.36e-01 1.37e-01 6.20e-02 6.01e-02
Synthesis of substrates in N-glycan biosythesis 60 4.75e-02 1.39e-01 0.19300 6.37e-02 1.82e-01 3.94e-01 1.47e-02
SHC-mediated cascade:FGFR4 19 3.68e-01 5.75e-01 0.19300 4.60e-02 1.87e-01 7.29e-01 1.58e-01
MyD88:MAL(TIRAP) cascade initiated on plasma membrane 106 3.36e-03 1.75e-02 0.19200 3.23e-02 1.90e-01 5.65e-01 7.41e-04
Toll Like Receptor TLR6:TLR2 Cascade 106 3.36e-03 1.75e-02 0.19200 3.23e-02 1.90e-01 5.65e-01 7.41e-04
Interleukin-15 signaling 13 5.48e-01 7.29e-01 0.19200 1.26e-01 1.45e-01 4.33e-01 3.65e-01
Antimicrobial peptides 78 6.50e-03 2.99e-02 0.19100 1.78e-01 -6.96e-02 6.47e-03 2.88e-01
Late endosomal microautophagy 33 1.85e-01 3.59e-01 0.19100 5.31e-02 1.84e-01 5.97e-01 6.75e-02
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs 11 5.42e-01 7.25e-01 0.19100 1.21e-02 1.91e-01 9.45e-01 2.73e-01
AKT phosphorylates targets in the cytosol 14 5.24e-01 7.10e-01 0.19100 1.15e-01 1.53e-01 4.57e-01 3.23e-01
MyD88 dependent cascade initiated on endosome 96 8.60e-03 3.76e-02 0.19100 6.45e-02 1.80e-01 2.75e-01 2.35e-03
Toll Like Receptor 7/8 (TLR7/8) Cascade 96 8.60e-03 3.76e-02 0.19100 6.45e-02 1.80e-01 2.75e-01 2.35e-03
MyD88 cascade initiated on plasma membrane 91 1.15e-02 4.50e-02 0.19100 6.79e-02 1.78e-01 2.63e-01 3.31e-03
Toll Like Receptor 10 (TLR10) Cascade 91 1.15e-02 4.50e-02 0.19100 6.79e-02 1.78e-01 2.63e-01 3.31e-03
Toll Like Receptor 5 (TLR5) Cascade 91 1.15e-02 4.50e-02 0.19100 6.79e-02 1.78e-01 2.63e-01 3.31e-03
Maturation of nucleoprotein 9694631 15 3.63e-01 5.70e-01 0.19000 1.35e-01 -1.35e-01 3.67e-01 3.67e-01
RHOQ GTPase cycle 57 4.59e-02 1.35e-01 0.19000 -1.89e-01 -1.84e-02 1.35e-02 8.10e-01
Presynaptic phase of homologous DNA pairing and strand exchange 38 1.79e-01 3.52e-01 0.19000 1.17e-01 1.49e-01 2.11e-01 1.12e-01
Interleukin-20 family signaling 24 2.60e-01 4.52e-01 0.18900 3.02e-03 -1.89e-01 9.80e-01 1.09e-01
Protein methylation 16 4.37e-01 6.37e-01 0.18900 3.46e-02 1.86e-01 8.11e-01 1.98e-01
HuR (ELAVL1) binds and stabilizes mRNA 10 5.20e-01 7.09e-01 0.18900 -9.94e-02 1.61e-01 5.86e-01 3.79e-01
Disorders of Developmental Biology 11 5.22e-01 7.09e-01 0.18900 -3.01e-02 1.87e-01 8.63e-01 2.84e-01
Disorders of Nervous System Development 11 5.22e-01 7.09e-01 0.18900 -3.01e-02 1.87e-01 8.63e-01 2.84e-01
Loss of function of MECP2 in Rett syndrome 11 5.22e-01 7.09e-01 0.18900 -3.01e-02 1.87e-01 8.63e-01 2.84e-01
Pervasive developmental disorders 11 5.22e-01 7.09e-01 0.18900 -3.01e-02 1.87e-01 8.63e-01 2.84e-01
ERK/MAPK targets 20 3.44e-01 5.53e-01 0.18900 2.02e-02 1.88e-01 8.75e-01 1.46e-01
BBSome-mediated cargo-targeting to cilium 23 3.43e-01 5.51e-01 0.18900 1.67e-01 8.90e-02 1.66e-01 4.60e-01
Mitochondrial biogenesis 69 2.61e-02 8.75e-02 0.18900 2.23e-02 1.87e-01 7.49e-01 7.10e-03
Nonhomologous End-Joining (NHEJ) 32 2.27e-01 4.12e-01 0.18900 8.95e-02 1.66e-01 3.81e-01 1.04e-01
Signaling by NTRK1 (TRKA) 114 4.43e-03 2.17e-02 0.18900 7.24e-02 1.74e-01 1.81e-01 1.31e-03
TCF dependent signaling in response to WNT 168 5.83e-04 3.85e-03 0.18800 1.18e-01 1.46e-01 8.09e-03 1.07e-03
Homologous DNA Pairing and Strand Exchange 41 1.63e-01 3.28e-01 0.18800 1.23e-01 1.42e-01 1.74e-01 1.15e-01
PI3K events in ERBB4 signaling 10 5.23e-01 7.09e-01 0.18800 1.01e-01 -1.58e-01 5.80e-01 3.86e-01
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane 18 3.31e-01 5.37e-01 0.18700 -6.19e-02 1.77e-01 6.49e-01 1.94e-01
Defective homologous recombination repair (HRR) due to BRCA2 loss of function 39 1.80e-01 3.53e-01 0.18700 1.26e-01 1.38e-01 1.73e-01 1.35e-01
Diseases of DNA Double-Strand Break Repair 39 1.80e-01 3.53e-01 0.18700 1.26e-01 1.38e-01 1.73e-01 1.35e-01
Vitamin B5 (pantothenate) metabolism 19 4.20e-01 6.24e-01 0.18700 8.95e-02 1.64e-01 5.00e-01 2.15e-01
MECP2 regulates neuronal receptors and channels 17 3.93e-01 5.98e-01 0.18700 -1.87e-01 4.21e-03 1.82e-01 9.76e-01
Regulation of TLR by endogenous ligand 20 2.72e-01 4.65e-01 0.18700 -1.39e-01 1.25e-01 2.84e-01 3.32e-01
Advanced glycosylation endproduct receptor signaling 13 5.39e-01 7.22e-01 0.18700 1.75e-01 6.36e-02 2.73e-01 6.91e-01
Pre-NOTCH Expression and Processing 61 2.54e-02 8.63e-02 0.18600 -5.80e-02 1.77e-01 4.33e-01 1.68e-02
Potential therapeutics for SARS 92 7.87e-03 3.50e-02 0.18600 1.02e-02 1.86e-01 8.66e-01 2.06e-03
Regulation of beta-cell development 41 1.67e-01 3.35e-01 0.18600 1.12e-01 1.49e-01 2.16e-01 9.97e-02
CRMPs in Sema3A signaling 15 3.93e-01 5.98e-01 0.18500 9.01e-02 -1.62e-01 5.46e-01 2.79e-01
SUMOylation 165 2.79e-04 2.06e-03 0.18500 3.12e-02 1.82e-01 4.89e-01 5.25e-05
Signaling by Leptin 11 6.18e-01 7.80e-01 0.18500 1.56e-01 9.99e-02 3.72e-01 5.66e-01
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 95 1.18e-02 4.60e-02 0.18500 6.01e-02 1.75e-01 3.12e-01 3.22e-03
Gene expression (Transcription) 1441 3.37e-28 1.07e-25 0.18500 6.43e-02 1.73e-01 3.99e-05 1.71e-28
Toll-like Receptor Cascades 157 5.25e-04 3.54e-03 0.18400 4.27e-02 1.79e-01 3.55e-01 1.03e-04
Regulation of TP53 Activity 154 7.95e-04 5.07e-03 0.18400 5.86e-02 1.75e-01 2.09e-01 1.84e-04
MAP2K and MAPK activation 38 1.71e-01 3.40e-01 0.18400 5.83e-02 1.74e-01 5.34e-01 6.28e-02
mRNA decay by 5’ to 3’ exoribonuclease 15 4.88e-01 6.89e-01 0.18300 4.20e-02 1.79e-01 7.78e-01 2.31e-01
GRB2 events in EGFR signaling 13 4.43e-01 6.44e-01 0.18300 -1.32e-01 1.27e-01 4.11e-01 4.26e-01
Organic cation transport 10 5.36e-01 7.19e-01 0.18300 -1.34e-01 1.24e-01 4.62e-01 4.96e-01
Infectious disease 848 4.64e-16 3.68e-14 0.18300 9.77e-02 1.55e-01 1.26e-06 1.59e-14
Diseases of DNA repair 49 1.20e-01 2.71e-01 0.18200 8.79e-02 1.60e-01 2.87e-01 5.28e-02
Presynaptic depolarization and calcium channel opening 12 5.98e-01 7.65e-01 0.18200 -9.41e-02 -1.56e-01 5.73e-01 3.49e-01
GP1b-IX-V activation signalling 11 6.10e-01 7.73e-01 0.18200 -6.43e-02 -1.70e-01 7.12e-01 3.28e-01
Base Excision Repair 45 9.97e-02 2.39e-01 0.18200 2.35e-03 1.82e-01 9.78e-01 3.48e-02
Downstream signaling of activated FGFR3 24 3.62e-01 5.70e-01 0.18200 9.61e-02 1.54e-01 4.15e-01 1.91e-01
Notch-HLH transcription pathway 24 2.32e-01 4.18e-01 0.18200 -1.07e-01 1.47e-01 3.66e-01 2.13e-01
DNA strand elongation 31 2.69e-01 4.61e-01 0.18100 9.34e-02 1.55e-01 3.68e-01 1.34e-01
RNA Polymerase II Transcription 1282 5.85e-24 1.55e-21 0.18100 7.29e-02 1.66e-01 1.03e-05 1.04e-23
Heme signaling 45 1.11e-01 2.57e-01 0.18100 -1.80e-01 -2.15e-02 3.67e-02 8.03e-01
PI3K events in ERBB2 signaling 16 3.77e-01 5.83e-01 0.18100 1.18e-01 -1.37e-01 4.15e-01 3.41e-01
Signaling by FGFR1 in disease 37 1.75e-01 3.47e-01 0.18100 3.52e-02 1.77e-01 7.11e-01 6.17e-02
Amine ligand-binding receptors 41 1.24e-01 2.77e-01 0.18100 -1.81e-01 -7.69e-05 4.51e-02 9.99e-01
Extension of Telomeres 48 1.16e-01 2.64e-01 0.18100 5.70e-02 1.72e-01 4.95e-01 3.97e-02
Negative regulation of MET activity 20 3.48e-01 5.56e-01 0.18000 -2.09e-02 1.79e-01 8.71e-01 1.67e-01
Signaling by NOTCH 182 5.90e-04 3.85e-03 0.18000 1.02e-01 1.48e-01 1.76e-02 5.70e-04
Transport of organic anions 10 6.63e-01 8.17e-01 0.18000 -1.47e-01 -1.03e-01 4.20e-01 5.74e-01
Termination of translesion DNA synthesis 31 2.76e-01 4.68e-01 0.17900 8.98e-02 1.55e-01 3.87e-01 1.35e-01
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release 19 4.15e-01 6.18e-01 0.17900 3.35e-02 1.76e-01 8.00e-01 1.85e-01
trans-Golgi Network Vesicle Budding 67 2.60e-02 8.73e-02 0.17900 -4.45e-02 1.73e-01 5.29e-01 1.42e-02
Toll Like Receptor 4 (TLR4) Cascade 138 2.05e-03 1.17e-02 0.17900 4.54e-02 1.73e-01 3.57e-01 4.48e-04
Signaling by ERBB2 ECD mutants 15 5.48e-01 7.29e-01 0.17900 1.23e-01 1.30e-01 4.11e-01 3.83e-01
Syndecan interactions 26 3.44e-01 5.53e-01 0.17900 -1.52e-01 -9.38e-02 1.80e-01 4.08e-01
SHC-mediated cascade:FGFR2 22 3.91e-01 5.97e-01 0.17800 6.77e-02 1.65e-01 5.82e-01 1.80e-01
Interferon alpha/beta signaling 74 3.76e-02 1.18e-01 0.17800 1.71e-01 4.90e-02 1.07e-02 4.66e-01
SUMO E3 ligases SUMOylate target proteins 159 6.72e-04 4.33e-03 0.17800 3.08e-02 1.76e-01 5.03e-01 1.33e-04
Sensory processing of sound by inner hair cells of the cochlea 64 5.09e-02 1.46e-01 0.17800 -2.62e-02 -1.76e-01 7.17e-01 1.48e-02
N-Glycan antennae elongation 15 4.12e-01 6.15e-01 0.17800 -1.26e-01 1.26e-01 3.98e-01 3.99e-01
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors 11 5.59e-01 7.38e-01 0.17800 1.75e-01 -3.27e-02 3.15e-01 8.51e-01
mRNA Editing 10 6.00e-01 7.65e-01 0.17800 1.65e-02 -1.77e-01 9.28e-01 3.33e-01
Glycolysis 70 5.22e-02 1.48e-01 0.17800 6.95e-02 1.64e-01 3.14e-01 1.80e-02
SARS-CoV Infections 386 8.80e-08 1.22e-06 0.17700 6.28e-02 1.66e-01 3.38e-02 2.10e-08
Pentose phosphate pathway 12 5.01e-01 6.96e-01 0.17700 -9.55e-02 1.49e-01 5.67e-01 3.71e-01
Metabolism of porphyrins 27 2.67e-01 4.58e-01 0.17700 1.78e-03 -1.77e-01 9.87e-01 1.12e-01
Constitutive Signaling by EGFRvIII 15 5.56e-01 7.36e-01 0.17700 1.30e-01 1.20e-01 3.84e-01 4.22e-01
Signaling by EGFRvIII in Cancer 15 5.56e-01 7.36e-01 0.17700 1.30e-01 1.20e-01 3.84e-01 4.22e-01
InlB-mediated entry of Listeria monocytogenes into host cell 14 5.80e-01 7.52e-01 0.17600 1.22e-01 1.28e-01 4.31e-01 4.08e-01
YAP1- and WWTR1 (TAZ)-stimulated gene expression 15 4.93e-01 6.94e-01 0.17600 1.76e-01 1.20e-02 2.38e-01 9.36e-01
Disassembly of the destruction complex and recruitment of AXIN to the membrane 30 2.65e-01 4.57e-01 0.17600 3.84e-02 1.72e-01 7.16e-01 1.03e-01
Plasma lipoprotein assembly 19 4.38e-01 6.38e-01 0.17600 -1.70e-01 -4.66e-02 2.00e-01 7.25e-01
Disorders of transmembrane transporters 167 1.51e-03 9.03e-03 0.17600 1.39e-01 1.08e-01 1.94e-03 1.59e-02
Common Pathway of Fibrin Clot Formation 21 4.34e-01 6.35e-01 0.17600 -1.51e-01 -9.06e-02 2.32e-01 4.73e-01
Nephrin family interactions 22 4.06e-01 6.09e-01 0.17500 -6.83e-02 -1.61e-01 5.79e-01 1.91e-01
Extracellular matrix organization 292 1.51e-05 1.36e-04 0.17500 -1.15e-01 -1.32e-01 7.19e-04 1.04e-04
Signaling by cytosolic FGFR1 fusion mutants 17 4.21e-01 6.24e-01 0.17500 -3.07e-02 1.72e-01 8.27e-01 2.19e-01
Formation of tubulin folding intermediates by CCT/TriC 26 3.14e-01 5.16e-01 0.17500 1.72e-01 2.81e-02 1.28e-01 8.04e-01
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 32 2.64e-01 4.57e-01 0.17400 1.65e-01 5.76e-02 1.07e-01 5.73e-01
Formation of the cornified envelope 127 3.61e-03 1.84e-02 0.17400 -2.56e-02 -1.72e-01 6.18e-01 8.08e-04
Signaling by FGFR2 in disease 42 1.98e-01 3.78e-01 0.17400 1.46e-01 9.39e-02 1.02e-01 2.92e-01
Integrin cell surface interactions 83 3.89e-02 1.21e-01 0.17300 -8.09e-02 -1.53e-01 2.03e-01 1.58e-02
Regulation of cholesterol biosynthesis by SREBP (SREBF) 54 9.37e-02 2.28e-01 0.17300 2.73e-02 1.71e-01 7.28e-01 2.97e-02
Interleukin-12 family signaling 53 1.20e-01 2.71e-01 0.17300 6.97e-02 1.59e-01 3.80e-01 4.59e-02
Generic Transcription Pathway 1162 4.78e-20 7.57e-18 0.17300 6.88e-02 1.59e-01 7.21e-05 4.81e-20
Signaling by NODAL 21 3.10e-01 5.13e-01 0.17300 1.25e-01 -1.20e-01 3.23e-01 3.42e-01
Caspase-mediated cleavage of cytoskeletal proteins 12 5.76e-01 7.51e-01 0.17300 5.67e-03 1.73e-01 9.73e-01 3.00e-01
Regulation of TP53 Activity through Acetylation 29 2.31e-01 4.18e-01 0.17300 -4.00e-02 1.68e-01 7.09e-01 1.18e-01
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 13 5.90e-01 7.58e-01 0.17200 5.82e-02 1.62e-01 7.17e-01 3.11e-01
Sensory processing of sound 71 5.42e-02 1.51e-01 0.17200 -5.04e-02 -1.65e-01 4.62e-01 1.64e-02
MASTL Facilitates Mitotic Progression 10 5.85e-01 7.54e-01 0.17200 -7.86e-02 1.53e-01 6.67e-01 4.02e-01
Toll Like Receptor 2 (TLR2) Cascade 109 1.01e-02 4.19e-02 0.17200 3.71e-02 1.68e-01 5.03e-01 2.44e-03
Toll Like Receptor TLR1:TLR2 Cascade 109 1.01e-02 4.19e-02 0.17200 3.71e-02 1.68e-01 5.03e-01 2.44e-03
SLBP independent Processing of Histone Pre-mRNAs 10 6.34e-01 7.95e-01 0.17200 3.86e-03 1.72e-01 9.83e-01 3.47e-01
Maturation of spike protein 9694548 35 1.59e-01 3.25e-01 0.17200 -6.78e-02 1.58e-01 4.88e-01 1.06e-01
Aggrephagy 42 1.96e-01 3.76e-01 0.17200 1.54e-01 7.63e-02 8.45e-02 3.92e-01
Peroxisomal lipid metabolism 28 3.56e-01 5.62e-01 0.17100 1.30e-01 1.12e-01 2.35e-01 3.05e-01
Retrograde neurotrophin signalling 14 5.98e-01 7.65e-01 0.17100 1.23e-01 1.20e-01 4.27e-01 4.38e-01
Activated NOTCH1 Transmits Signal to the Nucleus 30 2.70e-01 4.62e-01 0.17100 1.70e-01 1.99e-02 1.07e-01 8.50e-01
FLT3 Signaling 38 2.50e-01 4.39e-01 0.17000 1.11e-01 1.30e-01 2.38e-01 1.67e-01
Gap-filling DNA repair synthesis and ligation in GG-NER 25 4.01e-01 6.04e-01 0.17000 9.93e-02 1.38e-01 3.90e-01 2.34e-01
Signaling by NTRKs 133 6.17e-03 2.86e-02 0.17000 6.71e-02 1.56e-01 1.82e-01 1.92e-03
Cholesterol biosynthesis 24 4.20e-01 6.24e-01 0.17000 1.10e-01 1.29e-01 3.51e-01 2.74e-01
CS/DS degradation 12 5.30e-01 7.15e-01 0.16900 -9.70e-02 1.39e-01 5.60e-01 4.05e-01
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants 54 1.40e-01 2.96e-01 0.16900 9.05e-02 1.42e-01 2.50e-01 7.00e-02
Constitutive Signaling by NOTCH1 PEST Domain Mutants 54 1.40e-01 2.96e-01 0.16900 9.05e-02 1.42e-01 2.50e-01 7.00e-02
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer 54 1.40e-01 2.96e-01 0.16900 9.05e-02 1.42e-01 2.50e-01 7.00e-02
Signaling by NOTCH1 PEST Domain Mutants in Cancer 54 1.40e-01 2.96e-01 0.16900 9.05e-02 1.42e-01 2.50e-01 7.00e-02
Signaling by NOTCH1 in Cancer 54 1.40e-01 2.96e-01 0.16900 9.05e-02 1.42e-01 2.50e-01 7.00e-02
NCAM1 interactions 41 1.36e-01 2.92e-01 0.16800 4.80e-02 -1.61e-01 5.95e-01 7.43e-02
FCERI mediated MAPK activation 32 1.92e-01 3.68e-01 0.16800 -1.43e-01 8.79e-02 1.61e-01 3.90e-01
Deactivation of the beta-catenin transactivating complex 39 2.33e-01 4.18e-01 0.16700 6.68e-02 1.53e-01 4.71e-01 9.72e-02
Synthesis of glycosylphosphatidylinositol (GPI) 17 4.45e-01 6.45e-01 0.16700 -4.42e-02 1.61e-01 7.52e-01 2.51e-01
Chylomicron assembly 10 7.01e-01 8.39e-01 0.16700 -9.02e-02 -1.40e-01 6.21e-01 4.43e-01
O-linked glycosylation 107 2.17e-02 7.56e-02 0.16600 -1.46e-01 -7.91e-02 9.03e-03 1.57e-01
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors 12 5.62e-01 7.38e-01 0.16600 -5.49e-02 1.56e-01 7.42e-01 3.48e-01
Molecules associated with elastic fibres 37 2.06e-01 3.87e-01 0.16600 -1.66e-01 -7.02e-04 8.12e-02 9.94e-01
Resolution of Abasic Sites (AP sites) 37 2.17e-01 4.01e-01 0.16600 1.45e-02 1.65e-01 8.79e-01 8.25e-02
Regulated proteolysis of p75NTR 11 6.10e-01 7.73e-01 0.16500 1.64e-01 -2.25e-02 3.46e-01 8.97e-01
Crosslinking of collagen fibrils 16 4.75e-01 6.77e-01 0.16500 4.00e-02 -1.60e-01 7.82e-01 2.67e-01
Sensory processing of sound by outer hair cells of the cochlea 51 1.60e-01 3.25e-01 0.16500 -7.15e-02 -1.49e-01 3.77e-01 6.58e-02
SARS-CoV-2 activates/modulates innate and adaptive immune responses 113 1.59e-02 5.82e-02 0.16500 6.10e-02 1.54e-01 2.63e-01 4.80e-03
Caspase activation via extrinsic apoptotic signalling pathway 25 4.24e-01 6.26e-01 0.16500 1.28e-01 1.04e-01 2.67e-01 3.68e-01
Aflatoxin activation and detoxification 19 3.93e-01 5.98e-01 0.16500 7.81e-02 -1.45e-01 5.56e-01 2.74e-01
Metabolism of nucleotides 95 1.92e-02 6.85e-02 0.16500 4.34e-03 1.64e-01 9.42e-01 5.58e-03
SUMOylation of transcription cofactors 43 1.68e-01 3.35e-01 0.16500 6.21e-03 1.64e-01 9.44e-01 6.21e-02
Sphingolipid de novo biosynthesis 32 2.19e-01 4.01e-01 0.16400 -1.53e-01 5.92e-02 1.34e-01 5.62e-01
Interleukin-17 signaling 66 6.41e-02 1.72e-01 0.16300 -6.07e-04 1.63e-01 9.93e-01 2.16e-02
Asparagine N-linked glycosylation 296 1.76e-05 1.58e-04 0.16300 4.33e-02 1.57e-01 1.99e-01 3.10e-06
Regulation of PLK1 Activity at G2/M Transition 83 4.47e-02 1.33e-01 0.16200 3.75e-02 1.58e-01 5.55e-01 1.27e-02
Transcriptional activation of mitochondrial biogenesis 51 1.58e-01 3.23e-01 0.16200 5.25e-02 1.54e-01 5.16e-01 5.75e-02
Beta-catenin independent WNT signaling 144 8.90e-03 3.87e-02 0.16200 1.12e-01 1.17e-01 2.00e-02 1.53e-02
RHOF GTPase cycle 40 2.67e-01 4.58e-01 0.16200 -1.03e-01 -1.25e-01 2.59e-01 1.71e-01
FGFR2b ligand binding and activation 10 6.37e-01 7.97e-01 0.16200 1.56e-01 -4.48e-02 3.94e-01 8.06e-01
MAPK targets/ Nuclear events mediated by MAP kinases 29 3.40e-01 5.48e-01 0.16200 3.67e-02 1.58e-01 7.32e-01 1.42e-01
Myogenesis 29 2.89e-01 4.82e-01 0.16100 -1.60e-01 2.25e-02 1.36e-01 8.34e-01
Glutathione synthesis and recycling 12 6.08e-01 7.73e-01 0.16100 -8.95e-03 1.61e-01 9.57e-01 3.34e-01
Activation of gene expression by SREBF (SREBP) 42 1.84e-01 3.58e-01 0.16100 2.16e-03 1.61e-01 9.81e-01 7.07e-02
Telomere C-strand (Lagging Strand) Synthesis 32 2.81e-01 4.72e-01 0.16100 7.64e-03 1.61e-01 9.40e-01 1.15e-01
Resolution of D-loop Structures through Holliday Junction Intermediates 30 3.68e-01 5.75e-01 0.16100 8.25e-02 1.38e-01 4.34e-01 1.90e-01
Reversible hydration of carbon dioxide 11 6.83e-01 8.29e-01 0.16000 6.07e-02 1.48e-01 7.28e-01 3.94e-01
Regulation of CDH11 Expression and Function 28 2.83e-01 4.73e-01 0.16000 -1.49e-01 5.71e-02 1.71e-01 6.01e-01
Antigen processing: Ubiquitination & Proteasome degradation 293 4.77e-05 4.11e-04 0.16000 6.02e-02 1.48e-01 7.58e-02 1.29e-05
Glycogen synthesis 13 6.57e-01 8.15e-01 0.15900 8.73e-02 1.33e-01 5.86e-01 4.06e-01
Blood group systems biosynthesis 22 4.94e-01 6.94e-01 0.15900 -1.29e-01 -9.21e-02 2.94e-01 4.55e-01
Lewis blood group biosynthesis 18 5.63e-01 7.38e-01 0.15900 -1.29e-01 -9.24e-02 3.44e-01 4.97e-01
Pregnenolone biosynthesis 10 7.17e-01 8.48e-01 0.15800 6.65e-02 1.44e-01 7.16e-01 4.31e-01
Glycosphingolipid catabolism 32 3.20e-01 5.24e-01 0.15800 3.72e-02 1.54e-01 7.15e-01 1.32e-01
Signaling by FGFR in disease 61 1.47e-01 3.08e-01 0.15800 1.04e-01 1.20e-01 1.62e-01 1.06e-01
Receptor-type tyrosine-protein phosphatases 16 5.15e-01 7.05e-01 0.15800 2.61e-02 -1.56e-01 8.56e-01 2.80e-01
Metabolism of steroid hormones 33 2.46e-01 4.35e-01 0.15800 3.76e-02 -1.54e-01 7.09e-01 1.27e-01
ABC transporters in lipid homeostasis 17 5.66e-01 7.41e-01 0.15800 -6.04e-02 -1.46e-01 6.67e-01 2.97e-01
RHOH GTPase cycle 36 1.89e-01 3.64e-01 0.15800 -1.02e-01 1.20e-01 2.88e-01 2.12e-01
Class I MHC mediated antigen processing & presentation 361 6.27e-06 5.99e-05 0.15800 5.73e-02 1.47e-01 6.14e-02 1.57e-06
Pre-NOTCH Transcription and Translation 45 1.90e-01 3.65e-01 0.15700 1.53e-02 1.56e-01 8.59e-01 6.98e-02
Signaling by ERBB2 TMD/JMD mutants 21 5.21e-01 7.09e-01 0.15700 1.22e-01 9.86e-02 3.33e-01 4.34e-01
Presynaptic nicotinic acetylcholine receptors 12 6.84e-01 8.29e-01 0.15700 8.23e-02 1.33e-01 6.22e-01 4.24e-01
Resolution of D-Loop Structures 31 3.69e-01 5.75e-01 0.15700 7.03e-02 1.40e-01 4.98e-01 1.78e-01
HCMV Early Events 73 8.02e-02 2.05e-01 0.15600 3.80e-02 1.52e-01 5.75e-01 2.49e-02
EGFR downregulation 30 4.00e-01 6.03e-01 0.15600 1.02e-01 1.18e-01 3.35e-01 2.62e-01
Signaling by EGFR 49 2.01e-01 3.80e-01 0.15600 5.70e-02 1.45e-01 4.90e-01 7.88e-02
SARS-CoV-2 Infection 275 1.88e-04 1.44e-03 0.15600 7.44e-02 1.37e-01 3.35e-02 9.52e-05
Synthesis of IP2, IP, and Ins in the cytosol 13 6.28e-01 7.90e-01 0.15500 -1.54e-01 -2.04e-02 3.36e-01 8.99e-01
Downstream signaling of activated FGFR1 31 3.83e-01 5.90e-01 0.15500 1.31e-01 8.35e-02 2.07e-01 4.21e-01
Creation of C4 and C2 activators 14 5.74e-01 7.49e-01 0.15500 2.20e-02 -1.54e-01 8.86e-01 3.19e-01
PKR-mediated signaling 72 1.13e-01 2.59e-01 0.15500 9.56e-02 1.22e-01 1.60e-01 7.28e-02
The phototransduction cascade 32 3.74e-01 5.80e-01 0.15500 -8.57e-02 -1.29e-01 4.01e-01 2.05e-01
Cellular hexose transport 21 4.30e-01 6.32e-01 0.15500 1.52e-01 -3.07e-02 2.29e-01 8.08e-01
Retinoid metabolism and transport 42 1.99e-01 3.79e-01 0.15500 1.22e-02 -1.54e-01 8.91e-01 8.38e-02
Transcriptional Regulation by MECP2 60 8.31e-02 2.11e-01 0.15400 -1.46e-01 4.92e-02 5.00e-02 5.09e-01
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal 89 6.42e-02 1.72e-01 0.15400 7.47e-02 1.35e-01 2.23e-01 2.77e-02
Amplification of signal from the kinetochores 89 6.42e-02 1.72e-01 0.15400 7.47e-02 1.35e-01 2.23e-01 2.77e-02
Dissolution of Fibrin Clot 13 6.72e-01 8.24e-01 0.15400 1.34e-01 7.59e-02 4.04e-01 6.36e-01
tRNA modification in the nucleus and cytosol 38 3.09e-01 5.11e-01 0.15400 6.96e-02 1.37e-01 4.58e-01 1.44e-01
Meiotic synapsis 32 2.47e-01 4.36e-01 0.15300 -1.02e-01 1.15e-01 3.20e-01 2.62e-01
Gene Silencing by RNA 80 5.98e-02 1.65e-01 0.15300 1.20e-02 1.52e-01 8.53e-01 1.84e-02
Apoptotic execution phase 43 1.60e-01 3.25e-01 0.15200 -8.32e-02 1.28e-01 3.45e-01 1.47e-01
Synthesis of bile acids and bile salts via 24-hydroxycholesterol 14 6.60e-01 8.15e-01 0.15200 -8.16e-02 -1.28e-01 5.97e-01 4.06e-01
FRS-mediated FGFR4 signaling 21 5.23e-01 7.09e-01 0.15200 5.84e-02 1.40e-01 6.43e-01 2.67e-01
Signalling to ERKs 34 2.73e-01 4.66e-01 0.15100 -2.68e-02 1.49e-01 7.87e-01 1.32e-01
RAS processing 23 4.98e-01 6.94e-01 0.15100 6.39e-02 1.37e-01 5.96e-01 2.55e-01
Interferon Signaling 256 6.92e-04 4.43e-03 0.15100 1.03e-01 1.10e-01 4.32e-03 2.35e-03
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known 37 2.07e-01 3.88e-01 0.15100 -1.03e-01 1.11e-01 2.79e-01 2.43e-01
Interleukin-4 and Interleukin-13 signaling 104 4.96e-02 1.42e-01 0.15100 1.22e-01 8.87e-02 3.10e-02 1.18e-01
Estrogen-dependent gene expression 91 5.92e-02 1.64e-01 0.15100 5.06e-02 1.42e-01 4.04e-01 1.89e-02
Keratan sulfate biosynthesis 28 3.96e-01 6.01e-01 0.15100 -1.49e-01 -2.61e-02 1.74e-01 8.11e-01
Acyl chain remodelling of PC 26 3.70e-01 5.76e-01 0.15000 3.40e-02 -1.46e-01 7.64e-01 1.96e-01
Regulation of Expression and Function of Type II Classical Cadherins 31 3.16e-01 5.19e-01 0.15000 -1.48e-01 2.44e-02 1.55e-01 8.14e-01
Regulation of Homotypic Cell-Cell Adhesion 31 3.16e-01 5.19e-01 0.15000 -1.48e-01 2.44e-02 1.55e-01 8.14e-01
Sodium/Calcium exchangers 11 6.37e-01 7.97e-01 0.14800 9.52e-02 -1.14e-01 5.84e-01 5.13e-01
Inactivation, recovery and regulation of the phototransduction cascade 31 4.24e-01 6.26e-01 0.14800 -9.31e-02 -1.15e-01 3.69e-01 2.66e-01
Diseases of signal transduction by growth factor receptors and second messengers 412 4.86e-06 4.76e-05 0.14800 4.78e-02 1.40e-01 9.53e-02 9.91e-07
Triglyceride catabolism 23 5.15e-01 7.05e-01 0.14800 -6.69e-02 -1.32e-01 5.79e-01 2.72e-01
Chromatin modifications during the maternal to zygotic transition (MZT) 11 7.09e-01 8.41e-01 0.14800 3.25e-02 1.44e-01 8.52e-01 4.07e-01
Glyoxylate metabolism and glycine degradation 30 3.59e-01 5.66e-01 0.14800 -1.40e-03 1.48e-01 9.89e-01 1.61e-01
VEGFA-VEGFR2 Pathway 95 2.19e-02 7.62e-02 0.14700 -1.13e-01 9.48e-02 5.76e-02 1.10e-01
FRS-mediated FGFR2 signaling 24 5.12e-01 7.04e-01 0.14700 7.68e-02 1.26e-01 5.15e-01 2.87e-01
Nicotinamide salvaging 17 5.32e-01 7.17e-01 0.14700 1.41e-01 -4.13e-02 3.15e-01 7.68e-01
Signaling by ALK fusions and activated point mutants 51 1.79e-01 3.52e-01 0.14700 -3.69e-03 1.47e-01 9.64e-01 7.02e-02
Signaling by ALK in cancer 51 1.79e-01 3.52e-01 0.14700 -3.69e-03 1.47e-01 9.64e-01 7.02e-02
Inositol phosphate metabolism 45 2.81e-01 4.72e-01 0.14600 -1.31e-01 -6.47e-02 1.27e-01 4.53e-01
Mitotic Prometaphase 188 4.02e-03 2.00e-02 0.14600 4.39e-02 1.39e-01 2.99e-01 9.74e-04
Pyroptosis 26 3.67e-01 5.74e-01 0.14600 -6.70e-02 1.30e-01 5.54e-01 2.52e-01
G-protein activation 24 4.00e-01 6.03e-01 0.14600 -6.14e-02 1.32e-01 6.03e-01 2.61e-01
DDX58/IFIH1-mediated induction of interferon-alpha/beta 74 1.17e-01 2.65e-01 0.14600 4.80e-02 1.38e-01 4.75e-01 4.05e-02
Glutamate Neurotransmitter Release Cycle 23 4.85e-01 6.89e-01 0.14500 1.44e-01 1.72e-02 2.30e-01 8.87e-01
AURKA Activation by TPX2 68 1.36e-01 2.93e-01 0.14500 4.21e-02 1.39e-01 5.48e-01 4.70e-02
Acyl chain remodelling of PS 21 4.91e-01 6.92e-01 0.14500 1.08e-02 -1.45e-01 9.31e-01 2.50e-01
Serotonin receptors 11 7.47e-01 8.61e-01 0.14500 -9.92e-02 -1.06e-01 5.69e-01 5.42e-01
Type I hemidesmosome assembly 11 6.97e-01 8.39e-01 0.14500 -4.63e-04 -1.45e-01 9.98e-01 4.05e-01
Sulfur amino acid metabolism 28 4.65e-01 6.67e-01 0.14500 6.78e-02 1.28e-01 5.34e-01 2.41e-01
PI Metabolism 79 5.38e-02 1.51e-01 0.14500 -1.34e-01 5.36e-02 3.87e-02 4.10e-01
Synthesis of PA 35 3.93e-01 5.98e-01 0.14500 -8.01e-02 -1.20e-01 4.12e-01 2.18e-01
Signaling by ERBB2 in Cancer 25 4.96e-01 6.94e-01 0.14400 1.34e-01 5.45e-02 2.47e-01 6.37e-01
Regulation of MECP2 expression and activity 30 3.19e-01 5.23e-01 0.14400 -1.24e-01 7.33e-02 2.38e-01 4.87e-01
DSCAM interactions 11 7.21e-01 8.52e-01 0.14400 -1.41e-01 -3.19e-02 4.19e-01 8.54e-01
FGFR3 ligand binding and activation 12 7.26e-01 8.52e-01 0.14400 7.73e-02 1.22e-01 6.43e-01 4.65e-01
FGFR3c ligand binding and activation 12 7.26e-01 8.52e-01 0.14400 7.73e-02 1.22e-01 6.43e-01 4.65e-01
Activation of BH3-only proteins 30 3.19e-01 5.23e-01 0.14400 -8.30e-02 1.17e-01 4.32e-01 2.67e-01
Scavenging by Class A Receptors 19 5.80e-01 7.52e-01 0.14300 -3.99e-02 -1.38e-01 7.63e-01 2.99e-01
Cytokine Signaling in Immune system 728 1.23e-08 2.25e-07 0.14300 9.54e-02 1.07e-01 1.11e-05 8.78e-07
Interleukin-6 signaling 11 6.59e-01 8.15e-01 0.14300 8.95e-02 -1.11e-01 6.07e-01 5.22e-01
Interleukin-35 Signalling 12 6.96e-01 8.39e-01 0.14300 -1.86e-02 -1.42e-01 9.11e-01 3.95e-01
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation 52 2.62e-01 4.54e-01 0.14300 8.71e-02 1.13e-01 2.77e-01 1.58e-01
Acyl chain remodelling of PG 18 5.18e-01 7.08e-01 0.14300 6.12e-02 -1.29e-01 6.53e-01 3.44e-01
TP53 Regulates Transcription of Caspase Activators and Caspases 12 6.35e-01 7.95e-01 0.14300 -9.15e-02 1.10e-01 5.83e-01 5.11e-01
PIP3 activates AKT signaling 276 3.29e-04 2.34e-03 0.14300 2.79e-02 1.40e-01 4.25e-01 6.21e-05
HATs acetylate histones 71 1.48e-01 3.08e-01 0.14200 5.73e-02 1.30e-01 4.04e-01 5.77e-02
Phospholipase C-mediated cascade; FGFR2 17 6.38e-01 7.98e-01 0.14200 1.26e-01 6.49e-02 3.68e-01 6.43e-01
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters 20 6.00e-01 7.65e-01 0.14200 1.15e-01 8.38e-02 3.75e-01 5.17e-01
Glucose metabolism 89 1.03e-01 2.45e-01 0.14200 7.80e-02 1.18e-01 2.03e-01 5.39e-02
PCNA-Dependent Long Patch Base Excision Repair 21 5.62e-01 7.38e-01 0.14200 4.60e-02 1.34e-01 7.15e-01 2.88e-01
Metabolism of fat-soluble vitamins 46 2.05e-01 3.85e-01 0.14100 4.40e-02 -1.34e-01 6.05e-01 1.16e-01
Resolution of Sister Chromatid Cohesion 116 5.29e-02 1.49e-01 0.14000 6.94e-02 1.22e-01 1.97e-01 2.35e-02
Death Receptor Signaling 143 3.03e-02 9.90e-02 0.14000 1.00e-01 9.78e-02 3.84e-02 4.34e-02
Signaling by Erythropoietin 25 5.21e-01 7.09e-01 0.13900 5.38e-02 1.29e-01 6.42e-01 2.65e-01
Leading Strand Synthesis 13 7.29e-01 8.52e-01 0.13900 9.64e-02 1.00e-01 5.47e-01 5.31e-01
Polymerase switching 13 7.29e-01 8.52e-01 0.13900 9.64e-02 1.00e-01 5.47e-01 5.31e-01
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription 36 4.18e-01 6.21e-01 0.13900 8.83e-02 1.07e-01 3.59e-01 2.66e-01
Glucagon signaling in metabolic regulation 32 3.49e-01 5.56e-01 0.13900 -3.70e-02 1.33e-01 7.17e-01 1.91e-01
RAC2 GTPase cycle 80 6.47e-02 1.73e-01 0.13800 -1.26e-01 5.71e-02 5.10e-02 3.77e-01
Removal of the Flap Intermediate from the C-strand 17 5.45e-01 7.27e-01 0.13800 -9.16e-02 1.04e-01 5.13e-01 4.59e-01
Downstream signaling of activated FGFR2 29 4.98e-01 6.94e-01 0.13800 8.99e-02 1.05e-01 4.02e-01 3.27e-01
Acetylcholine binding and downstream events 14 7.01e-01 8.39e-01 0.13800 1.26e-01 5.74e-02 4.15e-01 7.10e-01
Postsynaptic nicotinic acetylcholine receptors 14 7.01e-01 8.39e-01 0.13800 1.26e-01 5.74e-02 4.15e-01 7.10e-01
Post-translational protein phosphorylation 100 9.00e-02 2.23e-01 0.13800 -1.11e-01 -8.16e-02 5.42e-02 1.58e-01
Disease 1584 4.91e-17 4.58e-15 0.13800 5.76e-02 1.25e-01 1.19e-04 5.85e-17
Synthesis of PC 27 4.33e-01 6.35e-01 0.13800 -1.71e-02 1.37e-01 8.78e-01 2.19e-01
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) 20 5.81e-01 7.52e-01 0.13800 2.96e-02 1.34e-01 8.19e-01 2.98e-01
Downstream signaling of activated FGFR4 26 5.33e-01 7.18e-01 0.13800 7.65e-02 1.14e-01 4.99e-01 3.13e-01
Signaling by Interleukins 434 3.95e-05 3.44e-04 0.13800 9.39e-02 1.01e-01 7.84e-04 3.18e-04
RA biosynthesis pathway 22 4.98e-01 6.94e-01 0.13700 -2.88e-02 1.34e-01 8.15e-01 2.76e-01
Plasma lipoprotein clearance 37 4.09e-01 6.12e-01 0.13700 7.05e-02 1.17e-01 4.58e-01 2.17e-01
Prostacyclin signalling through prostacyclin receptor 19 5.69e-01 7.45e-01 0.13700 -7.26e-03 1.36e-01 9.56e-01 3.03e-01
C-type lectin receptors (CLRs) 137 3.97e-02 1.23e-01 0.13600 7.29e-02 1.15e-01 1.40e-01 2.05e-02
Arachidonic acid metabolism 56 2.50e-01 4.39e-01 0.13600 1.26e-01 5.05e-02 1.03e-01 5.14e-01
Elastic fibre formation 44 2.55e-01 4.46e-01 0.13500 -1.32e-01 3.07e-02 1.30e-01 7.25e-01
Apoptotic cleavage of cellular proteins 35 3.04e-01 5.05e-01 0.13500 -9.59e-02 9.52e-02 3.26e-01 3.30e-01
GPVI-mediated activation cascade 34 3.49e-01 5.56e-01 0.13500 -3.18e-02 1.31e-01 7.48e-01 1.85e-01
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) 14 7.25e-01 8.52e-01 0.13500 -8.50e-02 -1.05e-01 5.82e-01 4.97e-01
Diseases of hemostasis 14 7.25e-01 8.52e-01 0.13500 -8.50e-02 -1.05e-01 5.82e-01 4.97e-01
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers 28 5.05e-01 6.99e-01 0.13400 -1.25e-01 -4.95e-02 2.52e-01 6.51e-01
Mucopolysaccharidoses 10 7.42e-01 8.59e-01 0.13400 -1.32e-01 2.25e-02 4.69e-01 9.02e-01
Triglyceride metabolism 35 4.23e-01 6.26e-01 0.13400 -4.31e-02 -1.27e-01 6.59e-01 1.95e-01
MAPK1/MAPK3 signaling 272 2.31e-03 1.30e-02 0.13300 1.08e-01 7.75e-02 2.07e-03 2.77e-02
Acyl chain remodelling of PE 24 4.77e-01 6.78e-01 0.13300 4.58e-02 -1.24e-01 6.98e-01 2.91e-01
Processive synthesis on the C-strand of the telomere 19 5.38e-01 7.21e-01 0.13200 -8.60e-02 1.01e-01 5.16e-01 4.47e-01
RAF/MAP kinase cascade 266 2.91e-03 1.56e-02 0.13200 1.07e-01 7.73e-02 2.58e-03 2.98e-02
BMAL1:CLOCK,NPAS2 activates circadian gene expression 27 5.46e-01 7.28e-01 0.13200 -1.12e-01 -6.96e-02 3.13e-01 5.31e-01
Regulation of signaling by CBL 22 6.13e-01 7.75e-01 0.13200 1.10e-01 7.25e-02 3.70e-01 5.56e-01
Neurotransmitter release cycle 47 2.85e-01 4.77e-01 0.13200 1.32e-01 4.16e-03 1.18e-01 9.61e-01
Resolution of AP sites via the multiple-nucleotide patch replacement pathway 24 5.28e-01 7.13e-01 0.13200 5.44e-03 1.32e-01 9.63e-01 2.64e-01
Growth hormone receptor signaling 24 5.02e-01 6.98e-01 0.13200 2.09e-02 -1.30e-01 8.60e-01 2.70e-01
Regulation of lipid metabolism by PPARalpha 116 4.06e-02 1.25e-01 0.13200 -8.76e-03 1.31e-01 8.70e-01 1.45e-02
Phospholipase C-mediated cascade; FGFR4 14 7.34e-01 8.55e-01 0.13200 1.09e-01 7.34e-02 4.79e-01 6.34e-01
Metabolism of proteins 1777 7.82e-17 6.56e-15 0.13200 6.68e-02 1.13e-01 2.55e-06 1.29e-15
Stimuli-sensing channels 101 1.06e-01 2.48e-01 0.13100 -6.77e-02 -1.13e-01 2.39e-01 5.05e-02
HDMs demethylate histones 18 6.24e-01 7.86e-01 0.13100 7.61e-03 1.31e-01 9.55e-01 3.36e-01
Retrograde transport at the Trans-Golgi-Network 47 3.52e-01 5.59e-01 0.13100 6.55e-02 1.14e-01 4.37e-01 1.78e-01
ADP signalling through P2Y purinoceptor 12 22 5.06e-01 6.99e-01 0.13100 -5.98e-02 1.17e-01 6.27e-01 3.44e-01
Phase 4 - resting membrane potential 19 6.51e-01 8.11e-01 0.13100 -5.59e-02 -1.18e-01 6.73e-01 3.73e-01
Glycosphingolipid metabolism 42 3.54e-01 5.61e-01 0.13100 2.32e-02 1.28e-01 7.94e-01 1.50e-01
G beta:gamma signalling through PI3Kgamma 25 4.67e-01 6.69e-01 0.13100 -5.29e-02 1.19e-01 6.47e-01 3.01e-01
Transcriptional regulation by RUNX1 182 1.43e-02 5.36e-02 0.13000 3.73e-02 1.24e-01 3.85e-01 3.75e-03
Centrosome maturation 76 1.55e-01 3.20e-01 0.13000 2.22e-02 1.28e-01 7.37e-01 5.37e-02
Recruitment of mitotic centrosome proteins and complexes 76 1.55e-01 3.20e-01 0.13000 2.22e-02 1.28e-01 7.37e-01 5.37e-02
Amino acids regulate mTORC1 52 2.42e-01 4.30e-01 0.13000 -1.39e-02 1.29e-01 8.63e-01 1.07e-01
Activated point mutants of FGFR2 16 7.05e-01 8.39e-01 0.13000 1.13e-01 6.45e-02 4.36e-01 6.55e-01
GABA synthesis, release, reuptake and degradation 19 5.51e-01 7.32e-01 0.13000 9.39e-02 -8.94e-02 4.78e-01 5.00e-01
Signaling by WNT 263 3.46e-03 1.78e-02 0.13000 6.38e-02 1.13e-01 7.46e-02 1.63e-03
Signaling by VEGF 103 4.16e-02 1.27e-01 0.12900 -1.03e-01 7.78e-02 6.99e-02 1.73e-01
PPARA activates gene expression 114 4.52e-02 1.34e-01 0.12900 -1.63e-02 1.28e-01 7.63e-01 1.81e-02
RND2 GTPase cycle 41 4.13e-01 6.16e-01 0.12900 -1.13e-01 -6.26e-02 2.11e-01 4.88e-01
Regulation of localization of FOXO transcription factors 11 7.88e-01 8.85e-01 0.12900 -1.14e-01 -6.02e-02 5.13e-01 7.29e-01
Synthesis of IP3 and IP4 in the cytosol 25 5.97e-01 7.65e-01 0.12800 -9.18e-02 -8.96e-02 4.27e-01 4.38e-01
EML4 and NUDC in mitotic spindle formation 111 9.86e-02 2.38e-01 0.12800 7.06e-02 1.07e-01 1.99e-01 5.18e-02
Sealing of the nuclear envelope (NE) by ESCRT-III 31 5.28e-01 7.13e-01 0.12800 8.13e-02 9.88e-02 4.33e-01 3.41e-01
Golgi Associated Vesicle Biogenesis 51 2.16e-01 4.01e-01 0.12800 -6.83e-02 1.08e-01 3.99e-01 1.81e-01
G alpha (s) signalling events 154 4.33e-02 1.31e-01 0.12800 -9.47e-02 -8.59e-02 4.25e-02 6.57e-02
Prolactin receptor signaling 15 7.09e-01 8.41e-01 0.12800 3.32e-02 1.23e-01 8.24e-01 4.08e-01
PI-3K cascade:FGFR3 17 7.00e-01 8.39e-01 0.12700 1.09e-01 6.56e-02 4.35e-01 6.39e-01
Signaling by high-kinase activity BRAF mutants 34 4.61e-01 6.63e-01 0.12700 3.32e-02 1.23e-01 7.38e-01 2.15e-01
APC truncation mutants have impaired AXIN binding 13 7.05e-01 8.39e-01 0.12700 -2.19e-02 1.25e-01 8.91e-01 4.34e-01
AXIN missense mutants destabilize the destruction complex 13 7.05e-01 8.39e-01 0.12700 -2.19e-02 1.25e-01 8.91e-01 4.34e-01
Signaling by AMER1 mutants 13 7.05e-01 8.39e-01 0.12700 -2.19e-02 1.25e-01 8.91e-01 4.34e-01
Signaling by APC mutants 13 7.05e-01 8.39e-01 0.12700 -2.19e-02 1.25e-01 8.91e-01 4.34e-01
Signaling by AXIN mutants 13 7.05e-01 8.39e-01 0.12700 -2.19e-02 1.25e-01 8.91e-01 4.34e-01
Truncations of AMER1 destabilize the destruction complex 13 7.05e-01 8.39e-01 0.12700 -2.19e-02 1.25e-01 8.91e-01 4.34e-01
Regulation of actin dynamics for phagocytic cup formation 59 3.05e-01 5.06e-01 0.12700 9.35e-02 8.56e-02 2.14e-01 2.55e-01
Repression of WNT target genes 13 6.86e-01 8.30e-01 0.12700 5.73e-02 -1.13e-01 7.20e-01 4.80e-01
Chromatin modifying enzymes 185 1.08e-02 4.40e-02 0.12600 4.11e-03 1.26e-01 9.23e-01 3.01e-03
Chromatin organization 185 1.08e-02 4.40e-02 0.12600 4.11e-03 1.26e-01 9.23e-01 3.01e-03
Neurexins and neuroligins 52 3.46e-01 5.55e-01 0.12600 -6.81e-02 -1.06e-01 3.95e-01 1.85e-01
Loss of Nlp from mitotic centrosomes 65 2.20e-01 4.02e-01 0.12600 1.64e-02 1.25e-01 8.19e-01 8.25e-02
Loss of proteins required for interphase microtubule organization from the centrosome 65 2.20e-01 4.02e-01 0.12600 1.64e-02 1.25e-01 8.19e-01 8.25e-02
Recruitment of NuMA to mitotic centrosomes 89 1.37e-01 2.93e-01 0.12500 2.78e-02 1.22e-01 6.50e-01 4.62e-02
PIWI-interacting RNA (piRNA) biogenesis 29 5.37e-01 7.21e-01 0.12500 1.18e-01 3.99e-02 2.70e-01 7.10e-01
Signaling by NOTCH1 69 2.39e-01 4.27e-01 0.12500 5.05e-02 1.14e-01 4.69e-01 1.01e-01
Reduction of cytosolic Ca++ levels 11 7.28e-01 8.52e-01 0.12500 7.44e-02 -1.00e-01 6.69e-01 5.65e-01
Iron uptake and transport 57 3.29e-01 5.35e-01 0.12500 8.39e-02 9.23e-02 2.73e-01 2.28e-01
VEGFR2 mediated cell proliferation 19 5.86e-01 7.54e-01 0.12400 -1.07e-01 6.33e-02 4.21e-01 6.33e-01
SHC1 events in ERBB4 signaling 14 7.15e-01 8.47e-01 0.12400 -6.23e-04 1.24e-01 9.97e-01 4.22e-01
CTNNB1 S33 mutants aren’t phosphorylated 14 6.77e-01 8.24e-01 0.12400 -6.05e-02 1.08e-01 6.95e-01 4.85e-01
CTNNB1 S37 mutants aren’t phosphorylated 14 6.77e-01 8.24e-01 0.12400 -6.05e-02 1.08e-01 6.95e-01 4.85e-01
CTNNB1 S45 mutants aren’t phosphorylated 14 6.77e-01 8.24e-01 0.12400 -6.05e-02 1.08e-01 6.95e-01 4.85e-01
CTNNB1 T41 mutants aren’t phosphorylated 14 6.77e-01 8.24e-01 0.12400 -6.05e-02 1.08e-01 6.95e-01 4.85e-01
Signaling by CTNNB1 phospho-site mutants 14 6.77e-01 8.24e-01 0.12400 -6.05e-02 1.08e-01 6.95e-01 4.85e-01
Signaling by GSK3beta mutants 14 6.77e-01 8.24e-01 0.12400 -6.05e-02 1.08e-01 6.95e-01 4.85e-01
Intracellular signaling by second messengers 314 1.01e-03 6.31e-03 0.12400 2.16e-02 1.22e-01 5.10e-01 2.04e-04
RHOB GTPase cycle 66 2.74e-01 4.66e-01 0.12400 -1.06e-01 -6.42e-02 1.38e-01 3.67e-01
Post-translational modification: synthesis of GPI-anchored proteins 89 9.64e-02 2.33e-01 0.12300 3.62e-02 -1.18e-01 5.55e-01 5.43e-02
Signaling by ERBB2 KD Mutants 24 6.14e-01 7.76e-01 0.12300 1.13e-01 4.80e-02 3.36e-01 6.84e-01
Adherens junctions interactions 52 3.72e-01 5.78e-01 0.12300 -9.46e-02 -7.87e-02 2.38e-01 3.26e-01
Phenylalanine and tyrosine metabolism 10 8.06e-01 8.96e-01 0.12300 2.75e-02 1.20e-01 8.80e-01 5.12e-01
MAPK3 (ERK1) activation 10 7.80e-01 8.81e-01 0.12200 1.21e-01 -1.99e-02 5.08e-01 9.13e-01
Circadian Clock 69 1.47e-01 3.08e-01 0.12200 -9.14e-02 8.11e-02 1.89e-01 2.44e-01
Signaling by KIT in disease 20 6.59e-01 8.15e-01 0.12200 3.33e-02 1.17e-01 7.97e-01 3.63e-01
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants 20 6.59e-01 8.15e-01 0.12200 3.33e-02 1.17e-01 7.97e-01 3.63e-01
Nuclear signaling by ERBB4 32 4.26e-01 6.28e-01 0.12200 5.04e-02 -1.11e-01 6.22e-01 2.76e-01
Cell-cell junction organization 82 2.18e-01 4.01e-01 0.12200 -8.05e-02 -9.14e-02 2.08e-01 1.52e-01
Downstream signal transduction 29 5.20e-01 7.09e-01 0.12200 7.12e-03 1.22e-01 9.47e-01 2.57e-01
Association of TriC/CCT with target proteins during biosynthesis 36 5.08e-01 7.01e-01 0.12200 9.96e-02 7.00e-02 3.01e-01 4.67e-01
Innate Immune System 999 1.97e-09 4.22e-08 0.12100 2.93e-02 1.18e-01 1.16e-01 2.57e-10
Axon guidance 526 4.64e-05 4.02e-04 0.12100 1.09e-01 5.37e-02 1.92e-05 3.46e-02
Negative regulation of NMDA receptor-mediated neuronal transmission 20 6.53e-01 8.13e-01 0.12000 -1.77e-02 -1.19e-01 8.91e-01 3.57e-01
Translocation of SLC2A4 (GLUT4) to the plasma membrane 71 1.83e-01 3.57e-01 0.12000 -2.02e-02 1.18e-01 7.68e-01 8.44e-02
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 14 7.35e-01 8.55e-01 0.12000 6.70e-03 1.20e-01 9.65e-01 4.37e-01
SARS-CoV-2 targets host intracellular signalling and regulatory pathways 12 7.39e-01 8.57e-01 0.12000 -1.14e-01 3.86e-02 4.95e-01 8.17e-01
Visual phototransduction 93 1.61e-01 3.27e-01 0.11900 -3.69e-02 -1.14e-01 5.38e-01 5.82e-02
Signaling by ERBB2 49 4.08e-01 6.11e-01 0.11900 5.91e-02 1.03e-01 4.74e-01 2.11e-01
Translation of Structural Proteins 9694635 55 3.35e-01 5.42e-01 0.11900 3.11e-02 1.15e-01 6.90e-01 1.41e-01
Signaling by Retinoic Acid 41 3.69e-01 5.75e-01 0.11900 -3.41e-02 1.14e-01 7.05e-01 2.08e-01
Mismatch Repair 15 7.44e-01 8.60e-01 0.11900 3.16e-02 1.14e-01 8.32e-01 4.43e-01
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 126 4.34e-02 1.31e-01 0.11800 1.06e-01 -5.16e-02 3.98e-02 3.17e-01
Signal transduction by L1 20 6.89e-01 8.33e-01 0.11700 1.09e-01 4.33e-02 3.98e-01 7.38e-01
FGFR4 ligand binding and activation 13 7.99e-01 8.93e-01 0.11700 9.11e-02 7.36e-02 5.69e-01 6.46e-01
Intraflagellar transport 47 3.81e-01 5.88e-01 0.11700 1.16e-01 1.06e-02 1.67e-01 9.00e-01
PECAM1 interactions 12 7.93e-01 8.88e-01 0.11700 1.13e-01 2.85e-02 4.97e-01 8.64e-01
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 117 1.26e-01 2.78e-01 0.11700 -5.49e-02 -1.03e-01 3.05e-01 5.41e-02
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function 37 4.09e-01 6.12e-01 0.11700 -1.08e-01 4.50e-02 2.57e-01 6.35e-01
Nervous system development 550 5.77e-05 4.90e-04 0.11700 1.07e-01 4.73e-02 1.83e-05 5.76e-02
LDL clearance 19 7.00e-01 8.39e-01 0.11700 1.11e-01 3.52e-02 4.02e-01 7.90e-01
Synthesis of PE 12 7.51e-01 8.64e-01 0.11600 -4.13e-02 1.09e-01 8.04e-01 5.14e-01
Platelet calcium homeostasis 27 5.10e-01 7.03e-01 0.11600 -9.60e-02 6.56e-02 3.88e-01 5.55e-01
Pyruvate metabolism and Citric Acid (TCA) cycle 52 3.69e-01 5.75e-01 0.11600 2.57e-02 1.13e-01 7.49e-01 1.58e-01
G-protein beta:gamma signalling 30 4.72e-01 6.74e-01 0.11600 -7.75e-02 8.62e-02 4.62e-01 4.14e-01
Triglyceride biosynthesis 12 7.77e-01 8.81e-01 0.11600 2.42e-03 -1.16e-01 9.88e-01 4.88e-01
Synthesis of PIPs at the early endosome membrane 15 7.30e-01 8.52e-01 0.11500 -1.15e-01 3.98e-03 4.40e-01 9.79e-01
Carboxyterminal post-translational modifications of tubulin 44 3.78e-01 5.84e-01 0.11500 1.13e-01 -2.06e-02 1.93e-01 8.13e-01
RHO GTPases Activate Formins 132 1.13e-01 2.59e-01 0.11500 7.72e-02 8.53e-02 1.25e-01 9.05e-02
Chondroitin sulfate/dermatan sulfate metabolism 45 3.65e-01 5.73e-01 0.11500 -2.61e-02 1.12e-01 7.62e-01 1.93e-01
FOXO-mediated transcription 65 3.22e-01 5.26e-01 0.11500 1.04e-01 4.77e-02 1.46e-01 5.06e-01
MAPK family signaling cascades 313 5.84e-03 2.75e-02 0.11500 9.20e-02 6.83e-02 5.08e-03 3.75e-02
Pyruvate metabolism 29 4.99e-01 6.95e-01 0.11400 -6.05e-02 9.70e-02 5.72e-01 3.66e-01
Incretin synthesis, secretion, and inactivation 23 6.07e-01 7.72e-01 0.11400 -1.89e-02 1.13e-01 8.75e-01 3.49e-01
Zinc transporters 15 7.73e-01 8.81e-01 0.11400 1.02e-01 5.19e-02 4.95e-01 7.28e-01
Dermatan sulfate biosynthesis 10 7.86e-01 8.84e-01 0.11400 -8.81e-02 7.22e-02 6.29e-01 6.93e-01
Intrinsic Pathway for Apoptosis 52 4.30e-01 6.32e-01 0.11400 7.37e-02 8.66e-02 3.58e-01 2.80e-01
Mitochondrial Fatty Acid Beta-Oxidation 35 4.68e-01 6.69e-01 0.11300 -2.49e-02 1.11e-01 7.99e-01 2.58e-01
Synthesis of very long-chain fatty acyl-CoAs 23 6.77e-01 8.24e-01 0.11300 -4.78e-02 -1.03e-01 6.92e-01 3.94e-01
Synthesis, secretion, and deacylation of Ghrelin 19 7.37e-01 8.56e-01 0.11300 7.61e-02 8.36e-02 5.66e-01 5.28e-01
Transport of connexons to the plasma membrane 20 6.50e-01 8.10e-01 0.11300 1.10e-01 -2.61e-02 3.96e-01 8.40e-01
Netrin-1 signaling 49 4.58e-01 6.59e-01 0.11300 -8.72e-02 -7.13e-02 2.91e-01 3.88e-01
Signaling by Hippo 19 7.35e-01 8.55e-01 0.11300 -6.18e-02 -9.41e-02 6.41e-01 4.77e-01
Signaling by NTRK2 (TRKB) 25 6.58e-01 8.15e-01 0.11200 4.82e-02 1.02e-01 6.76e-01 3.79e-01
Synthesis of PIPs at the Golgi membrane 17 6.81e-01 8.27e-01 0.11200 -1.01e-01 4.86e-02 4.70e-01 7.29e-01
Regulation of Complement cascade 45 4.91e-01 6.92e-01 0.11200 -6.82e-02 -8.88e-02 4.29e-01 3.03e-01
Effects of PIP2 hydrolysis 26 6.66e-01 8.19e-01 0.11200 -7.87e-02 -7.93e-02 4.87e-01 4.84e-01
M-decay: degradation of maternal mRNAs by maternally stored factors 45 4.58e-01 6.59e-01 0.11200 3.14e-02 1.07e-01 7.15e-01 2.13e-01
Complement cascade 56 4.06e-01 6.09e-01 0.11200 -5.59e-02 -9.66e-02 4.69e-01 2.11e-01
Synaptic adhesion-like molecules 19 7.35e-01 8.55e-01 0.11200 9.84e-02 5.26e-02 4.58e-01 6.92e-01
Translation of Structural Proteins 9683701 29 6.33e-01 7.94e-01 0.11200 9.05e-02 6.52e-02 3.99e-01 5.43e-01
NCAM signaling for neurite out-growth 62 2.62e-01 4.54e-01 0.11100 3.64e-02 -1.05e-01 6.20e-01 1.52e-01
Transport of inorganic cations/anions and amino acids/oligopeptides 101 1.34e-01 2.89e-01 0.11100 1.03e-02 -1.11e-01 8.58e-01 5.43e-02
SARS-CoV-1 targets host intracellular signalling and regulatory pathways 16 7.12e-01 8.45e-01 0.11100 -3.16e-02 1.06e-01 8.27e-01 4.62e-01
Post-translational protein modification 1313 9.66e-10 2.25e-08 0.11000 3.32e-02 1.05e-01 4.22e-02 1.61e-10
Signaling by NTRK3 (TRKC) 17 7.47e-01 8.61e-01 0.10900 2.27e-02 1.07e-01 8.71e-01 4.45e-01
PLC beta mediated events 47 4.26e-01 6.27e-01 0.10900 -1.09e-01 -6.10e-03 1.96e-01 9.42e-01
Rab regulation of trafficking 113 1.05e-01 2.46e-01 0.10900 -2.36e-02 1.06e-01 6.65e-01 5.07e-02
Peptide hormone metabolism 81 1.98e-01 3.78e-01 0.10900 -1.06e-01 2.47e-02 9.93e-02 7.00e-01
Signaling by FGFR3 in disease 21 7.30e-01 8.52e-01 0.10800 5.49e-02 9.27e-02 6.63e-01 4.62e-01
NPAS4 regulates expression of target genes 21 6.57e-01 8.15e-01 0.10700 1.03e-01 -3.19e-02 4.16e-01 8.00e-01
ER to Golgi Anterograde Transport 152 8.30e-02 2.11e-01 0.10700 1.94e-02 1.05e-01 6.80e-01 2.57e-02
ESR-mediated signaling 161 6.70e-02 1.76e-01 0.10700 1.26e-02 1.06e-01 7.83e-01 2.05e-02
Basigin interactions 24 6.55e-01 8.14e-01 0.10600 3.63e-04 1.06e-01 9.98e-01 3.67e-01
G-protein mediated events 52 3.93e-01 5.98e-01 0.10600 -1.06e-01 5.61e-03 1.85e-01 9.44e-01
Post-chaperonin tubulin folding pathway 23 7.22e-01 8.52e-01 0.10600 7.31e-02 7.70e-02 5.44e-01 5.22e-01
DARPP-32 events 24 6.83e-01 8.29e-01 0.10600 2.62e-02 1.03e-01 8.24e-01 3.83e-01
Keratan sulfate degradation 15 8.10e-01 8.99e-01 0.10600 -6.79e-02 -8.09e-02 6.49e-01 5.88e-01
Immune System 1921 2.21e-12 8.55e-11 0.10600 3.80e-02 9.85e-02 5.56e-03 6.32e-13
Activation of AMPK downstream of NMDARs 28 6.71e-01 8.24e-01 0.10500 8.92e-02 5.62e-02 4.14e-01 6.07e-01
Metabolic disorders of biological oxidation enzymes 32 5.56e-01 7.36e-01 0.10500 1.64e-02 -1.04e-01 8.73e-01 3.08e-01
GPER1 signaling 45 4.00e-01 6.03e-01 0.10500 -5.78e-02 8.80e-02 5.02e-01 3.07e-01
Tight junction interactions 28 6.74e-01 8.24e-01 0.10500 -5.88e-02 -8.71e-02 5.90e-01 4.25e-01
EPHA-mediated growth cone collapse 29 6.14e-01 7.76e-01 0.10500 -1.05e-01 -4.31e-03 3.29e-01 9.68e-01
Protein folding 94 2.66e-01 4.58e-01 0.10400 5.16e-02 9.08e-02 3.87e-01 1.28e-01
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding 38 5.78e-01 7.52e-01 0.10400 4.36e-02 9.49e-02 6.42e-01 3.12e-01
G beta:gamma signalling through BTK 17 7.46e-01 8.61e-01 0.10400 -3.34e-03 1.04e-01 9.81e-01 4.56e-01
Signaling by PDGFRA extracellular domain mutants 12 7.86e-01 8.84e-01 0.10400 -5.88e-02 8.61e-02 7.24e-01 6.05e-01
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants 12 7.86e-01 8.84e-01 0.10400 -5.88e-02 8.61e-02 7.24e-01 6.05e-01
G beta:gamma signalling through CDC42 19 7.14e-01 8.46e-01 0.10400 -1.25e-02 1.04e-01 9.25e-01 4.35e-01
Cell surface interactions at the vascular wall 129 7.72e-02 2.00e-01 0.10400 -6.37e-02 8.18e-02 2.11e-01 1.09e-01
RHO GTPases activate PAKs 19 7.75e-01 8.81e-01 0.10300 -7.74e-02 -6.86e-02 5.59e-01 6.05e-01
Formation of WDR5-containing histone-modifying complexes 37 5.06e-01 6.99e-01 0.10300 -2.94e-02 9.91e-02 7.57e-01 2.97e-01
Cargo recognition for clathrin-mediated endocytosis 98 2.38e-01 4.26e-01 0.10300 3.18e-02 9.82e-02 5.86e-01 9.29e-02
Interleukin-27 signaling 11 8.31e-01 9.09e-01 0.10300 5.16e-03 -1.03e-01 9.76e-01 5.56e-01
RMTs methylate histone arginines 30 5.63e-01 7.38e-01 0.10200 -5.21e-02 8.82e-02 6.21e-01 4.03e-01
Cobalamin (Cbl, vitamin B12) transport and metabolism 20 7.04e-01 8.39e-01 0.10200 2.06e-02 -1.00e-01 8.73e-01 4.38e-01
Adaptive Immune System 733 7.65e-05 6.35e-04 0.10200 5.45e-02 8.60e-02 1.17e-02 7.04e-05
Biotin transport and metabolism 10 8.51e-01 9.22e-01 0.10200 -1.79e-04 1.02e-01 9.99e-01 5.77e-01
Removal of the Flap Intermediate 13 8.41e-01 9.16e-01 0.10200 5.20e-02 8.75e-02 7.46e-01 5.85e-01
RAC3 GTPase cycle 84 2.08e-01 3.88e-01 0.10200 -8.92e-02 4.87e-02 1.57e-01 4.40e-01
Platelet sensitization by LDL 17 7.37e-01 8.56e-01 0.10200 -3.26e-02 9.62e-02 8.16e-01 4.92e-01
Interleukin-3, Interleukin-5 and GM-CSF signaling 45 5.56e-01 7.36e-01 0.10100 5.96e-02 8.21e-02 4.89e-01 3.41e-01
RND1 GTPase cycle 41 4.96e-01 6.94e-01 0.10100 -9.97e-02 1.82e-02 2.69e-01 8.41e-01
VxPx cargo-targeting to cilium 20 7.63e-01 8.75e-01 0.10100 -4.28e-02 -9.16e-02 7.40e-01 4.78e-01
Deadenylation of mRNA 25 6.64e-01 8.17e-01 0.10100 -1.01e-01 7.32e-03 3.83e-01 9.49e-01
RAF activation 33 5.60e-01 7.38e-01 0.10100 -3.05e-02 9.60e-02 7.61e-01 3.40e-01
PI-3K cascade:FGFR2 22 7.28e-01 8.52e-01 0.10000 9.81e-02 2.13e-02 4.26e-01 8.63e-01
Paradoxical activation of RAF signaling by kinase inactive BRAF 43 5.83e-01 7.52e-01 0.10000 6.95e-02 7.22e-02 4.31e-01 4.13e-01
Signaling by RAS mutants 43 5.83e-01 7.52e-01 0.10000 6.95e-02 7.22e-02 4.31e-01 4.13e-01
Signaling by moderate kinase activity BRAF mutants 43 5.83e-01 7.52e-01 0.10000 6.95e-02 7.22e-02 4.31e-01 4.13e-01
Signaling downstream of RAS mutants 43 5.83e-01 7.52e-01 0.10000 6.95e-02 7.22e-02 4.31e-01 4.13e-01
FCGR3A-mediated phagocytosis 57 4.87e-01 6.89e-01 0.10000 7.82e-02 6.25e-02 3.07e-01 4.14e-01
Leishmania phagocytosis 57 4.87e-01 6.89e-01 0.10000 7.82e-02 6.25e-02 3.07e-01 4.14e-01
Parasite infection 57 4.87e-01 6.89e-01 0.10000 7.82e-02 6.25e-02 3.07e-01 4.14e-01
Long-term potentiation 22 6.84e-01 8.29e-01 0.09990 2.94e-02 -9.55e-02 8.12e-01 4.38e-01
Tandem pore domain potassium channels 12 8.51e-01 9.22e-01 0.09980 -9.27e-02 -3.71e-02 5.78e-01 8.24e-01
Regulation of pyruvate dehydrogenase (PDH) complex 14 7.76e-01 8.81e-01 0.09950 -5.03e-02 8.58e-02 7.44e-01 5.78e-01
Metabolism of folate and pterines 16 7.52e-01 8.64e-01 0.09930 -4.59e-02 8.80e-02 7.50e-01 5.42e-01
Cardiac conduction 125 1.61e-01 3.27e-01 0.09930 -1.18e-02 -9.86e-02 8.20e-01 5.69e-02
Signaling by ERBB4 57 4.74e-01 6.76e-01 0.09920 9.08e-02 3.99e-02 2.36e-01 6.02e-01
Amyloid fiber formation 53 4.89e-01 6.90e-01 0.09910 9.41e-02 3.13e-02 2.36e-01 6.93e-01
Factors involved in megakaryocyte development and platelet production 147 6.97e-02 1.82e-01 0.09880 -7.03e-02 6.94e-02 1.41e-01 1.46e-01
Glycogen metabolism 22 7.23e-01 8.52e-01 0.09790 3.73e-03 9.79e-02 9.76e-01 4.27e-01
Gap junction assembly 36 5.34e-01 7.19e-01 0.09790 8.61e-02 -4.67e-02 3.71e-01 6.27e-01
Activation of BAD and translocation to mitochondria 15 7.68e-01 8.80e-01 0.09760 -7.88e-02 5.77e-02 5.97e-01 6.99e-01
Glutamate binding, activation of AMPA receptors and synaptic plasticity 29 6.73e-01 8.24e-01 0.09710 9.55e-02 1.79e-02 3.74e-01 8.68e-01
Trafficking of AMPA receptors 29 6.73e-01 8.24e-01 0.09710 9.55e-02 1.79e-02 3.74e-01 8.68e-01
Interleukin-37 signaling 20 7.05e-01 8.39e-01 0.09700 -5.97e-02 7.64e-02 6.44e-01 5.54e-01
Phase I - Functionalization of compounds 100 1.85e-01 3.59e-01 0.09680 4.35e-02 -8.65e-02 4.52e-01 1.35e-01
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer 49 5.03e-01 6.98e-01 0.09680 9.37e-03 9.63e-02 9.10e-01 2.43e-01
Processive synthesis on the lagging strand 14 8.35e-01 9.11e-01 0.09670 3.04e-02 9.18e-02 8.44e-01 5.52e-01
Listeria monocytogenes entry into host cells 19 7.90e-01 8.86e-01 0.09660 4.05e-02 8.78e-02 7.60e-01 5.08e-01
MHC class II antigen presentation 122 2.39e-01 4.27e-01 0.09640 5.77e-02 7.73e-02 2.71e-01 1.40e-01
ADORA2B mediated anti-inflammatory cytokines production 42 4.87e-01 6.89e-01 0.09640 -5.40e-02 7.99e-02 5.45e-01 3.70e-01
Endogenous sterols 26 7.30e-01 8.52e-01 0.09640 -8.48e-02 -4.58e-02 4.54e-01 6.86e-01
Norepinephrine Neurotransmitter Release Cycle 16 8.28e-01 9.07e-01 0.09630 -5.43e-02 -7.96e-02 7.07e-01 5.82e-01
Chaperonin-mediated protein folding 88 3.55e-01 5.61e-01 0.09630 5.43e-02 7.96e-02 3.79e-01 1.97e-01
Ion transport by P-type ATPases 51 4.44e-01 6.44e-01 0.09610 2.77e-02 -9.20e-02 7.32e-01 2.56e-01
Activation of the AP-1 family of transcription factors 10 8.52e-01 9.23e-01 0.09590 9.11e-02 -2.98e-02 6.18e-01 8.70e-01
Ephrin signaling 17 8.03e-01 8.96e-01 0.09570 -9.26e-02 -2.41e-02 5.09e-01 8.64e-01
Bacterial Infection Pathways 68 4.57e-01 6.59e-01 0.09560 5.83e-02 7.58e-02 4.06e-01 2.80e-01
PKMTs methylate histone lysines 36 5.44e-01 7.27e-01 0.09530 -7.09e-02 6.36e-02 4.62e-01 5.09e-01
NRAGE signals death through JNK 53 5.50e-01 7.31e-01 0.09480 -7.29e-02 -6.05e-02 3.59e-01 4.46e-01
Sema4D in semaphorin signaling 24 6.90e-01 8.33e-01 0.09460 -2.79e-02 9.04e-02 8.13e-01 4.43e-01
Membrane Trafficking 605 1.92e-04 1.47e-03 0.09460 -9.14e-03 9.41e-02 7.00e-01 7.39e-05
Meiosis 56 3.99e-01 6.03e-01 0.09430 -5.35e-02 7.77e-02 4.88e-01 3.14e-01
ERBB2 Regulates Cell Motility 15 7.80e-01 8.81e-01 0.09430 6.51e-02 -6.82e-02 6.63e-01 6.47e-01
Formation of the beta-catenin:TCF transactivating complex 32 5.99e-01 7.65e-01 0.09410 8.40e-02 -4.25e-02 4.11e-01 6.77e-01
Rap1 signalling 16 8.34e-01 9.11e-01 0.09300 4.16e-02 8.32e-02 7.73e-01 5.65e-01
CD28 co-stimulation 32 6.02e-01 7.66e-01 0.09230 -6.38e-02 6.67e-02 5.32e-01 5.14e-01
Adenylate cyclase activating pathway 10 8.63e-01 9.30e-01 0.09180 3.05e-02 -8.65e-02 8.67e-01 6.36e-01
Acetylcholine Neurotransmitter Release Cycle 16 7.82e-01 8.81e-01 0.09160 4.87e-02 -7.76e-02 7.36e-01 5.91e-01
RND3 GTPase cycle 41 6.00e-01 7.65e-01 0.09110 -9.07e-02 -8.39e-03 3.15e-01 9.26e-01
Neurotoxicity of clostridium toxins 10 8.94e-01 9.47e-01 0.09070 -3.21e-02 -8.49e-02 8.61e-01 6.42e-01
Ion channel transport 173 1.52e-01 3.15e-01 0.09060 -3.60e-02 -8.32e-02 4.14e-01 5.90e-02
Transport to the Golgi and subsequent modification 183 9.17e-02 2.26e-01 0.09060 -6.28e-03 9.04e-02 8.83e-01 3.49e-02
Signaling by Non-Receptor Tyrosine Kinases 55 4.68e-01 6.69e-01 0.09030 -2.10e-02 8.78e-02 7.88e-01 2.60e-01
Signaling by PTK6 55 4.68e-01 6.69e-01 0.09030 -2.10e-02 8.78e-02 7.88e-01 2.60e-01
Signaling by Activin 17 7.73e-01 8.81e-01 0.09020 6.49e-02 -6.27e-02 6.43e-01 6.54e-01
Heme biosynthesis 13 8.33e-01 9.11e-01 0.09020 2.49e-02 -8.67e-02 8.76e-01 5.88e-01
IL-6-type cytokine receptor ligand interactions 17 8.13e-01 9.01e-01 0.08950 -6.11e-03 -8.93e-02 9.65e-01 5.24e-01
Cell junction organization 107 3.34e-01 5.40e-01 0.08940 -4.61e-02 -7.66e-02 4.10e-01 1.71e-01
Gap junction trafficking 47 5.15e-01 7.05e-01 0.08920 8.21e-02 -3.48e-02 3.30e-01 6.80e-01
RAC1 GTPase cycle 170 1.07e-01 2.50e-01 0.08900 -8.76e-02 1.57e-02 4.86e-02 7.23e-01
Protein-protein interactions at synapses 78 4.45e-01 6.45e-01 0.08900 -4.02e-02 -7.94e-02 5.39e-01 2.25e-01
Azathioprine ADME 22 7.43e-01 8.59e-01 0.08900 -2.22e-02 8.62e-02 8.57e-01 4.84e-01
Ca2+ pathway 62 5.35e-01 7.19e-01 0.08900 -7.39e-02 -4.95e-02 3.14e-01 5.00e-01
Cell-Cell communication 144 2.33e-01 4.18e-01 0.08890 -4.62e-02 -7.59e-02 3.38e-01 1.16e-01
Muscle contraction 197 9.35e-02 2.28e-01 0.08890 -3.63e-03 -8.88e-02 9.30e-01 3.15e-02
Keratan sulfate/keratin metabolism 36 6.24e-01 7.86e-01 0.08890 -8.76e-02 1.50e-02 3.63e-01 8.76e-01
Other semaphorin interactions 18 8.04e-01 8.96e-01 0.08870 -8.87e-02 -2.72e-03 5.15e-01 9.84e-01
Signaling by BRAF and RAF1 fusions 62 4.31e-01 6.33e-01 0.08850 -2.67e-02 8.44e-02 7.16e-01 2.50e-01
Clathrin-mediated endocytosis 137 2.32e-01 4.18e-01 0.08780 2.51e-02 8.41e-02 6.12e-01 8.90e-02
Metabolism of nitric oxide: NOS3 activation and regulation 14 8.29e-01 9.07e-01 0.08770 -8.32e-02 2.77e-02 5.90e-01 8.57e-01
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes 29 6.61e-01 8.15e-01 0.08770 6.89e-02 -5.42e-02 5.21e-01 6.13e-01
Interleukin-7 signaling 21 7.79e-01 8.81e-01 0.08770 8.76e-02 1.90e-03 4.87e-01 9.88e-01
RHO GTPase Effectors 250 8.18e-02 2.09e-01 0.08760 3.85e-02 7.87e-02 2.94e-01 3.21e-02
Formation of annular gap junctions 11 8.99e-01 9.51e-01 0.08650 7.44e-02 4.40e-02 6.69e-01 8.00e-01
Response to metal ions 14 8.62e-01 9.30e-01 0.08640 8.40e-02 2.01e-02 5.86e-01 8.96e-01
Signaling by Nuclear Receptors 238 4.97e-02 1.42e-01 0.08620 -2.25e-02 8.32e-02 5.50e-01 2.69e-02
Sema4D induced cell migration and growth-cone collapse 20 7.76e-01 8.81e-01 0.08610 -2.14e-02 8.34e-02 8.68e-01 5.18e-01
Unblocking of NMDA receptors, glutamate binding and activation 19 7.82e-01 8.81e-01 0.08590 2.91e-02 -8.08e-02 8.26e-01 5.42e-01
Phospholipid metabolism 192 7.84e-02 2.02e-01 0.08580 -7.57e-02 4.05e-02 7.04e-02 3.33e-01
eNOS activation 10 8.92e-01 9.47e-01 0.08580 -8.58e-02 -2.00e-03 6.39e-01 9.91e-01
Signaling by RAF1 mutants 39 7.00e-01 8.39e-01 0.08540 5.72e-02 6.35e-02 5.37e-01 4.93e-01
Glycosaminoglycan metabolism 120 2.13e-01 3.96e-01 0.08540 -7.89e-02 3.26e-02 1.35e-01 5.38e-01
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane 19 7.94e-01 8.88e-01 0.08530 8.38e-02 -1.59e-02 5.27e-01 9.05e-01
G alpha (i) signalling events 305 6.43e-02 1.72e-01 0.08520 -6.11e-02 -5.94e-02 6.62e-02 7.41e-02
The role of Nef in HIV-1 replication and disease pathogenesis 27 7.79e-01 8.81e-01 0.08510 7.08e-02 4.72e-02 5.25e-01 6.71e-01
Signaling by SCF-KIT 43 5.62e-01 7.38e-01 0.08510 -5.24e-02 6.70e-02 5.52e-01 4.47e-01
FCERI mediated Ca+2 mobilization 30 7.31e-01 8.53e-01 0.08480 -8.35e-02 -1.51e-02 4.29e-01 8.86e-01
Metabolism 1969 2.71e-08 4.48e-07 0.08480 3.47e-02 7.74e-02 1.04e-02 1.08e-08
Leishmania infection 157 2.01e-01 3.81e-01 0.08460 1.76e-02 8.27e-02 7.03e-01 7.35e-02
Parasitic Infection Pathways 157 2.01e-01 3.81e-01 0.08460 1.76e-02 8.27e-02 7.03e-01 7.35e-02
Organelle biogenesis and maintenance 254 8.36e-02 2.11e-01 0.08450 2.60e-02 8.04e-02 4.75e-01 2.71e-02
Glycogen breakdown (glycogenolysis) 11 9.02e-01 9.51e-01 0.08440 -7.61e-02 -3.66e-02 6.62e-01 8.34e-01
PKA-mediated phosphorylation of CREB 19 7.77e-01 8.81e-01 0.08440 -6.03e-02 5.91e-02 6.49e-01 6.56e-01
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 29 7.72e-01 8.81e-01 0.08400 5.08e-02 6.69e-02 6.36e-01 5.33e-01
PI-3K cascade:FGFR4 19 8.28e-01 9.07e-01 0.08380 8.12e-02 2.07e-02 5.40e-01 8.76e-01
SHC1 events in ERBB2 signaling 22 8.25e-01 9.06e-01 0.08370 5.80e-02 6.03e-02 6.38e-01 6.24e-01
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane 10 9.08e-01 9.54e-01 0.08360 2.45e-02 8.00e-02 8.93e-01 6.62e-01
GPCR downstream signalling 604 5.74e-03 2.71e-02 0.08340 -6.37e-02 -5.38e-02 7.40e-03 2.35e-02
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion 42 6.02e-01 7.66e-01 0.08300 -2.89e-02 7.78e-02 7.46e-01 3.83e-01
Role of phospholipids in phagocytosis 23 8.19e-01 9.04e-01 0.08290 -4.92e-02 -6.67e-02 6.83e-01 5.80e-01
CaMK IV-mediated phosphorylation of CREB 10 8.92e-01 9.47e-01 0.08230 8.05e-02 -1.73e-02 6.59e-01 9.25e-01
Defective B3GALT6 causes EDSP2 and SEMDJL1 17 8.54e-01 9.24e-01 0.08210 -2.62e-02 -7.78e-02 8.52e-01 5.79e-01
Integrin signaling 27 7.39e-01 8.57e-01 0.08170 -8.02e-02 1.58e-02 4.71e-01 8.87e-01
Interferon gamma signaling 93 4.61e-01 6.63e-01 0.08160 5.36e-02 6.15e-02 3.72e-01 3.05e-01
Sphingolipid metabolism 83 3.59e-01 5.66e-01 0.08150 -6.10e-02 5.40e-02 3.36e-01 3.95e-01
RHOG GTPase cycle 69 4.79e-01 6.80e-01 0.08130 -8.10e-02 7.79e-03 2.45e-01 9.11e-01
Fcgamma receptor (FCGR) dependent phagocytosis 82 4.85e-01 6.89e-01 0.08130 3.18e-02 7.47e-02 6.18e-01 2.42e-01
Oncogenic MAPK signaling 78 4.36e-01 6.37e-01 0.08120 -8.21e-03 8.07e-02 9.00e-01 2.17e-01
HS-GAG biosynthesis 28 7.82e-01 8.81e-01 0.08080 -7.50e-02 -2.99e-02 4.92e-01 7.84e-01
EGR2 and SOX10-mediated initiation of Schwann cell myelination 27 7.58e-01 8.70e-01 0.08010 5.33e-03 -8.00e-02 9.62e-01 4.72e-01
GAB1 signalosome 17 8.26e-01 9.06e-01 0.07910 -3.48e-02 7.10e-02 8.04e-01 6.12e-01
Regulation of gene expression in beta cells 21 8.23e-01 9.06e-01 0.07900 7.84e-02 9.53e-03 5.34e-01 9.40e-01
Serotonin Neurotransmitter Release Cycle 16 8.83e-01 9.43e-01 0.07880 -5.08e-02 -6.02e-02 7.25e-01 6.76e-01
Vesicle-mediated transport 643 1.42e-03 8.58e-03 0.07870 -1.72e-02 7.67e-02 4.55e-01 8.74e-04
Deadenylation-dependent mRNA decay 53 6.61e-01 8.15e-01 0.07860 6.29e-02 4.71e-02 4.28e-01 5.53e-01
Nicotinate metabolism 29 7.73e-01 8.81e-01 0.07810 7.69e-02 1.33e-02 4.73e-01 9.01e-01
PKA activation in glucagon signalling 17 8.27e-01 9.07e-01 0.07800 -4.16e-02 6.60e-02 7.66e-01 6.38e-01
Defects in vitamin and cofactor metabolism 20 8.36e-01 9.11e-01 0.07800 1.10e-02 7.72e-02 9.32e-01 5.50e-01
Regulation of KIT signaling 16 8.85e-01 9.44e-01 0.07760 -6.40e-02 -4.38e-02 6.58e-01 7.61e-01
Phase II - Conjugation of compounds 106 4.51e-01 6.51e-01 0.07750 -5.82e-02 -5.12e-02 3.00e-01 3.62e-01
MicroRNA (miRNA) biogenesis 26 8.25e-01 9.06e-01 0.07680 5.50e-02 5.37e-02 6.27e-01 6.36e-01
CD28 dependent PI3K/Akt signaling 22 8.20e-01 9.04e-01 0.07680 3.33e-03 7.67e-02 9.78e-01 5.33e-01
Peptide ligand-binding receptors 190 1.29e-01 2.81e-01 0.07680 6.35e-02 -4.32e-02 1.31e-01 3.05e-01
Pyrimidine catabolism 12 8.89e-01 9.45e-01 0.07670 -7.54e-02 1.42e-02 6.51e-01 9.32e-01
Downregulation of SMAD2/3:SMAD4 transcriptional activity 29 7.42e-01 8.59e-01 0.07610 -2.97e-02 7.00e-02 7.82e-01 5.14e-01
Signaling by MET 78 4.96e-01 6.94e-01 0.07560 -7.56e-02 2.08e-03 2.48e-01 9.75e-01
HS-GAG degradation 21 8.05e-01 8.96e-01 0.07550 6.71e-02 -3.47e-02 5.95e-01 7.83e-01
Fatty acid metabolism 168 2.83e-01 4.74e-01 0.07540 3.12e-02 6.86e-02 4.85e-01 1.25e-01
Cytochrome P450 - arranged by substrate type 64 5.79e-01 7.52e-01 0.07520 -6.08e-03 -7.50e-02 9.33e-01 2.99e-01
Signaling by TGF-beta Receptor Complex 92 4.08e-01 6.12e-01 0.07500 -2.29e-02 7.14e-02 7.04e-01 2.36e-01
EPH-ephrin mediated repulsion of cells 50 6.21e-01 7.84e-01 0.07470 -1.92e-02 7.21e-02 8.14e-01 3.77e-01
Phase 2 - plateau phase 14 8.87e-01 9.45e-01 0.07420 -2.83e-04 -7.42e-02 9.99e-01 6.31e-01
COPI-mediated anterograde transport 101 4.97e-01 6.94e-01 0.07410 5.88e-02 4.52e-02 3.07e-01 4.32e-01
FOXO-mediated transcription of cell cycle genes 16 8.94e-01 9.47e-01 0.07390 3.85e-02 6.31e-02 7.90e-01 6.62e-01
RHO GTPase cycle 419 1.54e-02 5.70e-02 0.07380 -5.78e-02 4.59e-02 4.21e-02 1.07e-01
G beta:gamma signalling through PLC beta 20 8.18e-01 9.04e-01 0.07360 -4.40e-02 5.90e-02 7.33e-01 6.48e-01
IGF1R signaling cascade 51 6.89e-01 8.33e-01 0.07360 2.68e-02 6.85e-02 7.41e-01 3.97e-01
Sema3A PAK dependent Axon repulsion 14 8.78e-01 9.39e-01 0.07350 -7.07e-02 1.99e-02 6.47e-01 8.97e-01
RHOC GTPase cycle 69 5.39e-01 7.22e-01 0.07260 -7.05e-02 1.75e-02 3.11e-01 8.02e-01
Hemostasis 575 3.98e-03 1.99e-02 0.07260 -5.47e-02 4.78e-02 2.47e-02 4.97e-02
A tetrasaccharide linker sequence is required for GAG synthesis 23 8.60e-01 9.29e-01 0.07230 -5.41e-02 -4.79e-02 6.53e-01 6.91e-01
Heparan sulfate/heparin (HS-GAG) metabolism 52 7.04e-01 8.39e-01 0.07220 -6.29e-02 -3.54e-02 4.32e-01 6.59e-01
Lagging Strand Synthesis 19 8.78e-01 9.39e-01 0.07190 3.12e-02 6.48e-02 8.14e-01 6.25e-01
Insulin receptor recycling 29 8.17e-01 9.04e-01 0.07180 2.63e-02 6.68e-02 8.07e-01 5.34e-01
Platelet Aggregation (Plug Formation) 39 7.44e-01 8.60e-01 0.07120 -7.09e-02 -7.37e-03 4.44e-01 9.36e-01
Gap junction trafficking and regulation 49 6.40e-01 7.99e-01 0.07100 6.32e-02 -3.24e-02 4.44e-01 6.95e-01
Recycling pathway of L1 43 7.25e-01 8.52e-01 0.07050 6.00e-03 7.03e-02 9.46e-01 4.25e-01
Signal attenuation 10 9.23e-01 9.58e-01 0.07000 6.95e-02 -8.14e-03 7.04e-01 9.64e-01
Attachment and Entry 9694614 16 8.66e-01 9.31e-01 0.06970 -4.38e-02 5.42e-02 7.62e-01 7.07e-01
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) 12 9.21e-01 9.57e-01 0.06940 -1.59e-02 -6.75e-02 9.24e-01 6.85e-01
RAB GEFs exchange GTP for GDP on RABs 82 5.04e-01 6.99e-01 0.06860 -6.30e-02 2.70e-02 3.24e-01 6.73e-01
GABA receptor activation 57 6.30e-01 7.91e-01 0.06850 -6.54e-02 2.04e-02 3.93e-01 7.90e-01
Processing of SMDT1 15 9.16e-01 9.54e-01 0.06820 -4.23e-02 -5.35e-02 7.77e-01 7.20e-01
CLEC7A (Dectin-1) induces NFAT activation 11 9.18e-01 9.54e-01 0.06810 1.43e-02 -6.66e-02 9.35e-01 7.02e-01
Nuclear Receptor transcription pathway 51 6.60e-01 8.15e-01 0.06770 -6.23e-02 2.66e-02 4.42e-01 7.42e-01
Biological oxidations 213 2.39e-01 4.27e-01 0.06760 -8.72e-03 -6.71e-02 8.26e-01 9.14e-02
Aquaporin-mediated transport 51 7.24e-01 8.52e-01 0.06750 -6.48e-02 -1.90e-02 4.24e-01 8.14e-01
Diseases associated with glycosaminoglycan metabolism 38 8.05e-01 8.96e-01 0.06700 -5.55e-02 -3.75e-02 5.54e-01 6.89e-01
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion 13 9.02e-01 9.51e-01 0.06700 -2.45e-02 6.23e-02 8.78e-01 6.97e-01
Metabolism of carbohydrates 281 1.36e-01 2.92e-01 0.06670 -5.86e-03 6.65e-02 8.66e-01 5.49e-02
Signaling by Insulin receptor 80 6.30e-01 7.91e-01 0.06640 2.98e-02 5.94e-02 6.45e-01 3.58e-01
SLC transporter disorders 92 5.90e-01 7.58e-01 0.06630 3.08e-02 5.87e-02 6.10e-01 3.30e-01
Assembly and cell surface presentation of NMDA receptors 41 7.30e-01 8.52e-01 0.06620 6.23e-02 -2.26e-02 4.90e-01 8.02e-01
Meiotic recombination 26 8.62e-01 9.30e-01 0.06620 3.17e-02 5.81e-02 7.80e-01 6.08e-01
Striated Muscle Contraction 35 8.22e-01 9.06e-01 0.06590 -3.43e-02 -5.63e-02 7.25e-01 5.64e-01
GPCR ligand binding 443 9.56e-02 2.32e-01 0.06550 -4.95e-02 -4.29e-02 7.36e-02 1.21e-01
COPI-independent Golgi-to-ER retrograde traffic 52 6.73e-01 8.24e-01 0.06550 6.01e-02 -2.59e-02 4.53e-01 7.47e-01
SLC-mediated transmembrane transport 236 1.77e-01 3.50e-01 0.06530 1.97e-02 -6.23e-02 6.03e-01 9.91e-02
Metabolism of Angiotensinogen to Angiotensins 15 9.06e-01 9.54e-01 0.06490 -6.49e-02 1.43e-04 6.63e-01 9.99e-01
Diseases of glycosylation 137 4.47e-01 6.47e-01 0.06480 -6.26e-02 -1.66e-02 2.05e-01 7.37e-01
Regulation of IFNG signaling 14 9.03e-01 9.51e-01 0.06450 -2.15e-02 6.08e-02 8.89e-01 6.94e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 12 9.12e-01 9.54e-01 0.06450 3.48e-02 -5.43e-02 8.35e-01 7.45e-01
Defective EXT2 causes exostoses 2 12 9.12e-01 9.54e-01 0.06450 3.48e-02 -5.43e-02 8.35e-01 7.45e-01
RHO GTPases activate CIT 19 8.70e-01 9.33e-01 0.06450 5.98e-02 -2.41e-02 6.52e-01 8.56e-01
Sialic acid metabolism 33 8.35e-01 9.11e-01 0.06440 2.86e-02 5.77e-02 7.76e-01 5.66e-01
Platelet activation, signaling and aggregation 247 1.52e-01 3.15e-01 0.06430 -4.25e-02 4.83e-02 2.50e-01 1.91e-01
Transferrin endocytosis and recycling 30 8.24e-01 9.06e-01 0.06400 -2.19e-03 6.39e-02 9.83e-01 5.44e-01
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 619 1.50e-02 5.57e-02 0.06390 -1.51e-02 6.21e-02 5.21e-01 8.16e-03
Metal ion SLC transporters 23 8.42e-01 9.16e-01 0.06380 -3.42e-02 5.38e-02 7.76e-01 6.55e-01
Diseases of carbohydrate metabolism 30 8.57e-01 9.27e-01 0.06300 3.13e-02 5.47e-02 7.67e-01 6.04e-01
Metallothioneins bind metals 11 9.29e-01 9.61e-01 0.06250 6.04e-02 -1.60e-02 7.29e-01 9.27e-01
Extra-nuclear estrogen signaling 74 5.93e-01 7.60e-01 0.06220 -3.26e-02 5.30e-02 6.28e-01 4.31e-01
Organic cation/anion/zwitterion transport 15 9.13e-01 9.54e-01 0.06210 8.95e-04 -6.21e-02 9.95e-01 6.77e-01
Metabolism of water-soluble vitamins and cofactors 121 5.24e-01 7.10e-01 0.06170 1.56e-02 5.96e-02 7.66e-01 2.57e-01
Vasopressin regulates renal water homeostasis via Aquaporins 42 7.45e-01 8.60e-01 0.06160 -4.96e-02 3.64e-02 5.78e-01 6.83e-01
Cargo trafficking to the periciliary membrane 49 7.52e-01 8.64e-01 0.06150 6.15e-02 2.18e-03 4.56e-01 9.79e-01
Signaling by GPCR 671 4.46e-02 1.33e-01 0.06140 -4.79e-02 -3.85e-02 3.40e-02 8.81e-02
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 14 9.16e-01 9.54e-01 0.06140 -9.63e-03 6.06e-02 9.50e-01 6.94e-01
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling 25 8.89e-01 9.45e-01 0.06140 -4.28e-02 -4.40e-02 7.11e-01 7.03e-01
RHO GTPases activate PKNs 34 7.89e-01 8.86e-01 0.06130 -4.77e-02 3.85e-02 6.30e-01 6.98e-01
Beta-oxidation of very long chain fatty acids 10 9.47e-01 9.72e-01 0.06080 6.01e-02 9.01e-03 7.42e-01 9.61e-01
ROS and RNS production in phagocytes 35 8.13e-01 9.01e-01 0.06070 -4.94e-03 6.05e-02 9.60e-01 5.36e-01
Signaling by Rho GTPases 605 2.37e-02 8.15e-02 0.06060 -1.69e-02 5.82e-02 4.78e-01 1.43e-02
Transport of bile salts and organic acids, metal ions and amine compounds 82 5.85e-01 7.54e-01 0.06050 2.54e-02 -5.49e-02 6.91e-01 3.90e-01
Hyaluronan uptake and degradation 12 9.27e-01 9.59e-01 0.06050 1.76e-02 -5.78e-02 9.16e-01 7.29e-01
Defective B3GAT3 causes JDSSDHD 17 9.17e-01 9.54e-01 0.06030 -1.61e-02 -5.82e-02 9.09e-01 6.78e-01
CD209 (DC-SIGN) signaling 20 9.10e-01 9.54e-01 0.06020 -5.26e-02 -2.92e-02 6.84e-01 8.21e-01
Anchoring of the basal body to the plasma membrane 92 5.85e-01 7.54e-01 0.06010 -5.67e-03 5.98e-02 9.25e-01 3.21e-01
Insulin receptor signalling cascade 53 7.88e-01 8.85e-01 0.05980 3.84e-02 4.59e-02 6.29e-01 5.64e-01
Prolonged ERK activation events 14 9.39e-01 9.68e-01 0.05950 -4.95e-02 -3.30e-02 7.48e-01 8.30e-01
Opioid Signalling 88 5.76e-01 7.51e-01 0.05940 -5.46e-02 2.34e-02 3.76e-01 7.05e-01
G alpha (12/13) signalling events 74 6.43e-01 8.03e-01 0.05890 -5.66e-02 1.64e-02 4.00e-01 8.07e-01
COPI-dependent Golgi-to-ER retrograde traffic 99 5.82e-01 7.52e-01 0.05870 -3.24e-03 5.86e-02 9.56e-01 3.14e-01
Adrenaline,noradrenaline inhibits insulin secretion 28 8.58e-01 9.27e-01 0.05860 5.86e-02 -2.75e-03 5.92e-01 9.80e-01
Class B/2 (Secretin family receptors) 93 5.90e-01 7.58e-01 0.05840 -1.04e-02 5.75e-02 8.62e-01 3.38e-01
Defective B4GALT7 causes EDS, progeroid type 17 9.27e-01 9.59e-01 0.05820 -5.19e-02 -2.63e-02 7.11e-01 8.51e-01
Voltage gated Potassium channels 42 7.69e-01 8.81e-01 0.05820 -4.72e-02 3.40e-02 5.97e-01 7.03e-01
Estrogen-dependent nuclear events downstream of ESR-membrane signaling 23 8.92e-01 9.47e-01 0.05720 -5.71e-02 -3.82e-03 6.36e-01 9.75e-01
IRS-related events triggered by IGF1R 50 8.07e-01 8.96e-01 0.05670 2.21e-02 5.22e-02 7.87e-01 5.23e-01
Late SARS-CoV-2 Infection Events 67 7.22e-01 8.52e-01 0.05640 2.47e-03 5.64e-02 9.72e-01 4.25e-01
PKA activation 18 9.03e-01 9.51e-01 0.05580 -2.72e-02 4.88e-02 8.42e-01 7.20e-01
IRS-mediated signalling 47 8.19e-01 9.04e-01 0.05560 1.73e-02 5.29e-02 8.38e-01 5.31e-01
Interleukin receptor SHC signaling 24 9.09e-01 9.54e-01 0.05550 -4.84e-02 -2.72e-02 6.82e-01 8.17e-01
Constitutive Signaling by AKT1 E17K in Cancer 25 8.69e-01 9.33e-01 0.05540 -2.83e-02 4.76e-02 8.07e-01 6.80e-01
Intra-Golgi and retrograde Golgi-to-ER traffic 199 4.62e-01 6.63e-01 0.05530 2.99e-02 4.65e-02 4.67e-01 2.58e-01
p130Cas linkage to MAPK signaling for integrins 15 9.38e-01 9.68e-01 0.05500 -1.35e-02 -5.33e-02 9.28e-01 7.21e-01
Interleukin-6 family signaling 24 8.75e-01 9.37e-01 0.05490 4.33e-02 -3.37e-02 7.13e-01 7.75e-01
Smooth Muscle Contraction 43 7.90e-01 8.86e-01 0.05440 4.37e-02 -3.24e-02 6.20e-01 7.13e-01
Signaling by Receptor Tyrosine Kinases 511 1.06e-01 2.48e-01 0.05410 2.61e-03 5.40e-02 9.19e-01 3.62e-02
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 52 8.18e-01 9.04e-01 0.05410 2.33e-02 4.88e-02 7.72e-01 5.42e-01
EPH-Ephrin signaling 90 6.75e-01 8.24e-01 0.05410 5.27e-03 5.38e-02 9.31e-01 3.77e-01
G alpha (q) signalling events 206 4.04e-01 6.08e-01 0.05400 -5.39e-02 -3.56e-03 1.82e-01 9.30e-01
Uptake and actions of bacterial toxins 29 8.64e-01 9.31e-01 0.05400 -5.18e-02 1.53e-02 6.29e-01 8.87e-01
CDC42 GTPase cycle 143 5.12e-01 7.04e-01 0.05380 -5.34e-02 6.14e-03 2.70e-01 8.99e-01
DAP12 signaling 28 8.73e-01 9.35e-01 0.05320 -1.42e-02 5.13e-02 8.97e-01 6.38e-01
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain 21 9.12e-01 9.54e-01 0.05310 4.84e-04 5.31e-02 9.97e-01 6.74e-01
Downregulation of TGF-beta receptor signaling 26 8.93e-01 9.47e-01 0.05300 9.97e-04 5.30e-02 9.93e-01 6.40e-01
Ion homeostasis 52 8.05e-01 8.96e-01 0.05280 -5.20e-03 -5.25e-02 9.48e-01 5.12e-01
Inwardly rectifying K+ channels 35 8.73e-01 9.35e-01 0.05270 -1.41e-02 -5.08e-02 8.85e-01 6.03e-01
The canonical retinoid cycle in rods (twilight vision) 23 9.24e-01 9.59e-01 0.05230 -3.51e-02 -3.87e-02 7.70e-01 7.48e-01
Signaling by ALK 26 8.85e-01 9.44e-01 0.05210 5.00e-02 -1.48e-02 6.59e-01 8.96e-01
Mitochondrial calcium ion transport 22 8.96e-01 9.49e-01 0.05200 -4.23e-02 3.02e-02 7.31e-01 8.06e-01
Surfactant metabolism 28 9.11e-01 9.54e-01 0.05140 -4.05e-02 -3.15e-02 7.11e-01 7.73e-01
Glycosphingolipid biosynthesis 10 9.54e-01 9.75e-01 0.05130 -2.16e-02 4.66e-02 9.06e-01 7.99e-01
Plasma lipoprotein assembly, remodeling, and clearance 73 7.05e-01 8.39e-01 0.05080 3.99e-02 -3.15e-02 5.56e-01 6.42e-01
Fatty acyl-CoA biosynthesis 36 8.83e-01 9.43e-01 0.05050 -1.84e-02 -4.71e-02 8.48e-01 6.25e-01
Kinesins 60 7.65e-01 8.78e-01 0.05020 -1.91e-02 4.64e-02 7.98e-01 5.34e-01
Integration of energy metabolism 105 6.27e-01 7.89e-01 0.04930 -2.71e-02 4.11e-02 6.31e-01 4.66e-01
Defects in cobalamin (B12) metabolism 12 9.64e-01 9.80e-01 0.04880 2.97e-02 3.87e-02 8.58e-01 8.16e-01
Ras activation upon Ca2+ influx through NMDA receptor 19 9.42e-01 9.71e-01 0.04880 -2.22e-02 -4.35e-02 8.67e-01 7.43e-01
Cilium Assembly 185 5.78e-01 7.52e-01 0.04840 2.73e-02 4.00e-02 5.22e-01 3.48e-01
Platelet homeostasis 85 7.77e-01 8.81e-01 0.04830 -4.06e-02 -2.61e-02 5.17e-01 6.78e-01
Vitamin D (calciferol) metabolism 12 9.64e-01 9.80e-01 0.04750 -1.84e-02 -4.38e-02 9.12e-01 7.93e-01
RHO GTPases Activate ROCKs 19 9.44e-01 9.71e-01 0.04630 -4.51e-02 -1.06e-02 7.34e-01 9.36e-01
Signal regulatory protein family interactions 16 9.48e-01 9.72e-01 0.04600 -1.78e-03 4.59e-02 9.90e-01 7.50e-01
Anti-inflammatory response favouring Leishmania parasite infection 75 7.80e-01 8.81e-01 0.04600 -4.60e-02 6.54e-04 4.91e-01 9.92e-01
Leishmania parasite growth and survival 75 7.80e-01 8.81e-01 0.04600 -4.60e-02 6.54e-04 4.91e-01 9.92e-01
Transport of small molecules 694 9.13e-02 2.26e-01 0.04590 9.57e-03 -4.49e-02 6.67e-01 4.35e-02
RHO GTPases activate IQGAPs 31 9.01e-01 9.51e-01 0.04580 4.57e-02 -3.32e-03 6.60e-01 9.74e-01
Constitutive Signaling by Aberrant PI3K in Cancer 77 8.00e-01 8.93e-01 0.04570 4.38e-02 1.29e-02 5.06e-01 8.45e-01
L1CAM interactions 112 7.04e-01 8.39e-01 0.04570 -3.90e-03 -4.55e-02 9.43e-01 4.05e-01
Platelet degranulation 115 7.23e-01 8.52e-01 0.04530 -4.31e-02 -1.38e-02 4.24e-01 7.98e-01
Ca-dependent events 35 9.11e-01 9.54e-01 0.04520 -4.00e-02 -2.11e-02 6.82e-01 8.29e-01
Trafficking of GluR2-containing AMPA receptors 15 9.60e-01 9.79e-01 0.04510 -1.91e-02 -4.09e-02 8.98e-01 7.84e-01
EPHB-mediated forward signaling 41 8.70e-01 9.33e-01 0.04500 -9.31e-03 4.40e-02 9.18e-01 6.26e-01
Glycerophospholipid biosynthesis 114 6.55e-01 8.14e-01 0.04490 -3.63e-02 2.64e-02 5.04e-01 6.26e-01
Developmental Biology 1158 5.13e-02 1.46e-01 0.04470 4.13e-02 1.72e-02 1.74e-02 3.23e-01
Dopamine Neurotransmitter Release Cycle 20 9.44e-01 9.71e-01 0.04400 -6.27e-03 -4.36e-02 9.61e-01 7.36e-01
PI3K Cascade 43 8.99e-01 9.51e-01 0.04400 3.71e-02 2.37e-02 6.74e-01 7.88e-01
Presynaptic function of Kainate receptors 21 9.33e-01 9.64e-01 0.04340 -1.37e-02 4.12e-02 9.14e-01 7.44e-01
G alpha (z) signalling events 48 8.67e-01 9.33e-01 0.04330 -1.55e-03 4.33e-02 9.85e-01 6.04e-01
RUNX2 regulates osteoblast differentiation 22 9.47e-01 9.72e-01 0.04280 3.96e-02 1.63e-02 7.48e-01 8.94e-01
Potassium Channels 102 7.91e-01 8.86e-01 0.04280 -2.74e-02 -3.28e-02 6.32e-01 5.67e-01
Signal Transduction 2446 1.99e-03 1.15e-02 0.04160 -4.23e-03 4.14e-02 7.31e-01 7.40e-04
DAG and IP3 signaling 39 9.08e-01 9.54e-01 0.04080 -4.05e-02 -4.90e-03 6.62e-01 9.58e-01
Nucleotide catabolism 35 9.17e-01 9.54e-01 0.04080 4.05e-02 4.14e-03 6.78e-01 9.66e-01
Metabolism of lipids 697 1.36e-01 2.93e-01 0.03970 -2.61e-02 2.99e-02 2.39e-01 1.77e-01
Metabolism of vitamins and cofactors 184 6.98e-01 8.39e-01 0.03950 2.53e-02 3.04e-02 5.54e-01 4.77e-01
Adenylate cyclase inhibitory pathway 14 9.71e-01 9.83e-01 0.03950 -1.51e-02 -3.64e-02 9.22e-01 8.13e-01
RUNX2 regulates bone development 29 9.32e-01 9.63e-01 0.03930 3.93e-02 -1.02e-03 7.14e-01 9.92e-01
Regulation of insulin secretion 77 8.22e-01 9.06e-01 0.03920 -6.88e-03 3.86e-02 9.17e-01 5.58e-01
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 104 8.17e-01 9.04e-01 0.03900 2.08e-02 3.30e-02 7.13e-01 5.61e-01
Other interleukin signaling 24 9.45e-01 9.72e-01 0.03880 6.65e-04 3.88e-02 9.96e-01 7.42e-01
Negative regulation of the PI3K/AKT network 111 7.70e-01 8.81e-01 0.03820 -3.73e-03 3.80e-02 9.46e-01 4.89e-01
Signaling by PDGF 57 9.03e-01 9.51e-01 0.03730 -1.94e-02 -3.19e-02 8.00e-01 6.77e-01
Intra-Golgi traffic 43 9.20e-01 9.56e-01 0.03710 8.67e-03 3.60e-02 9.22e-01 6.83e-01
TRAF6 mediated IRF7 activation 25 9.52e-01 9.75e-01 0.03670 5.89e-03 3.62e-02 9.59e-01 7.54e-01
PI3K/AKT Signaling in Cancer 103 8.42e-01 9.16e-01 0.03650 2.80e-02 2.34e-02 6.23e-01 6.82e-01
Z-decay: degradation of maternal mRNAs by zygotically expressed factors 12 9.77e-01 9.84e-01 0.03590 -2.92e-03 -3.57e-02 9.86e-01 8.30e-01
Amino acid transport across the plasma membrane 30 9.43e-01 9.71e-01 0.03580 2.87e-03 3.57e-02 9.78e-01 7.35e-01
Frs2-mediated activation 12 9.75e-01 9.83e-01 0.03510 3.37e-02 -1.00e-02 8.40e-01 9.52e-01
FGFRL1 modulation of FGFR1 signaling 13 9.77e-01 9.84e-01 0.03430 1.68e-03 3.43e-02 9.92e-01 8.30e-01
Golgi-to-ER retrograde transport 133 8.00e-01 8.93e-01 0.03390 4.98e-03 3.35e-02 9.21e-01 5.04e-01
p75 NTR receptor-mediated signalling 90 8.83e-01 9.43e-01 0.03260 2.86e-02 1.56e-02 6.39e-01 7.98e-01
Reproduction 94 8.51e-01 9.22e-01 0.03220 -3.18e-02 5.20e-03 5.94e-01 9.31e-01
Response to elevated platelet cytosolic Ca2+ 120 8.45e-01 9.19e-01 0.03210 -3.02e-02 -1.07e-02 5.67e-01 8.39e-01
Gluconeogenesis 33 9.48e-01 9.72e-01 0.03200 3.20e-02 -1.08e-03 7.50e-01 9.91e-01
RHOA GTPase cycle 140 7.76e-01 8.81e-01 0.03190 -1.35e-02 2.89e-02 7.83e-01 5.55e-01
Maternal to zygotic transition (MZT) 76 9.09e-01 9.54e-01 0.03080 2.78e-02 1.33e-02 6.76e-01 8.41e-01
Cell death signalling via NRAGE, NRIF and NADE 69 9.26e-01 9.59e-01 0.02990 2.17e-02 2.06e-02 7.55e-01 7.68e-01
Neuronal System 389 6.54e-01 8.14e-01 0.02970 -2.02e-02 -2.18e-02 4.93e-01 4.60e-01
Activation of G protein gated Potassium channels 29 9.61e-01 9.79e-01 0.02970 2.97e-02 -1.60e-04 7.82e-01 9.99e-01
G protein gated Potassium channels 29 9.61e-01 9.79e-01 0.02970 2.97e-02 -1.60e-04 7.82e-01 9.99e-01
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits 29 9.61e-01 9.79e-01 0.02970 2.97e-02 -1.60e-04 7.82e-01 9.99e-01
RET signaling 41 9.53e-01 9.75e-01 0.02960 -2.73e-02 -1.15e-02 7.62e-01 8.99e-01
Metabolism of steroids 148 8.48e-01 9.21e-01 0.02920 -1.28e-02 -2.62e-02 7.88e-01 5.82e-01
Diseases of metabolism 234 7.72e-01 8.81e-01 0.02900 -2.63e-02 -1.21e-02 4.88e-01 7.50e-01
Semaphorin interactions 61 9.17e-01 9.54e-01 0.02880 -7.85e-03 2.77e-02 9.16e-01 7.09e-01
CTLA4 inhibitory signaling 21 9.72e-01 9.83e-01 0.02850 -5.70e-03 2.79e-02 9.64e-01 8.25e-01
Signaling by FGFR4 in disease 11 9.84e-01 9.88e-01 0.02820 1.89e-02 -2.10e-02 9.14e-01 9.04e-01
TRP channels 27 9.73e-01 9.83e-01 0.02820 -2.44e-02 -1.42e-02 8.26e-01 8.98e-01
Gap junction degradation 12 9.84e-01 9.88e-01 0.02730 1.74e-02 -2.10e-02 9.17e-01 9.00e-01
Activation of NMDA receptors and postsynaptic events 87 9.16e-01 9.54e-01 0.02720 9.63e-03 2.55e-02 8.77e-01 6.81e-01
FCGR3A-mediated IL10 synthesis 37 9.67e-01 9.81e-01 0.02700 -1.71e-02 -2.09e-02 8.57e-01 8.25e-01
Activation of kainate receptors upon glutamate binding 29 9.73e-01 9.83e-01 0.02590 -2.53e-02 -5.83e-03 8.14e-01 9.57e-01
Hyaluronan metabolism 17 9.82e-01 9.88e-01 0.02430 -1.42e-02 1.98e-02 9.19e-01 8.88e-01
GRB2 events in ERBB2 signaling 16 9.87e-01 9.91e-01 0.02410 2.29e-02 7.53e-03 8.74e-01 9.58e-01
Transport of vitamins, nucleosides, and related molecules 38 9.62e-01 9.79e-01 0.02400 -8.91e-03 2.23e-02 9.24e-01 8.12e-01
RHOD GTPase cycle 48 9.65e-01 9.80e-01 0.02370 -2.17e-02 -9.62e-03 7.95e-01 9.08e-01
CaM pathway 33 9.70e-01 9.83e-01 0.02290 -2.10e-02 9.13e-03 8.35e-01 9.28e-01
Calmodulin induced events 33 9.70e-01 9.83e-01 0.02290 -2.10e-02 9.13e-03 8.35e-01 9.28e-01
TGF-beta receptor signaling activates SMADs 47 9.62e-01 9.79e-01 0.02190 -2.09e-02 6.57e-03 8.04e-01 9.38e-01
Physiological factors 14 9.92e-01 9.94e-01 0.02050 1.05e-02 1.76e-02 9.46e-01 9.09e-01
Post NMDA receptor activation events 76 9.58e-01 9.79e-01 0.02050 7.78e-03 1.89e-02 9.07e-01 7.75e-01
Transcriptional Regulation by NPAS4 33 9.78e-01 9.85e-01 0.02020 3.32e-03 -1.99e-02 9.74e-01 8.43e-01
Class A/1 (Rhodopsin-like receptors) 311 8.48e-01 9.21e-01 0.01950 -4.87e-03 -1.88e-02 8.82e-01 5.67e-01
Activation of GABAB receptors 43 9.71e-01 9.83e-01 0.01930 1.51e-02 -1.20e-02 8.64e-01 8.92e-01
GABA B receptor activation 43 9.71e-01 9.83e-01 0.01930 1.51e-02 -1.20e-02 8.64e-01 8.92e-01
GRB2:SOS provides linkage to MAPK signaling for Integrins 15 9.93e-01 9.94e-01 0.01910 6.96e-03 1.78e-02 9.63e-01 9.05e-01
Neurotransmitter receptors and postsynaptic signal transmission 193 9.26e-01 9.59e-01 0.01520 -4.68e-03 1.45e-02 9.11e-01 7.28e-01
Costimulation by the CD28 family 65 9.74e-01 9.83e-01 0.01500 6.16e-03 -1.37e-02 9.32e-01 8.49e-01
Glucagon-type ligand receptors 32 9.92e-01 9.94e-01 0.01430 9.46e-03 1.07e-02 9.26e-01 9.16e-01
Transmission across Chemical Synapses 255 9.52e-01 9.75e-01 0.01220 1.06e-02 5.95e-03 7.70e-01 8.70e-01
Signaling by TGFB family members 121 9.82e-01 9.88e-01 0.01090 6.98e-03 8.38e-03 8.94e-01 8.73e-01
Interleukin-2 family signaling 40 9.94e-01 9.96e-01 0.01030 -9.44e-03 -4.24e-03 9.18e-01 9.63e-01
Gastrin-CREB signalling pathway via PKC and MAPK 17 9.98e-01 9.98e-01 0.01010 -4.60e-03 -8.97e-03 9.74e-01 9.49e-01
DAP12 interactions 40 9.96e-01 9.96e-01 0.00771 -6.23e-03 4.55e-03 9.46e-01 9.60e-01


Detailed Gene set reports


Class C/3 (Metabotropic glutamate/pheromone receptors)

Class C/3 (Metabotropic glutamate/pheromone receptors)
metric value
setSize 39
pMANOVA 1.81e-10
p.adjustMANOVA 5.51e-09
s.dist 0.677
s.bl -0.49
s.gu -0.468
p.bl 1.16e-07
p.gu 4.29e-07




Top 20 genes
Gene bl gu
TAS2R43 -20301 -17476
TAS2R39 -21100 -16412
TAS2R1 -20635 -16629
TAS2R3 -21161 -16122
TAS2R42 -21057 -16140
TAS2R20 -21087 -15956
TAS2R30 -20441 -16313
TAS2R50 -21189 -15633
TAS2R10 -21093 -15608
TAS2R9 -20781 -15404
TAS2R8 -20965 -15268
GPRC6A -20304 -15299
TAS2R19 -17769 -17281
TAS2R14 -20616 -14805
TAS2R41 -18506 -15380
TAS2R7 -20556 -13241
TAS2R16 -17596 -15285
TAS2R60 -15769 -16828
TAS2R4 -13108 -17407
TAS2R5 -18019 -10797

Click HERE to show all gene set members

All member genes
bl gu
CASR -5293 -623
GABBR1 -11390 -8966
GABBR2 -4208 -5543
GPRC6A -20304 -15299
GRM1 -16224 -11048
GRM2 -5675 -216
GRM3 -7834 -10622
GRM4 -4847 -8801
GRM5 -16036 -7419
GRM6 -10353 -11729
GRM7 -8371 -10844
GRM8 -3496 -12183
TAS1R1 -2580 -10716
TAS1R2 -2297 4050
TAS1R3 -9249 4467
TAS2R1 -20635 -16629
TAS2R10 -21093 -15608
TAS2R13 -18249 4625
TAS2R14 -20616 -14805
TAS2R16 -17596 -15285
TAS2R19 -17769 -17281
TAS2R20 -21087 -15956
TAS2R3 -21161 -16122
TAS2R30 -20441 -16313
TAS2R31 -20094 -4227
TAS2R38 -8087 -11255
TAS2R39 -21100 -16412
TAS2R4 -13108 -17407
TAS2R40 -18098 1554
TAS2R41 -18506 -15380
TAS2R42 -21057 -16140
TAS2R43 -20301 -17476
TAS2R46 -20746 -9370
TAS2R5 -18019 -10797
TAS2R50 -21189 -15633
TAS2R60 -15769 -16828
TAS2R7 -20556 -13241
TAS2R8 -20965 -15268
TAS2R9 -20781 -15404



TICAM1-dependent activation of IRF3/IRF7

TICAM1-dependent activation of IRF3/IRF7
metric value
setSize 12
pMANOVA 0.00124
p.adjustMANOVA 0.00762
s.dist 0.667
s.bl 0.45
s.gu 0.492
p.bl 0.00692
p.gu 0.00316




Top 20 genes
Gene bl gu
TLR3 3432 5652
UBB 3278 4141
RPS27A 2633 5083

Click HERE to show all gene set members

All member genes
bl gu
IKBKE -3863 -7503
IRF3 -2294 711
IRF7 -2525 3289
RPS27A 2633 5083
TANK -9140 1964
TBK1 -5736 3411
TICAM1 -1572 432
TLR3 3432 5652
TRAF3 -16727 -3327
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Scavenging of heme from plasma

Scavenging of heme from plasma
metric value
setSize 12
pMANOVA 0.00197
p.adjustMANOVA 0.0114
s.dist 0.643
s.bl -0.473
s.gu -0.436
p.bl 0.00452
p.gu 0.00898




Top 20 genes
Gene bl gu
HBA1 -20492 -17033
HBB -20298 -16008
ALB -20900 -15234
APOL1 -20613 -12055
HPX -18409 -11860
JCHAIN -12281 -17188
AMBP -11260 -14218
CD163 -16282 -8683
HPR -14504 -7583
APOA1 -5372 -4007
LRP1 -2496 -3040

Click HERE to show all gene set members

All member genes
bl gu
ALB -20900 -15234
AMBP -11260 -14218
APOA1 -5372 -4007
APOL1 -20613 -12055
CD163 -16282 -8683
HBA1 -20492 -17033
HBB -20298 -16008
HP -14625 1886
HPR -14504 -7583
HPX -18409 -11860
JCHAIN -12281 -17188
LRP1 -2496 -3040



Eicosanoids

Eicosanoids
metric value
setSize 12
pMANOVA 0.000296
p.adjustMANOVA 0.00216
s.dist 0.64
s.bl 0.631
s.gu -0.102
p.bl 0.000152
p.gu 0.541




Top 20 genes
Gene bl gu
CYP8B1 2902 -14599
CYP4F2 2357 -13024
CYP4F8 1192 -15481
CYP4F11 626 -11827

Click HERE to show all gene set members

All member genes
bl gu
CYP4A11 3815 1402
CYP4A22 3037 4100
CYP4B1 -8587 -13995
CYP4F11 626 -11827
CYP4F12 -883 7280
CYP4F2 2357 -13024
CYP4F22 -1207 -2486
CYP4F3 -43 3401
CYP4F8 1192 -15481
CYP8B1 2902 -14599
PTGIS -312 -13498
TBXAS1 -10068 -4830



Pexophagy

Pexophagy
metric value
setSize 11
pMANOVA 0.00413
p.adjustMANOVA 0.0204
s.dist 0.626
s.bl 0.515
s.gu 0.356
p.bl 0.00311
p.gu 0.0408




Top 20 genes
Gene bl gu
UBB 3278 4141
RPS27A 2633 5083

Click HERE to show all gene set members

All member genes
bl gu
ATM 1939 -2867
EPAS1 -11215 -9857
MAP1LC3B -6322 4627
NBR1 2099 -8899
PEX5 -4821 1218
RPS27A 2633 5083
SQSTM1 -4938 -851
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
USP30 -3108 568



SARS-CoV-1 modulates host translation machinery

SARS-CoV-1 modulates host translation machinery
metric value
setSize 34
pMANOVA 1.09e-07
p.adjustMANOVA 1.47e-06
s.dist 0.604
s.bl 0.522
s.gu 0.305
p.bl 1.4e-07
p.gu 0.00211




Top 20 genes
Gene bl gu
HNRNPA1 3521 6834
RPS27A 2633 5083
RPS19 2541 4237
RPS27 1289 6541
EEF1A1 1152 6931
RPS16 1209 4604
RPS17 1222 3419
RPSA 559 7037
RPS18 709 1936
RPS23 983 1243

Click HERE to show all gene set members

All member genes
bl gu
EEF1A1 1152 6931
FAU 339 -8142
HNRNPA1 3521 6834
RPS10 -4517 2368
RPS11 2207 -13804
RPS12 3518 -1497
RPS13 -3760 -14339
RPS14 -8453 7156
RPS15 -5601 3218
RPS15A -3699 4700
RPS16 1209 4604
RPS17 1222 3419
RPS18 709 1936
RPS19 2541 4237
RPS2 -830 -12504
RPS20 -1591 -5511
RPS21 908 -5285
RPS23 983 1243
RPS24 -5861 5913
RPS25 -3493 -1399
RPS26 -7211 6898
RPS27 1289 6541
RPS27A 2633 5083
RPS27L 859 -7524
RPS28 -13883 -2888
RPS29 1292 -12538
RPS3 -747 1694
RPS3A -699 -804
RPS5 -9203 -15424
RPS6 -9677 325
RPS7 -4265 -4644
RPS8 -2232 5018
RPS9 -7704 -9762
RPSA 559 7037



Sensory perception of sweet, bitter, and umami (glutamate) taste

Sensory perception of sweet, bitter, and umami (glutamate) taste
metric value
setSize 41
pMANOVA 1.17e-08
p.adjustMANOVA 2.18e-07
s.dist 0.594
s.bl -0.465
s.gu -0.37
p.bl 2.48e-07
p.gu 4.17e-05




Top 20 genes
Gene bl gu
TAS2R43 -20301 -17476
GNAT3 -21044 -16497
TAS2R39 -21100 -16412
TAS2R1 -20635 -16629
TAS2R3 -21161 -16122
TAS2R20 -21087 -15956
TAS2R30 -20441 -16313
TAS2R50 -21189 -15633
TAS2R10 -21093 -15608
TAS2R8 -20965 -15268
TAS2R14 -20616 -14805
TAS2R41 -18506 -15380
TAS2R7 -20556 -13241
TAS2R16 -17596 -15285
TAS2R4 -13108 -17407
SCN1B -15607 -12626
TAS2R5 -18019 -10797
TAS2R46 -20746 -9370
GRM1 -16224 -11048
SCN9A -15411 -10728

Click HERE to show all gene set members

All member genes
bl gu
CALHM1 -12276 -6058
CALHM3 -12788 -12696
GNAT3 -21044 -16497
GNB1 -16858 -3249
GNB3 -12531 5837
GNG13 -7640 -1360
GRM1 -16224 -11048
GRM4 -4847 -8801
ITPR3 -11478 -12700
PLCB2 -12670 -6069
SCN1B -15607 -12626
SCN2A -10570 -11434
SCN2B -8927 -629
SCN3A -9666 -9622
SCN4B -8620 -6101
SCN9A -15411 -10728
TAS1R1 -2580 -10716
TAS1R2 -2297 4050
TAS1R3 -9249 4467
TAS2R1 -20635 -16629
TAS2R10 -21093 -15608
TAS2R13 -18249 4625
TAS2R14 -20616 -14805
TAS2R16 -17596 -15285
TAS2R20 -21087 -15956
TAS2R3 -21161 -16122
TAS2R30 -20441 -16313
TAS2R31 -20094 -4227
TAS2R38 -8087 -11255
TAS2R39 -21100 -16412
TAS2R4 -13108 -17407
TAS2R40 -18098 1554
TAS2R41 -18506 -15380
TAS2R43 -20301 -17476
TAS2R46 -20746 -9370
TAS2R5 -18019 -10797
TAS2R50 -21189 -15633
TAS2R7 -20556 -13241
TAS2R8 -20965 -15268
TRPM4 -5452 -10967
TRPM5 -3798 -4287



TICAM1,TRAF6-dependent induction of TAK1 complex

TICAM1,TRAF6-dependent induction of TAK1 complex
metric value
setSize 10
pMANOVA 0.0146
p.adjustMANOVA 0.0547
s.dist 0.58
s.bl 0.431
s.gu 0.388
p.bl 0.0182
p.gu 0.0336




Top 20 genes
Gene bl gu
TLR3 3432 5652
UBB 3278 4141
RPS27A 2633 5083

Click HERE to show all gene set members

All member genes
bl gu
MAP3K7 -7575 -9127
RPS27A 2633 5083
TAB1 -9799 6095
TAB2 -9801 -9844
TICAM1 -1572 432
TLR3 3432 5652
TRAF6 -9681 -4945
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Competing endogenous RNAs (ceRNAs) regulate PTEN translation

Competing endogenous RNAs (ceRNAs) regulate PTEN translation
metric value
setSize 16
pMANOVA 0.000127
p.adjustMANOVA 0.00102
s.dist 0.555
s.bl -0.482
s.gu 0.274
p.bl 0.000837
p.gu 0.0577




Top 20 genes
Gene bl gu
MIR20A -18057 7439
MIR19A -16631 7449
MIR19B1 -19684 5354
MIR17 -10078 6477
MOV10 -8488 5987
MIR106B -20027 2091
AGO3 -14012 625

Click HERE to show all gene set members

All member genes
bl gu
AGO1 -20797 -10713
AGO2 -8757 -82
AGO3 -14012 625
AGO4 -19507 -11950
CNOT6L -13667 -2535
MIR106B -20027 2091
MIR17 -10078 6477
MIR19A -16631 7449
MIR19B1 -19684 5354
MIR20A -18057 7439
MOV10 -8488 5987
PTENP1 -16012 -6105
TNRC6A -16547 -12111
TNRC6B -4964 -3964
TNRC6C -15450 -5248
VAPA -15857 -3503



TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling

TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
metric value
setSize 11
pMANOVA 0.0148
p.adjustMANOVA 0.0551
s.dist 0.55
s.bl 0.44
s.gu 0.331
p.bl 0.0116
p.gu 0.0576




Top 20 genes
Gene bl gu
UBB 3278 4141
RPS27A 2633 5083

Click HERE to show all gene set members

All member genes
bl gu
IRAK4 -9904 -7719
IRF7 -2525 3289
MYD88 2786 -2435
RPS27A 2633 5083
TLR9 -11696 -7659
TRAF6 -9681 -4945
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
UBE2N -3018 -6061
UBE2V1 -2949 5852



Glucuronidation

Glucuronidation
metric value
setSize 25
pMANOVA 8.06e-05
p.adjustMANOVA 0.000663
s.dist 0.548
s.bl -0.378
s.gu -0.397
p.bl 0.00106
p.gu 0.000587




Top 20 genes
Gene bl gu
UGT2B11 -21337 -17278
UGT2B4 -21311 -16951
UGT2B7 -19466 -16802
UGT2B10 -21288 -15316
UGT2B28 -21526 -14687
UGT2A2 -18383 -12817
UGT2A1 -20687 -11233
UGT2A3 -20744 -9744
UGT1A1 -11541 -16565
UGT1A8 -12587 -13229
UGT1A10 -12197 -13428
UGT1A7 -11787 -12600
UGT2B15 -13049 -10893
UGT1A9 -10674 -13288
SLC35D1 -16334 -8051
UGT1A6 -9529 -13378
UGT1A3 -9171 -12535
UGT1A5 -9602 -11810
UGT1A4 -8869 -10588
UGDH -6353 -3062

Click HERE to show all gene set members

All member genes
bl gu
ABHD10 80 3681
SLC35D1 -16334 -8051
UGDH -6353 -3062
UGP2 -8183 -740
UGT1A1 -11541 -16565
UGT1A10 -12197 -13428
UGT1A3 -9171 -12535
UGT1A4 -8869 -10588
UGT1A5 -9602 -11810
UGT1A6 -9529 -13378
UGT1A7 -11787 -12600
UGT1A8 -12587 -13229
UGT1A9 -10674 -13288
UGT2A1 -20687 -11233
UGT2A2 -18383 -12817
UGT2A3 -20744 -9744
UGT2B10 -21288 -15316
UGT2B11 -21337 -17278
UGT2B15 -13049 -10893
UGT2B17 -20950 1510
UGT2B28 -21526 -14687
UGT2B4 -21311 -16951
UGT2B7 -19466 -16802
UGT3A1 -1170 -4112
UGT3A2 -12605 5872



SCF(Skp2)-mediated degradation of p27/p21

SCF(Skp2)-mediated degradation of p27/p21
metric value
setSize 58
pMANOVA 3.6e-10
p.adjustMANOVA 9.91e-09
s.dist 0.547
s.bl 0.412
s.gu 0.359
p.bl 5.52e-08
p.gu 2.26e-06




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
CKS1B 1991 3982
CDK4 1512 5233
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842
SKP1 245 2633

Click HERE to show all gene set members

All member genes
bl gu
CCNA1 -7464 -6482
CCNA2 -1152 991
CCND1 -10740 1014
CCNE1 -14977 -3093
CCNE2 -2676 6813
CDK2 -11196 -1157
CDK4 1512 5233
CDKN1A -4145 5957
CDKN1B -2910 -188
CKS1B 1991 3982
CUL1 -10922 -3518
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSMF1 -7580 -2334
PTK6 -4516 -13859
RPS27A 2633 5083
SKP1 245 2633
SKP2 -1221 1281
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2

GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
metric value
setSize 50
pMANOVA 9.13e-09
p.adjustMANOVA 1.75e-07
s.dist 0.543
s.bl 0.411
s.gu 0.355
p.bl 4.82e-07
p.gu 1.43e-05




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842
SKP1 245 2633

Click HERE to show all gene set members

All member genes
bl gu
BTRC -17678 952
CUL1 -10922 -3518
GSK3B -6608 -12189
NFE2L2 -3398 4832
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSMF1 -7580 -2334
RBX1 -3011 5968
RPS27A 2633 5083
SKP1 245 2633
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



APC/C:Cdc20 mediated degradation of Cyclin B

APC/C:Cdc20 mediated degradation of Cyclin B
metric value
setSize 24
pMANOVA 0.000135
p.adjustMANOVA 0.00107
s.dist 0.539
s.bl 0.3
s.gu 0.448
p.bl 0.0108
p.gu 0.000144




Top 20 genes
Gene bl gu
UBB 3278 4141
RPS27A 2633 5083
ANAPC10 1568 7316

Click HERE to show all gene set members

All member genes
bl gu
ANAPC1 -214 5021
ANAPC10 1568 7316
ANAPC11 -853 1262
ANAPC15 -3568 -5708
ANAPC16 -3038 5076
ANAPC2 -6999 3577
ANAPC4 -12035 -5819
ANAPC5 -13436 3996
ANAPC7 -14 2634
CCNB1 -15483 5329
CDC16 -5235 -1817
CDC20 -4067 100
CDC23 1982 -12630
CDC26 -4616 5368
CDC27 -17169 -12590
CDK1 -1204 1566
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
UBE2C -148 -1659
UBE2D1 -11102 2093
UBE2E1 -12259 826
UBE2S -11896 5126



Peptide chain elongation

Peptide chain elongation
metric value
setSize 84
pMANOVA 2.22e-14
p.adjustMANOVA 1.41e-12
s.dist 0.538
s.bl 0.466
s.gu 0.269
p.bl 1.47e-13
p.gu 2e-05




Top 20 genes
Gene bl gu
RPL35 2168 7809
RPL35A 3383 4815
RPL34 3183 4879
RPS27A 2633 5083
RPL41 2936 3725
RPS19 2541 4237
RPS27 1289 6541
RPL7 1457 5763
RPL23 1855 4346
EEF1A1 1152 6931
RPS16 1209 4604
RPL28 2510 1892
RPS17 1222 3419
RPSA 559 7037
RPL27A 930 2052
RPS18 709 1936
RPS23 983 1243
RPL18 293 40

Click HERE to show all gene set members

All member genes
bl gu
EEF1A1 1152.0 6931.0
EEF2 -10566.0 -952.0
FAU 339.0 -8142.0
RPL10A -2144.0 5287.0
RPL10L -18378.0 4231.0
RPL11 -8721.0 -2458.0
RPL12 -421.0 1662.0
RPL13 -280.0 -4022.0
RPL13A -4574.5 -7793.5
RPL14 1943.0 -5790.0
RPL15 77.0 -187.0
RPL17 -4268.0 -14466.0
RPL18 293.0 40.0
RPL18A -559.0 -12160.0
RPL19 -9095.0 -3132.0
RPL21 -6004.0 2122.0
RPL22 -3790.0 -11781.0
RPL22L1 -12462.0 -13526.0
RPL23 1855.0 4346.0
RPL23A -998.0 1814.0
RPL24 -3971.0 5895.0
RPL26 -2641.0 4899.0
RPL26L1 -6478.0 -3312.0
RPL27 -330.0 -9130.0
RPL27A 930.0 2052.0
RPL28 2510.0 1892.0
RPL29 -2423.0 -8184.0
RPL3 -3206.0 5585.0
RPL30 9.0 -4032.0
RPL31 -9354.0 2635.0
RPL32 2647.0 -6251.0
RPL34 3183.0 4879.0
RPL35 2168.0 7809.0
RPL35A 3383.0 4815.0
RPL36 -1907.0 7118.0
RPL36AL -4561.0 1249.0
RPL37 -3913.0 -9634.0
RPL37A -2984.0 5752.0
RPL38 -14119.0 4190.0
RPL39L 1290.0 -4045.0
RPL3L -9104.0 -16679.0
RPL4 2609.0 -3763.0
RPL41 2936.0 3725.0
RPL5 -4937.0 -6727.0
RPL6 -16335.0 2149.0
RPL7 1457.0 5763.0
RPL7A -753.0 -3583.0
RPL8 -617.0 -1876.0
RPL9 -3269.0 3686.0
RPLP0 550.0 -4334.0
RPLP1 -12497.0 -6793.0
RPLP2 1382.0 -8896.0
RPS10 -4517.0 2368.0
RPS11 2207.0 -13804.0
RPS12 3518.0 -1497.0
RPS13 -3760.0 -14339.0
RPS14 -8453.0 7156.0
RPS15 -5601.0 3218.0
RPS15A -3699.0 4700.0
RPS16 1209.0 4604.0
RPS17 1222.0 3419.0
RPS18 709.0 1936.0
RPS19 2541.0 4237.0
RPS2 -830.0 -12504.0
RPS20 -1591.0 -5511.0
RPS21 908.0 -5285.0
RPS23 983.0 1243.0
RPS24 -5861.0 5913.0
RPS25 -3493.0 -1399.0
RPS26 -7211.0 6898.0
RPS27 1289.0 6541.0
RPS27A 2633.0 5083.0
RPS27L 859.0 -7524.0
RPS28 -13883.0 -2888.0
RPS29 1292.0 -12538.0
RPS3 -747.0 1694.0
RPS3A -699.0 -804.0
RPS5 -9203.0 -15424.0
RPS6 -9677.0 325.0
RPS7 -4265.0 -4644.0
RPS8 -2232.0 5018.0
RPS9 -7704.0 -9762.0
RPSA 559.0 7037.0
UBA52 -1582.0 2411.0



PINK1-PRKN Mediated Mitophagy

PINK1-PRKN Mediated Mitophagy
metric value
setSize 21
pMANOVA 0.000463
p.adjustMANOVA 0.00322
s.dist 0.534
s.bl 0.287
s.gu 0.45
p.bl 0.0227
p.gu 0.000353




Top 20 genes
Gene bl gu
UBB 3278 4141
RPS27A 2633 5083
TOMM6 2444 721

Click HERE to show all gene set members

All member genes
bl gu
ATG12 -7618 -6545
ATG5 -10356 2224
MAP1LC3A -16409 2604
MAP1LC3B -6322 4627
MFN1 -938 4389
MFN2 -8895 2711
MTERF3 418 -4922
PARK2 -5767 -8511
PINK1 -578 4062
RPS27A 2633 5083
SQSTM1 -4938 -851
TOMM20 -6383 -2940
TOMM22 -3837 -1943
TOMM40 -5635 7261
TOMM5 -12296 -2157
TOMM6 2444 721
TOMM7 -4647 4769
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
VDAC1 -17004 1350



Eukaryotic Translation Termination

Eukaryotic Translation Termination
metric value
setSize 87
pMANOVA 1.17e-14
p.adjustMANOVA 7.75e-13
s.dist 0.534
s.bl 0.464
s.gu 0.263
p.bl 6.84e-14
p.gu 2.17e-05




Top 20 genes
Gene bl gu
RPL35 2168 7809
RPL35A 3383 4815
RPL34 3183 4879
RPS27A 2633 5083
RPL41 2936 3725
RPS19 2541 4237
RPS27 1289 6541
RPL7 1457 5763
RPL23 1855 4346
RPS16 1209 4604
RPL28 2510 1892
RPS17 1222 3419
RPSA 559 7037
RPL27A 930 2052
RPS18 709 1936
RPS23 983 1243
RPL18 293 40

Click HERE to show all gene set members

All member genes
bl gu
APEH -7707.0 2313.0
ETF1 -3072.0 -10743.0
FAU 339.0 -8142.0
GSPT1 -8626.0 1941.0
N6AMT1 948.0 -3848.0
RPL10A -2144.0 5287.0
RPL10L -18378.0 4231.0
RPL11 -8721.0 -2458.0
RPL12 -421.0 1662.0
RPL13 -280.0 -4022.0
RPL13A -4574.5 -7793.5
RPL14 1943.0 -5790.0
RPL15 77.0 -187.0
RPL17 -4268.0 -14466.0
RPL18 293.0 40.0
RPL18A -559.0 -12160.0
RPL19 -9095.0 -3132.0
RPL21 -6004.0 2122.0
RPL22 -3790.0 -11781.0
RPL22L1 -12462.0 -13526.0
RPL23 1855.0 4346.0
RPL23A -998.0 1814.0
RPL24 -3971.0 5895.0
RPL26 -2641.0 4899.0
RPL26L1 -6478.0 -3312.0
RPL27 -330.0 -9130.0
RPL27A 930.0 2052.0
RPL28 2510.0 1892.0
RPL29 -2423.0 -8184.0
RPL3 -3206.0 5585.0
RPL30 9.0 -4032.0
RPL31 -9354.0 2635.0
RPL32 2647.0 -6251.0
RPL34 3183.0 4879.0
RPL35 2168.0 7809.0
RPL35A 3383.0 4815.0
RPL36 -1907.0 7118.0
RPL36AL -4561.0 1249.0
RPL37 -3913.0 -9634.0
RPL37A -2984.0 5752.0
RPL38 -14119.0 4190.0
RPL39L 1290.0 -4045.0
RPL3L -9104.0 -16679.0
RPL4 2609.0 -3763.0
RPL41 2936.0 3725.0
RPL5 -4937.0 -6727.0
RPL6 -16335.0 2149.0
RPL7 1457.0 5763.0
RPL7A -753.0 -3583.0
RPL8 -617.0 -1876.0
RPL9 -3269.0 3686.0
RPLP0 550.0 -4334.0
RPLP1 -12497.0 -6793.0
RPLP2 1382.0 -8896.0
RPS10 -4517.0 2368.0
RPS11 2207.0 -13804.0
RPS12 3518.0 -1497.0
RPS13 -3760.0 -14339.0
RPS14 -8453.0 7156.0
RPS15 -5601.0 3218.0
RPS15A -3699.0 4700.0
RPS16 1209.0 4604.0
RPS17 1222.0 3419.0
RPS18 709.0 1936.0
RPS19 2541.0 4237.0
RPS2 -830.0 -12504.0
RPS20 -1591.0 -5511.0
RPS21 908.0 -5285.0
RPS23 983.0 1243.0
RPS24 -5861.0 5913.0
RPS25 -3493.0 -1399.0
RPS26 -7211.0 6898.0
RPS27 1289.0 6541.0
RPS27A 2633.0 5083.0
RPS27L 859.0 -7524.0
RPS28 -13883.0 -2888.0
RPS29 1292.0 -12538.0
RPS3 -747.0 1694.0
RPS3A -699.0 -804.0
RPS5 -9203.0 -15424.0
RPS6 -9677.0 325.0
RPS7 -4265.0 -4644.0
RPS8 -2232.0 5018.0
RPS9 -7704.0 -9762.0
RPSA 559.0 7037.0
TRMT112 -1282.0 5702.0
UBA52 -1582.0 2411.0



Ubiquitin Mediated Degradation of Phosphorylated Cdc25A

Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
metric value
setSize 50
pMANOVA 2.24e-08
p.adjustMANOVA 3.78e-07
s.dist 0.527
s.bl 0.425
s.gu 0.313
p.bl 1.99e-07
p.gu 0.000131




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
CDC25A -5210 -131
CHEK1 -5848 -3310
CHEK2 -4820 5616
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



p53-Independent DNA Damage Response

p53-Independent DNA Damage Response
metric value
setSize 50
pMANOVA 2.24e-08
p.adjustMANOVA 3.78e-07
s.dist 0.527
s.bl 0.425
s.gu 0.313
p.bl 1.99e-07
p.gu 0.000131




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
CDC25A -5210 -131
CHEK1 -5848 -3310
CHEK2 -4820 5616
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



p53-Independent G1/S DNA damage checkpoint

p53-Independent G1/S DNA damage checkpoint
metric value
setSize 50
pMANOVA 2.24e-08
p.adjustMANOVA 3.78e-07
s.dist 0.527
s.bl 0.425
s.gu 0.313
p.bl 1.99e-07
p.gu 0.000131




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
CDC25A -5210 -131
CHEK1 -5848 -3310
CHEK2 -4820 5616
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Sensory perception of taste

Sensory perception of taste
metric value
setSize 47
pMANOVA 9.25e-08
p.adjustMANOVA 1.28e-06
s.dist 0.525
s.bl -0.365
s.gu -0.377
p.bl 1.49e-05
p.gu 7.81e-06




Top 20 genes
Gene bl gu
TAS2R43 -20301 -17476
GNAT3 -21044 -16497
TAS2R39 -21100 -16412
TAS2R1 -20635 -16629
TAS2R3 -21161 -16122
TAS2R20 -21087 -15956
TAS2R30 -20441 -16313
TAS2R50 -21189 -15633
TAS2R10 -21093 -15608
TAS2R8 -20965 -15268
TAS2R14 -20616 -14805
TAS2R41 -18506 -15380
TAS2R7 -20556 -13241
TAS2R16 -17596 -15285
TAS2R4 -13108 -17407
SCN1B -15607 -12626
TAS2R5 -18019 -10797
TAS2R46 -20746 -9370
GRM1 -16224 -11048
SCN9A -15411 -10728

Click HERE to show all gene set members

All member genes
bl gu
CALHM1 -12276 -6058
CALHM3 -12788 -12696
GNAT3 -21044 -16497
GNB1 -16858 -3249
GNB3 -12531 5837
GNG13 -7640 -1360
GRM1 -16224 -11048
GRM4 -4847 -8801
ITPR3 -11478 -12700
KCNJ2 -12114 -10127
OTOP1 316 -17156
PLCB2 -12670 -6069
SCN1B -15607 -12626
SCN2A -10570 -11434
SCN2B -8927 -629
SCN3A -9666 -9622
SCN4B -8620 -6101
SCN9A -15411 -10728
SCNN1A -10170 -11670
SCNN1B 982 -6516
SCNN1D -6233 -13029
SCNN1G -178 -3100
TAS1R1 -2580 -10716
TAS1R2 -2297 4050
TAS1R3 -9249 4467
TAS2R1 -20635 -16629
TAS2R10 -21093 -15608
TAS2R13 -18249 4625
TAS2R14 -20616 -14805
TAS2R16 -17596 -15285
TAS2R20 -21087 -15956
TAS2R3 -21161 -16122
TAS2R30 -20441 -16313
TAS2R31 -20094 -4227
TAS2R38 -8087 -11255
TAS2R39 -21100 -16412
TAS2R4 -13108 -17407
TAS2R40 -18098 1554
TAS2R41 -18506 -15380
TAS2R43 -20301 -17476
TAS2R46 -20746 -9370
TAS2R5 -18019 -10797
TAS2R50 -21189 -15633
TAS2R7 -20556 -13241
TAS2R8 -20965 -15268
TRPM4 -5452 -10967
TRPM5 -3798 -4287



Autodegradation of Cdh1 by Cdh1:APC/C

Autodegradation of Cdh1 by Cdh1:APC/C
metric value
setSize 62
pMANOVA 5.36e-10
p.adjustMANOVA 1.42e-08
s.dist 0.524
s.bl 0.372
s.gu 0.37
p.bl 4.13e-07
p.gu 4.61e-07




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
ANAPC10 1568 7316
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
ANAPC1 -214 5021
ANAPC10 1568 7316
ANAPC11 -853 1262
ANAPC15 -3568 -5708
ANAPC16 -3038 5076
ANAPC2 -6999 3577
ANAPC4 -12035 -5819
ANAPC5 -13436 3996
ANAPC7 -14 2634
CDC16 -5235 -1817
CDC23 1982 -12630
CDC26 -4616 5368
CDC27 -17169 -12590
FZR1 -15242 5573
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSMF1 -7580 -2334
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
UBE2C -148 -1659
UBE2D1 -11102 2093
UBE2E1 -12259 826
UBE2S -11896 5126



Hh mutants are degraded by ERAD

Hh mutants are degraded by ERAD
metric value
setSize 54
pMANOVA 8.26e-09
p.adjustMANOVA 1.6e-07
s.dist 0.523
s.bl 0.408
s.gu 0.328
p.bl 2.13e-07
p.gu 3.1e-05




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
OS9 1966 2664
PSME1 492 7331
PSMA3 835 3842
DERL2 1861 1250

Click HERE to show all gene set members

All member genes
bl gu
DERL2 1861 1250
ERLEC1 -2271 -5022
OS9 1966 2664
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
SEL1L -17085 -4295
SHH -2084 1951
SYVN1 -9156 5978
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
VCP -13994 6796



Eukaryotic Translation Elongation

Eukaryotic Translation Elongation
metric value
setSize 88
pMANOVA 2.89e-14
p.adjustMANOVA 1.7e-12
s.dist 0.522
s.bl 0.458
s.gu 0.251
p.bl 1.07e-13
p.gu 4.71e-05




Top 20 genes
Gene bl gu
RPL35 2168 7809
RPL35A 3383 4815
RPL34 3183 4879
RPS27A 2633 5083
RPL41 2936 3725
RPS19 2541 4237
RPS27 1289 6541
RPL7 1457 5763
RPL23 1855 4346
EEF1A1 1152 6931
RPS16 1209 4604
RPL28 2510 1892
RPS17 1222 3419
RPSA 559 7037
RPL27A 930 2052
RPS18 709 1936
RPS23 983 1243
RPL18 293 40

Click HERE to show all gene set members

All member genes
bl gu
EEF1A1 1152.0 6931.0
EEF1A2 -9460.0 -10759.0
EEF1B2 3353.0 -277.0
EEF1D -10136.0 -12713.0
EEF1G -3883.0 -2325.0
EEF2 -10566.0 -952.0
FAU 339.0 -8142.0
RPL10A -2144.0 5287.0
RPL10L -18378.0 4231.0
RPL11 -8721.0 -2458.0
RPL12 -421.0 1662.0
RPL13 -280.0 -4022.0
RPL13A -4574.5 -7793.5
RPL14 1943.0 -5790.0
RPL15 77.0 -187.0
RPL17 -4268.0 -14466.0
RPL18 293.0 40.0
RPL18A -559.0 -12160.0
RPL19 -9095.0 -3132.0
RPL21 -6004.0 2122.0
RPL22 -3790.0 -11781.0
RPL22L1 -12462.0 -13526.0
RPL23 1855.0 4346.0
RPL23A -998.0 1814.0
RPL24 -3971.0 5895.0
RPL26 -2641.0 4899.0
RPL26L1 -6478.0 -3312.0
RPL27 -330.0 -9130.0
RPL27A 930.0 2052.0
RPL28 2510.0 1892.0
RPL29 -2423.0 -8184.0
RPL3 -3206.0 5585.0
RPL30 9.0 -4032.0
RPL31 -9354.0 2635.0
RPL32 2647.0 -6251.0
RPL34 3183.0 4879.0
RPL35 2168.0 7809.0
RPL35A 3383.0 4815.0
RPL36 -1907.0 7118.0
RPL36AL -4561.0 1249.0
RPL37 -3913.0 -9634.0
RPL37A -2984.0 5752.0
RPL38 -14119.0 4190.0
RPL39L 1290.0 -4045.0
RPL3L -9104.0 -16679.0
RPL4 2609.0 -3763.0
RPL41 2936.0 3725.0
RPL5 -4937.0 -6727.0
RPL6 -16335.0 2149.0
RPL7 1457.0 5763.0
RPL7A -753.0 -3583.0
RPL8 -617.0 -1876.0
RPL9 -3269.0 3686.0
RPLP0 550.0 -4334.0
RPLP1 -12497.0 -6793.0
RPLP2 1382.0 -8896.0
RPS10 -4517.0 2368.0
RPS11 2207.0 -13804.0
RPS12 3518.0 -1497.0
RPS13 -3760.0 -14339.0
RPS14 -8453.0 7156.0
RPS15 -5601.0 3218.0
RPS15A -3699.0 4700.0
RPS16 1209.0 4604.0
RPS17 1222.0 3419.0
RPS18 709.0 1936.0
RPS19 2541.0 4237.0
RPS2 -830.0 -12504.0
RPS20 -1591.0 -5511.0
RPS21 908.0 -5285.0
RPS23 983.0 1243.0
RPS24 -5861.0 5913.0
RPS25 -3493.0 -1399.0
RPS26 -7211.0 6898.0
RPS27 1289.0 6541.0
RPS27A 2633.0 5083.0
RPS27L 859.0 -7524.0
RPS28 -13883.0 -2888.0
RPS29 1292.0 -12538.0
RPS3 -747.0 1694.0
RPS3A -699.0 -804.0
RPS5 -9203.0 -15424.0
RPS6 -9677.0 325.0
RPS7 -4265.0 -4644.0
RPS8 -2232.0 5018.0
RPS9 -7704.0 -9762.0
RPSA 559.0 7037.0
UBA52 -1582.0 2411.0



Autodegradation of the E3 ubiquitin ligase COP1

Autodegradation of the E3 ubiquitin ligase COP1
metric value
setSize 50
pMANOVA 3.12e-08
p.adjustMANOVA 5.04e-07
s.dist 0.521
s.bl 0.433
s.gu 0.289
p.bl 1.17e-07
p.gu 0.000403




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
ATM 1939 -2867
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RFWD2 -10106 -7493
RPS27A 2633 5083
TP53 -2599 -2481
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Ubiquitin-dependent degradation of Cyclin D

Ubiquitin-dependent degradation of Cyclin D
metric value
setSize 50
pMANOVA 3.46e-08
p.adjustMANOVA 5.38e-07
s.dist 0.52
s.bl 0.425
s.gu 0.3
p.bl 1.98e-07
p.gu 0.000243




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
CDK4 1512 5233
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
CCND1 -10740 1014
CDK4 1512 5233
GSK3B -6608 -12189
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Viral mRNA Translation

Viral mRNA Translation
metric value
setSize 84
pMANOVA 2.28e-13
p.adjustMANOVA 1.03e-11
s.dist 0.519
s.bl 0.445
s.gu 0.267
p.bl 1.75e-12
p.gu 2.29e-05




Top 20 genes
Gene bl gu
RPL35 2168 7809
RPL35A 3383 4815
RPL34 3183 4879
RPS27A 2633 5083
RPL41 2936 3725
RPS19 2541 4237
RPS27 1289 6541
RPL7 1457 5763
RPL23 1855 4346
RPS16 1209 4604
RPL28 2510 1892
RPS17 1222 3419
RPSA 559 7037
RPL27A 930 2052
RPS18 709 1936
RPS23 983 1243
RPL18 293 40

Click HERE to show all gene set members

All member genes
bl gu
DNAJC3 -17156.0 549.0
FAU 339.0 -8142.0
GRSF1 -15089.0 3351.0
RPL10A -2144.0 5287.0
RPL10L -18378.0 4231.0
RPL11 -8721.0 -2458.0
RPL12 -421.0 1662.0
RPL13 -280.0 -4022.0
RPL13A -4574.5 -7793.5
RPL14 1943.0 -5790.0
RPL15 77.0 -187.0
RPL17 -4268.0 -14466.0
RPL18 293.0 40.0
RPL18A -559.0 -12160.0
RPL19 -9095.0 -3132.0
RPL21 -6004.0 2122.0
RPL22 -3790.0 -11781.0
RPL22L1 -12462.0 -13526.0
RPL23 1855.0 4346.0
RPL23A -998.0 1814.0
RPL24 -3971.0 5895.0
RPL26 -2641.0 4899.0
RPL26L1 -6478.0 -3312.0
RPL27 -330.0 -9130.0
RPL27A 930.0 2052.0
RPL28 2510.0 1892.0
RPL29 -2423.0 -8184.0
RPL3 -3206.0 5585.0
RPL30 9.0 -4032.0
RPL31 -9354.0 2635.0
RPL32 2647.0 -6251.0
RPL34 3183.0 4879.0
RPL35 2168.0 7809.0
RPL35A 3383.0 4815.0
RPL36 -1907.0 7118.0
RPL36AL -4561.0 1249.0
RPL37 -3913.0 -9634.0
RPL37A -2984.0 5752.0
RPL38 -14119.0 4190.0
RPL39L 1290.0 -4045.0
RPL3L -9104.0 -16679.0
RPL4 2609.0 -3763.0
RPL41 2936.0 3725.0
RPL5 -4937.0 -6727.0
RPL6 -16335.0 2149.0
RPL7 1457.0 5763.0
RPL7A -753.0 -3583.0
RPL8 -617.0 -1876.0
RPL9 -3269.0 3686.0
RPLP0 550.0 -4334.0
RPLP1 -12497.0 -6793.0
RPLP2 1382.0 -8896.0
RPS10 -4517.0 2368.0
RPS11 2207.0 -13804.0
RPS12 3518.0 -1497.0
RPS13 -3760.0 -14339.0
RPS14 -8453.0 7156.0
RPS15 -5601.0 3218.0
RPS15A -3699.0 4700.0
RPS16 1209.0 4604.0
RPS17 1222.0 3419.0
RPS18 709.0 1936.0
RPS19 2541.0 4237.0
RPS2 -830.0 -12504.0
RPS20 -1591.0 -5511.0
RPS21 908.0 -5285.0
RPS23 983.0 1243.0
RPS24 -5861.0 5913.0
RPS25 -3493.0 -1399.0
RPS26 -7211.0 6898.0
RPS27 1289.0 6541.0
RPS27A 2633.0 5083.0
RPS27L 859.0 -7524.0
RPS28 -13883.0 -2888.0
RPS29 1292.0 -12538.0
RPS3 -747.0 1694.0
RPS3A -699.0 -804.0
RPS5 -9203.0 -15424.0
RPS6 -9677.0 325.0
RPS7 -4265.0 -4644.0
RPS8 -2232.0 5018.0
RPS9 -7704.0 -9762.0
RPSA 559.0 7037.0
UBA52 -1582.0 2411.0



Selenocysteine synthesis

Selenocysteine synthesis
metric value
setSize 87
pMANOVA 8.57e-14
p.adjustMANOVA 4.39e-12
s.dist 0.517
s.bl 0.448
s.gu 0.258
p.bl 4.6e-13
p.gu 3.23e-05




Top 20 genes
Gene bl gu
RPL35 2168 7809
RPL35A 3383 4815
RPL34 3183 4879
RPS27A 2633 5083
RPL41 2936 3725
RPS19 2541 4237
RPS27 1289 6541
RPL7 1457 5763
RPL23 1855 4346
RPS16 1209 4604
RPL28 2510 1892
RPS17 1222 3419
RPSA 559 7037
RPL27A 930 2052
RPS18 709 1936
RPS23 983 1243
RPL18 293 40

Click HERE to show all gene set members

All member genes
bl gu
EEFSEC -11516.0 -7253.0
FAU 339.0 -8142.0
PSTK -7111.0 785.0
RPL10A -2144.0 5287.0
RPL10L -18378.0 4231.0
RPL11 -8721.0 -2458.0
RPL12 -421.0 1662.0
RPL13 -280.0 -4022.0
RPL13A -4574.5 -7793.5
RPL14 1943.0 -5790.0
RPL15 77.0 -187.0
RPL17 -4268.0 -14466.0
RPL18 293.0 40.0
RPL18A -559.0 -12160.0
RPL19 -9095.0 -3132.0
RPL21 -6004.0 2122.0
RPL22 -3790.0 -11781.0
RPL22L1 -12462.0 -13526.0
RPL23 1855.0 4346.0
RPL23A -998.0 1814.0
RPL24 -3971.0 5895.0
RPL26 -2641.0 4899.0
RPL26L1 -6478.0 -3312.0
RPL27 -330.0 -9130.0
RPL27A 930.0 2052.0
RPL28 2510.0 1892.0
RPL29 -2423.0 -8184.0
RPL3 -3206.0 5585.0
RPL30 9.0 -4032.0
RPL31 -9354.0 2635.0
RPL32 2647.0 -6251.0
RPL34 3183.0 4879.0
RPL35 2168.0 7809.0
RPL35A 3383.0 4815.0
RPL36 -1907.0 7118.0
RPL36AL -4561.0 1249.0
RPL37 -3913.0 -9634.0
RPL37A -2984.0 5752.0
RPL38 -14119.0 4190.0
RPL39L 1290.0 -4045.0
RPL3L -9104.0 -16679.0
RPL4 2609.0 -3763.0
RPL41 2936.0 3725.0
RPL5 -4937.0 -6727.0
RPL6 -16335.0 2149.0
RPL7 1457.0 5763.0
RPL7A -753.0 -3583.0
RPL8 -617.0 -1876.0
RPL9 -3269.0 3686.0
RPLP0 550.0 -4334.0
RPLP1 -12497.0 -6793.0
RPLP2 1382.0 -8896.0
RPS10 -4517.0 2368.0
RPS11 2207.0 -13804.0
RPS12 3518.0 -1497.0
RPS13 -3760.0 -14339.0
RPS14 -8453.0 7156.0
RPS15 -5601.0 3218.0
RPS15A -3699.0 4700.0
RPS16 1209.0 4604.0
RPS17 1222.0 3419.0
RPS18 709.0 1936.0
RPS19 2541.0 4237.0
RPS2 -830.0 -12504.0
RPS20 -1591.0 -5511.0
RPS21 908.0 -5285.0
RPS23 983.0 1243.0
RPS24 -5861.0 5913.0
RPS25 -3493.0 -1399.0
RPS26 -7211.0 6898.0
RPS27 1289.0 6541.0
RPS27A 2633.0 5083.0
RPS27L 859.0 -7524.0
RPS28 -13883.0 -2888.0
RPS29 1292.0 -12538.0
RPS3 -747.0 1694.0
RPS3A -699.0 -804.0
RPS5 -9203.0 -15424.0
RPS6 -9677.0 325.0
RPS7 -4265.0 -4644.0
RPS8 -2232.0 5018.0
RPS9 -7704.0 -9762.0
RPSA 559.0 7037.0
SECISBP2 -12271.0 -1329.0
SEPHS2 -2195.0 -4938.0
SEPSECS -4187.0 1852.0
UBA52 -1582.0 2411.0



Vpu mediated degradation of CD4

Vpu mediated degradation of CD4
metric value
setSize 50
pMANOVA 5.45e-08
p.adjustMANOVA 7.93e-07
s.dist 0.515
s.bl 0.405
s.gu 0.318
p.bl 7.14e-07
p.gu 9.93e-05




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842
SKP1 245 2633

Click HERE to show all gene set members

All member genes
bl gu
BTRC -17678 952
CD4 -11176 2140
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
SKP1 245 2633
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



TICAM1, RIP1-mediated IKK complex recruitment

TICAM1, RIP1-mediated IKK complex recruitment
metric value
setSize 18
pMANOVA 0.00253
p.adjustMANOVA 0.0139
s.dist 0.514
s.bl 0.336
s.gu 0.389
p.bl 0.0135
p.gu 0.00427




Top 20 genes
Gene bl gu
TLR3 3432 5652
UBB 3278 4141
RPS27A 2633 5083

Click HERE to show all gene set members

All member genes
bl gu
BIRC2 -2998 -235
BIRC3 -2648 3567
CHUK -14624 -5696
IKBKB -11002 -9952
RIPK1 -12287 -6219
RIPK3 -7719 6119
RPS27A 2633 5083
TICAM1 -1572 432
TLR3 3432 5652
TRAF6 -9681 -4945
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
UBE2D1 -11102 2093
UBE2D2 -1933 4145
UBE2D3 -4271 -4948
UBE2N -3018 -6061
UBE2V1 -2949 5852



Stabilization of p53

Stabilization of p53
metric value
setSize 55
pMANOVA 1.09e-08
p.adjustMANOVA 2.05e-07
s.dist 0.514
s.bl 0.41
s.gu 0.31
p.bl 1.47e-07
p.gu 6.91e-05




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
ATM 1939 -2867
CDKN2A -95 2969
CHEK2 -4820 5616
MDM2 -2588 5308
MDM4 -10176 2303
PHF20 -14647 -7011
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RFWD2 -10106 -7493
RPS27A 2633 5083
TP53 -2599 -2481
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Formation of the posterior neural plate

Formation of the posterior neural plate
metric value
setSize 10
pMANOVA 0.0165
p.adjustMANOVA 0.0601
s.dist 0.512
s.bl -0.00479
s.gu 0.512
p.bl 0.979
p.gu 0.00505




Top 20 genes
Gene bl gu
GBX2 -17494 7134
FGF8 -14311 7321
SOX1 -9887 4199
OTX2 -4548 5563
SOX2 -7372 2030
TBX6 -2348 4128

Click HERE to show all gene set members

All member genes
bl gu
FGF8 -14311 7321
GBX2 -17494 7134
OTX2 -4548 5563
POU3F1 -3455 -5178
SOX1 -9887 4199
SOX2 -7372 2030
TBX6 -2348 4128
WNT3A -12305 -967
ZEB2 1012 2755
ZNF521 -17023 -9388



AUF1 (hnRNP D0) binds and destabilizes mRNA

AUF1 (hnRNP D0) binds and destabilizes mRNA
metric value
setSize 53
pMANOVA 2.15e-08
p.adjustMANOVA 3.75e-07
s.dist 0.512
s.bl 0.422
s.gu 0.289
p.bl 1.04e-07
p.gu 0.000275




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
HNRNPD 1515 4959
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
EIF4G1 -4091 -1993
HNRNPD 1515 4959
HSPA1A 2323 -4622
HSPA8 -1762 -1774
HSPB1 -9948 -5786
PABPC1 -15538 -7224
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Negative regulation of NOTCH4 signaling

Negative regulation of NOTCH4 signaling
metric value
setSize 52
pMANOVA 3.98e-08
p.adjustMANOVA 6.01e-07
s.dist 0.51
s.bl 0.394
s.gu 0.324
p.bl 8.64e-07
p.gu 5.24e-05




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842
SKP1 245 2633

Click HERE to show all gene set members

All member genes
bl gu
AKT1 -15503 -4591
CUL1 -10922 -3518
FBXW7 -16999 -11774
NOTCH4 -5925 -2761
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSMF1 -7580 -2334
RBX1 -3011 5968
RPS27A 2633 5083
SKP1 245 2633
TACC3 -5651 -166
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
YWHAZ -1840 -7978



SCF-beta-TrCP mediated degradation of Emi1

SCF-beta-TrCP mediated degradation of Emi1
metric value
setSize 53
pMANOVA 3.18e-08
p.adjustMANOVA 5.09e-07
s.dist 0.509
s.bl 0.392
s.gu 0.325
p.bl 7.97e-07
p.gu 4.25e-05




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842
SKP1 245 2633

Click HERE to show all gene set members

All member genes
bl gu
BTRC -17678 952
CDC20 -4067 100
CUL1 -10922 -3518
FBXO5 -566 2391
FZR1 -15242 5573
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
SKP1 245 2633
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Regulation of activated PAK-2p34 by proteasome mediated degradation

Regulation of activated PAK-2p34 by proteasome mediated degradation
metric value
setSize 48
pMANOVA 1.59e-07
p.adjustMANOVA 2.02e-06
s.dist 0.507
s.bl 0.411
s.gu 0.296
p.bl 8.06e-07
p.gu 0.000378




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
PAK2 -17637 -6091
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



FBXL7 down-regulates AURKA during mitotic entry and in early mitosis

FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
metric value
setSize 53
pMANOVA 3.31e-08
p.adjustMANOVA 5.25e-07
s.dist 0.506
s.bl 0.412
s.gu 0.295
p.bl 2.15e-07
p.gu 0.000207




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842
SKP1 245 2633

Click HERE to show all gene set members

All member genes
bl gu
AURKA -88 -639
CUL1 -10922 -3518
FBXL18 -10641 -2830
FBXL7 -10309 -14162
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RBX1 -3011 5968
RPS27A 2633 5083
SKP1 245 2633
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



Condensation of Prometaphase Chromosomes

Condensation of Prometaphase Chromosomes
metric value
setSize 11
pMANOVA 0.0198
p.adjustMANOVA 0.0705
s.dist 0.506
s.bl 0.142
s.gu 0.485
p.bl 0.415
p.gu 0.00533




Top 20 genes
Gene bl gu
SMC2 63 5783

Click HERE to show all gene set members

All member genes
bl gu
CCNB1 -15483 5329
CCNB2 -18433 3729
CDK1 -1204 1566
CSNK2A1 -5463 1253
CSNK2A2 -9549 -1047
CSNK2B -3053 -4459
NCAPD2 -5182 -2935
NCAPG -5877 5515
NCAPH -5610 -2551
SMC2 63 5783
SMC4 -5949 3384



APC/C:Cdc20 mediated degradation of Securin

APC/C:Cdc20 mediated degradation of Securin
metric value
setSize 66
pMANOVA 7.78e-10
p.adjustMANOVA 1.9e-08
s.dist 0.503
s.bl 0.381
s.gu 0.329
p.bl 8.61e-08
p.gu 3.79e-06




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
ANAPC10 1568 7316
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
ANAPC1 -214 5021
ANAPC10 1568 7316
ANAPC11 -853 1262
ANAPC15 -3568 -5708
ANAPC16 -3038 5076
ANAPC2 -6999 3577
ANAPC4 -12035 -5819
ANAPC5 -13436 3996
ANAPC7 -14 2634
CDC16 -5235 -1817
CDC20 -4067 100
CDC23 1982 -12630
CDC26 -4616 5368
CDC27 -17169 -12590
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
PTTG1 -2416 717
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
UBE2C -148 -1659
UBE2D1 -11102 2093
UBE2E1 -12259 826
UBE2S -11896 5126



Mitochondrial iron-sulfur cluster biogenesis

Mitochondrial iron-sulfur cluster biogenesis
metric value
setSize 12
pMANOVA 0.0209
p.adjustMANOVA 0.0739
s.dist 0.503
s.bl 0.281
s.gu 0.417
p.bl 0.0919
p.gu 0.0124




Top 20 genes
Gene bl gu
ISCU 1883 7056
HSCB 1181 5397

Click HERE to show all gene set members

All member genes
bl gu
FDX1 -9798 1832
FDXR -1318 587
FXN -11416 -5075
GLRX5 -135 2738
HSCB 1181 5397
ISCA1 -9350 -1871
ISCA2 1068 -13696
ISCU 1883 7056
LYRM4 -13231 -5673
NFS1 -9701 2853
SLC25A28 -1784 6079
SLC25A37 -8597 6182



Mitophagy

Mitophagy
metric value
setSize 27
pMANOVA 0.000168
p.adjustMANOVA 0.00132
s.dist 0.5
s.bl 0.256
s.gu 0.429
p.bl 0.0212
p.gu 0.000114




Top 20 genes
Gene bl gu
UBB 3278 4141
RPS27A 2633 5083
TOMM6 2444 721

Click HERE to show all gene set members

All member genes
bl gu
ATG12 -7618 -6545
ATG5 -10356 2224
CSNK2A1 -5463 1253
CSNK2A2 -9549 -1047
CSNK2B -3053 -4459
MAP1LC3A -16409 2604
MAP1LC3B -6322 4627
MFN1 -938 4389
MFN2 -8895 2711
MTERF3 418 -4922
PARK2 -5767 -8511
PGAM5 -6348 3837
PINK1 -578 4062
RPS27A 2633 5083
SQSTM1 -4938 -851
SRC -10340 -1794
TOMM20 -6383 -2940
TOMM22 -3837 -1943
TOMM40 -5635 7261
TOMM5 -12296 -2157
TOMM6 2444 721
TOMM7 -4647 4769
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
ULK1 -6159 589
VDAC1 -17004 1350



Aspirin ADME

Aspirin ADME
metric value
setSize 44
pMANOVA 7.56e-07
p.adjustMANOVA 8.62e-06
s.dist 0.498
s.bl -0.255
s.gu -0.428
p.bl 0.00344
p.gu 8.73e-07




Top 20 genes
Gene bl gu
UGT2B11 -21337 -17278
UGT2B4 -21311 -16951
ACSM2A -20361 -16931
GLYATL3 -20243 -16326
UGT2B7 -19466 -16802
CYP2D6 -19988 -16358
UGT2B10 -21288 -15316
ALB -20900 -15234
UGT2B28 -21526 -14687
CYP2C19 -19552 -16117
BCHE -19886 -15627
CYP2C8 -20447 -12768
UGT2A2 -18383 -12817
UGT2A1 -20687 -11233
UGT2A3 -20744 -9744
UGT1A1 -11541 -16565
GLYATL2 -17487 -9653
UGT1A8 -12587 -13229
SLC22A7 -9693 -15565
UGT1A7 -11787 -12600

Click HERE to show all gene set members

All member genes
bl gu
ABCC2 -8826 -9881
ABCC3 -5425 -9679
ACSM2A -20361 -16931
ACSM2B 3514 2656
ACSM4 720 -5188
ACSM5 3774 -16228
ALB -20900 -15234
BCHE -19886 -15627
BSG -6243 -10202
CES1 -711 -94
CES2 1469 -2861
CYP2C19 -19552 -16117
CYP2C8 -20447 -12768
CYP2C9 1974 -2058
CYP2D6 -19988 -16358
CYP2E1 -18631 -3171
CYP3A4 -15821 -8770
GLYAT -9060 -13895
GLYATL1 -1686 -15826
GLYATL2 -17487 -9653
GLYATL3 -20243 -16326
SLC16A1 -8056 6007
SLC22A7 -9693 -15565
SLCO2B1 596 -3822
UGT1A1 -11541 -16565
UGT1A3 -9171 -12535
UGT1A4 -8869 -10588
UGT1A5 -9602 -11810
UGT1A6 -9529 -13378
UGT1A7 -11787 -12600
UGT1A8 -12587 -13229
UGT1A9 -10674 -13288
UGT2A1 -20687 -11233
UGT2A2 -18383 -12817
UGT2A3 -20744 -9744
UGT2B10 -21288 -15316
UGT2B11 -21337 -17278
UGT2B15 -13049 -10893
UGT2B17 -20950 1510
UGT2B28 -21526 -14687
UGT2B4 -21311 -16951
UGT2B7 -19466 -16802
UGT3A1 -1170 -4112
UGT3A2 -12605 5872



Response of EIF2AK4 (GCN2) to amino acid deficiency

Response of EIF2AK4 (GCN2) to amino acid deficiency
metric value
setSize 95
pMANOVA 6.8e-14
p.adjustMANOVA 3.72e-12
s.dist 0.498
s.bl 0.427
s.gu 0.256
p.bl 5.9e-13
p.gu 1.62e-05




Top 20 genes
Gene bl gu
EIF2S2 3185 7441
RPL35 2168 7809
RPL35A 3383 4815
RPL34 3183 4879
RPS27A 2633 5083
RPL41 2936 3725
RPS19 2541 4237
RPS27 1289 6541
RPL7 1457 5763
RPL23 1855 4346
RPS16 1209 4604
RPL28 2510 1892
RPS17 1222 3419
RPSA 559 7037
ATF4 679 5685
RPL27A 930 2052
RPS18 709 1936
RPS23 983 1243
RPL18 293 40

Click HERE to show all gene set members

All member genes
bl gu
ASNS -1523.0 -8674.0
ATF2 749.0 -815.0
ATF3 -3893.0 -4204.0
ATF4 679.0 5685.0
CEBPB -7941.0 6378.0
CEBPG -16760.0 639.0
DDIT3 2210.0 -10839.0
EIF2AK4 -18322.0 -7163.0
EIF2S1 -5280.0 -4814.0
EIF2S2 3185.0 7441.0
FAU 339.0 -8142.0
GCN1 -16505.0 -3688.0
IMPACT -16476.0 -10581.0
RPL10A -2144.0 5287.0
RPL10L -18378.0 4231.0
RPL11 -8721.0 -2458.0
RPL12 -421.0 1662.0
RPL13 -280.0 -4022.0
RPL13A -4574.5 -7793.5
RPL14 1943.0 -5790.0
RPL15 77.0 -187.0
RPL17 -4268.0 -14466.0
RPL18 293.0 40.0
RPL18A -559.0 -12160.0
RPL19 -9095.0 -3132.0
RPL21 -6004.0 2122.0
RPL22 -3790.0 -11781.0
RPL22L1 -12462.0 -13526.0
RPL23 1855.0 4346.0
RPL23A -998.0 1814.0
RPL24 -3971.0 5895.0
RPL26 -2641.0 4899.0
RPL26L1 -6478.0 -3312.0
RPL27 -330.0 -9130.0
RPL27A 930.0 2052.0
RPL28 2510.0 1892.0
RPL29 -2423.0 -8184.0
RPL3 -3206.0 5585.0
RPL30 9.0 -4032.0
RPL31 -9354.0 2635.0
RPL32 2647.0 -6251.0
RPL34 3183.0 4879.0
RPL35 2168.0 7809.0
RPL35A 3383.0 4815.0
RPL36 -1907.0 7118.0
RPL36AL -4561.0 1249.0
RPL37 -3913.0 -9634.0
RPL37A -2984.0 5752.0
RPL38 -14119.0 4190.0
RPL39L 1290.0 -4045.0
RPL3L -9104.0 -16679.0
RPL4 2609.0 -3763.0
RPL41 2936.0 3725.0
RPL5 -4937.0 -6727.0
RPL6 -16335.0 2149.0
RPL7 1457.0 5763.0
RPL7A -753.0 -3583.0
RPL8 -617.0 -1876.0
RPL9 -3269.0 3686.0
RPLP0 550.0 -4334.0
RPLP1 -12497.0 -6793.0
RPLP2 1382.0 -8896.0
RPS10 -4517.0 2368.0
RPS11 2207.0 -13804.0
RPS12 3518.0 -1497.0
RPS13 -3760.0 -14339.0
RPS14 -8453.0 7156.0
RPS15 -5601.0 3218.0
RPS15A -3699.0 4700.0
RPS16 1209.0 4604.0
RPS17 1222.0 3419.0
RPS18 709.0 1936.0
RPS19 2541.0 4237.0
RPS2 -830.0 -12504.0
RPS20 -1591.0 -5511.0
RPS21 908.0 -5285.0
RPS23 983.0 1243.0
RPS24 -5861.0 5913.0
RPS25 -3493.0 -1399.0
RPS26 -7211.0 6898.0
RPS27 1289.0 6541.0
RPS27A 2633.0 5083.0
RPS27L 859.0 -7524.0
RPS28 -13883.0 -2888.0
RPS29 1292.0 -12538.0
RPS3 -747.0 1694.0
RPS3A -699.0 -804.0
RPS5 -9203.0 -15424.0
RPS6 -9677.0 325.0
RPS7 -4265.0 -4644.0
RPS8 -2232.0 5018.0
RPS9 -7704.0 -9762.0
RPSA 559.0 7037.0
TRIB3 -7142.0 5293.0
UBA52 -1582.0 2411.0



Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)

Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
metric value
setSize 89
pMANOVA 5.01e-13
p.adjustMANOVA 2.15e-11
s.dist 0.497
s.bl 0.427
s.gu 0.254
p.bl 3.05e-12
p.gu 3.51e-05




Top 20 genes
Gene bl gu
RPL35 2168 7809
RPL35A 3383 4815
RPL34 3183 4879
RPS27A 2633 5083
RPL41 2936 3725
RPS19 2541 4237
RPS27 1289 6541
RPL7 1457 5763
RPL23 1855 4346
RPS16 1209 4604
RPL28 2510 1892
RPS17 1222 3419
RPSA 559 7037
RPL27A 930 2052
RPS18 709 1936
RPS23 983 1243
RPL18 293 40

Click HERE to show all gene set members

All member genes
bl gu
EIF4G1 -4091.0 -1993.0
ETF1 -3072.0 -10743.0
FAU 339.0 -8142.0
GSPT1 -8626.0 1941.0
NCBP1 -11452.0 -1118.0
NCBP2 -12763.0 -1208.0
PABPC1 -15538.0 -7224.0
RPL10A -2144.0 5287.0
RPL10L -18378.0 4231.0
RPL11 -8721.0 -2458.0
RPL12 -421.0 1662.0
RPL13 -280.0 -4022.0
RPL13A -4574.5 -7793.5
RPL14 1943.0 -5790.0
RPL15 77.0 -187.0
RPL17 -4268.0 -14466.0
RPL18 293.0 40.0
RPL18A -559.0 -12160.0
RPL19 -9095.0 -3132.0
RPL21 -6004.0 2122.0
RPL22 -3790.0 -11781.0
RPL22L1 -12462.0 -13526.0
RPL23 1855.0 4346.0
RPL23A -998.0 1814.0
RPL24 -3971.0 5895.0
RPL26 -2641.0 4899.0
RPL26L1 -6478.0 -3312.0
RPL27 -330.0 -9130.0
RPL27A 930.0 2052.0
RPL28 2510.0 1892.0
RPL29 -2423.0 -8184.0
RPL3 -3206.0 5585.0
RPL30 9.0 -4032.0
RPL31 -9354.0 2635.0
RPL32 2647.0 -6251.0
RPL34 3183.0 4879.0
RPL35 2168.0 7809.0
RPL35A 3383.0 4815.0
RPL36 -1907.0 7118.0
RPL36AL -4561.0 1249.0
RPL37 -3913.0 -9634.0
RPL37A -2984.0 5752.0
RPL38 -14119.0 4190.0
RPL39L 1290.0 -4045.0
RPL3L -9104.0 -16679.0
RPL4 2609.0 -3763.0
RPL41 2936.0 3725.0
RPL5 -4937.0 -6727.0
RPL6 -16335.0 2149.0
RPL7 1457.0 5763.0
RPL7A -753.0 -3583.0
RPL8 -617.0 -1876.0
RPL9 -3269.0 3686.0
RPLP0 550.0 -4334.0
RPLP1 -12497.0 -6793.0
RPLP2 1382.0 -8896.0
RPS10 -4517.0 2368.0
RPS11 2207.0 -13804.0
RPS12 3518.0 -1497.0
RPS13 -3760.0 -14339.0
RPS14 -8453.0 7156.0
RPS15 -5601.0 3218.0
RPS15A -3699.0 4700.0
RPS16 1209.0 4604.0
RPS17 1222.0 3419.0
RPS18 709.0 1936.0
RPS19 2541.0 4237.0
RPS2 -830.0 -12504.0
RPS20 -1591.0 -5511.0
RPS21 908.0 -5285.0
RPS23 983.0 1243.0
RPS24 -5861.0 5913.0
RPS25 -3493.0 -1399.0
RPS26 -7211.0 6898.0
RPS27 1289.0 6541.0
RPS27A 2633.0 5083.0
RPS27L 859.0 -7524.0
RPS28 -13883.0 -2888.0
RPS29 1292.0 -12538.0
RPS3 -747.0 1694.0
RPS3A -699.0 -804.0
RPS5 -9203.0 -15424.0
RPS6 -9677.0 325.0
RPS7 -4265.0 -4644.0
RPS8 -2232.0 5018.0
RPS9 -7704.0 -9762.0
RPSA 559.0 7037.0
UBA52 -1582.0 2411.0
UPF1 -11718.0 1763.0



Digestion

Digestion
metric value
setSize 18
pMANOVA 0.00342
p.adjustMANOVA 0.0177
s.dist 0.497
s.bl -0.273
s.gu -0.415
p.bl 0.0453
p.gu 0.00228




Top 20 genes
Gene bl gu
LIPF -20262 -17214
PNLIPRP3 -20689 -16570
PNLIP -20281 -13530
AMY2A -16371 -15095
CHIA -20583 -11981
ALPI -14618 -15947
CEL -15999 -13747
AMY2B -19612 -10144
LCT -9863 -9414
GUCA2B -6553 -13387
CLPS -7290 -9627
PNLIPRP1 -4238 -13317
PNLIPRP2 -10499 -4654
MGAM -12568 -3309
TREH -2796 -14407
GUCY2C -2313 -8964

Click HERE to show all gene set members

All member genes
bl gu
ALPI -14618 -15947
AMY2A -16371 -15095
AMY2B -19612 -10144
CEL -15999 -13747
CHIA -20583 -11981
CHIT1 -2167 5673
CLPS -7290 -9627
GUCA2A -13132 2823
GUCA2B -6553 -13387
GUCY2C -2313 -8964
LCT -9863 -9414
LIPF -20262 -17214
MGAM -12568 -3309
PNLIP -20281 -13530
PNLIPRP1 -4238 -13317
PNLIPRP2 -10499 -4654
PNLIPRP3 -20689 -16570
TREH -2796 -14407



CASP8 activity is inhibited

CASP8 activity is inhibited
metric value
setSize 11
pMANOVA 0.0259
p.adjustMANOVA 0.0871
s.dist 0.496
s.bl 0.461
s.gu 0.184
p.bl 0.0081
p.gu 0.291




Top 20 genes
Gene bl gu
CASP8 2222 5385

Click HERE to show all gene set members

All member genes
bl gu
CASP8 2222 5385
CFLAR -129 -1701
FADD -6056 1668
FAS -385 5000
FASLG 3492 -17314
RIPK1 -12287 -6219
TNFRSF10A -7625 -11302
TNFRSF10B -557 7040
TNFSF10 -1643 -16223
TRADD -4346 1334
TRAF2 -3336 5275



Dimerization of procaspase-8

Dimerization of procaspase-8
metric value
setSize 11
pMANOVA 0.0259
p.adjustMANOVA 0.0871
s.dist 0.496
s.bl 0.461
s.gu 0.184
p.bl 0.0081
p.gu 0.291




Top 20 genes
Gene bl gu
CASP8 2222 5385

Click HERE to show all gene set members

All member genes
bl gu
CASP8 2222 5385
CFLAR -129 -1701
FADD -6056 1668
FAS -385 5000
FASLG 3492 -17314
RIPK1 -12287 -6219
TNFRSF10A -7625 -11302
TNFRSF10B -557 7040
TNFSF10 -1643 -16223
TRADD -4346 1334
TRAF2 -3336 5275



Regulation by c-FLIP

Regulation by c-FLIP
metric value
setSize 11
pMANOVA 0.0259
p.adjustMANOVA 0.0871
s.dist 0.496
s.bl 0.461
s.gu 0.184
p.bl 0.0081
p.gu 0.291




Top 20 genes
Gene bl gu
CASP8 2222 5385

Click HERE to show all gene set members

All member genes
bl gu
CASP8 2222 5385
CFLAR -129 -1701
FADD -6056 1668
FAS -385 5000
FASLG 3492 -17314
RIPK1 -12287 -6219
TNFRSF10A -7625 -11302
TNFRSF10B -557 7040
TNFSF10 -1643 -16223
TRADD -4346 1334
TRAF2 -3336 5275



Vif-mediated degradation of APOBEC3G

Vif-mediated degradation of APOBEC3G
metric value
setSize 50
pMANOVA 1.72e-07
p.adjustMANOVA 2.16e-06
s.dist 0.495
s.bl 0.404
s.gu 0.286
p.bl 7.52e-07
p.gu 0.00046




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
APOBEC3G -15296 -17185
CUL5 -10822 -3464
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
RBX1 -3011 5968
RPS27A 2633 5083
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764



APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1

APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
metric value
setSize 72
pMANOVA 2.43e-10
p.adjustMANOVA 7.08e-09
s.dist 0.495
s.bl 0.368
s.gu 0.331
p.bl 6.42e-08
p.gu 1.16e-06




Top 20 genes
Gene bl gu
PSMC2 2516 6995
PSMA5 2533 6234
UBB 3278 4141
RPS27A 2633 5083
ANAPC10 1568 7316
PSMD7 1895 4703
PSMD3 966 5596
PSME1 492 7331
PSMA3 835 3842

Click HERE to show all gene set members

All member genes
bl gu
ANAPC1 -214 5021
ANAPC10 1568 7316
ANAPC11 -853 1262
ANAPC15 -3568 -5708
ANAPC16 -3038 5076
ANAPC2 -6999 3577
ANAPC4 -12035 -5819
ANAPC5 -13436 3996
ANAPC7 -14 2634
AURKA -88 -639
AURKB -2451 -5471
CDC16 -5235 -1817
CDC20 -4067 100
CDC23 1982 -12630
CDC26 -4616 5368
CDC27 -17169 -12590
FZR1 -15242 5573
PLK1 -3953 681
PSMA1 -5876 3462
PSMA2 1248 -11310
PSMA3 835 3842
PSMA4 -277 3194
PSMA5 2533 6234
PSMA6 -1416 5811
PSMA7 -2787 6338
PSMA8 -4183 -4629
PSMB1 240 -2634
PSMB10 -7218 3436
PSMB11 802 -15989
PSMB2 -2726 1785
PSMB3 -1103 -5374
PSMB4 -7988 -12102
PSMB5 -3757 -2106
PSMB6 -5082 -8902
PSMB7 -4730 6188
PSMB8 -826 -4144
PSMB9 586 -6287
PSMC1 166 -8003
PSMC2 2516 6995
PSMC3 -2335 -5531
PSMC4 2790 -933
PSMC5 -7018 -1882
PSMC6 -9714 5528
PSMD1 -18772 -9583
PSMD11 -1036 2222
PSMD12 2017 -8571
PSMD13 -4023 4757
PSMD14 -18653 -2522
PSMD2 -4043 -965
PSMD3 966 5596
PSMD4 -2101 -612
PSMD5 -253 -577
PSMD6 -16102 -9371
PSMD7 1895 4703
PSMD8 -13096 1578
PSMD9 -3309 -320
PSME1 492 7331
PSME2 -7 1209
PSME3 1918 -1755
PSME4 -13353 -9824
PSMF1 -7580 -2334
PTTG1 -2416 717
RB1 -11703 -2971
RPS27A 2633 5083
SKP2 -1221 1281
UBA52 -1582 2411
UBB 3278 4141
UBC -1010 1764
UBE2C -148 -1659
UBE2D1 -11102 2093
UBE2E1 -12259 826
UBE2S -11896 5126



Here is the session info with all the versions of packages used.

sessionInfo()
## R version 4.3.2 (2023-10-31)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0 
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
## 
## attached base packages:
## [1] stats4    parallel  stats     graphics  grDevices utils     datasets 
## [8] methods   base     
## 
## other attached packages:
##  [1] pkgload_1.3.3                                      
##  [2] GGally_2.1.2                                       
##  [3] ggplot2_3.4.4                                      
##  [4] reshape2_1.4.4                                     
##  [5] beeswarm_0.4.0                                     
##  [6] gplots_3.1.3                                       
##  [7] gtools_3.9.4                                       
##  [8] tibble_3.2.1                                       
##  [9] dplyr_1.1.3                                        
## [10] echarts4r_0.4.5                                    
## [11] eulerr_7.0.0                                       
## [12] kableExtra_1.3.4                                   
## [13] data.table_1.14.8                                  
## [14] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [15] minfi_1.48.0                                       
## [16] bumphunter_1.44.0                                  
## [17] locfit_1.5-9.8                                     
## [18] iterators_1.0.14                                   
## [19] foreach_1.5.2                                      
## [20] Biostrings_2.70.1                                  
## [21] XVector_0.42.0                                     
## [22] SummarizedExperiment_1.32.0                        
## [23] Biobase_2.62.0                                     
## [24] MatrixGenerics_1.14.0                              
## [25] matrixStats_1.1.0                                  
## [26] GenomicRanges_1.54.1                               
## [27] GenomeInfoDb_1.38.1                                
## [28] IRanges_2.36.0                                     
## [29] S4Vectors_0.40.1                                   
## [30] BiocGenerics_0.48.1                                
## [31] mitch_1.14.0                                       
## [32] limma_3.58.1                                       
## 
## loaded via a namespace (and not attached):
##   [1] splines_4.3.2             later_1.3.1              
##   [3] BiocIO_1.12.0             bitops_1.0-7             
##   [5] filelock_1.0.2            preprocessCore_1.64.0    
##   [7] XML_3.99-0.15             lifecycle_1.0.4          
##   [9] lattice_0.22-5            MASS_7.3-60              
##  [11] base64_2.0.1              scrime_1.3.5             
##  [13] magrittr_2.0.3            sass_0.4.7               
##  [15] rmarkdown_2.25            jquerylib_0.1.4          
##  [17] yaml_2.3.7                httpuv_1.6.12            
##  [19] doRNG_1.8.6               askpass_1.2.0            
##  [21] DBI_1.1.3                 RColorBrewer_1.1-3       
##  [23] abind_1.4-5               zlibbioc_1.48.0          
##  [25] rvest_1.0.3               quadprog_1.5-8           
##  [27] purrr_1.0.2               RCurl_1.98-1.13          
##  [29] rappdirs_0.3.3            GenomeInfoDbData_1.2.11  
##  [31] genefilter_1.84.0         annotate_1.80.0          
##  [33] svglite_2.1.2             DelayedMatrixStats_1.24.0
##  [35] codetools_0.2-19          DelayedArray_0.28.0      
##  [37] xml2_1.3.5                tidyselect_1.2.0         
##  [39] farver_2.1.1              beanplot_1.3.1           
##  [41] BiocFileCache_2.10.1      illuminaio_0.44.0        
##  [43] webshot_0.5.5             GenomicAlignments_1.38.0 
##  [45] jsonlite_1.8.7            multtest_2.58.0          
##  [47] ellipsis_0.3.2            survival_3.5-7           
##  [49] systemfonts_1.0.5         tools_4.3.2              
##  [51] progress_1.2.2            Rcpp_1.0.11              
##  [53] glue_1.6.2                gridExtra_2.3            
##  [55] SparseArray_1.2.2         xfun_0.41                
##  [57] HDF5Array_1.30.0          withr_2.5.2              
##  [59] fastmap_1.1.1             rhdf5filters_1.14.1      
##  [61] fansi_1.0.5               openssl_2.1.1            
##  [63] caTools_1.18.2            digest_0.6.33            
##  [65] R6_2.5.1                  mime_0.12                
##  [67] colorspace_2.1-0          biomaRt_2.58.0           
##  [69] RSQLite_2.3.3             tidyr_1.3.0              
##  [71] utf8_1.2.4                generics_0.1.3           
##  [73] rtracklayer_1.62.0        prettyunits_1.2.0        
##  [75] httr_1.4.7                htmlwidgets_1.6.2        
##  [77] S4Arrays_1.2.0            pkgconfig_2.0.3          
##  [79] gtable_0.3.4              blob_1.2.4               
##  [81] siggenes_1.76.0           htmltools_0.5.7          
##  [83] scales_1.2.1              png_0.1-8                
##  [85] knitr_1.45                rstudioapi_0.15.0        
##  [87] tzdb_0.4.0                rjson_0.2.21             
##  [89] nlme_3.1-163              curl_5.1.0               
##  [91] cachem_1.0.8              rhdf5_2.46.0             
##  [93] stringr_1.5.0             KernSmooth_2.23-22       
##  [95] AnnotationDbi_1.64.1      restfulr_0.0.15          
##  [97] GEOquery_2.70.0           pillar_1.9.0             
##  [99] grid_4.3.2                reshape_0.8.9            
## [101] vctrs_0.6.4               promises_1.2.1           
## [103] dbplyr_2.4.0              xtable_1.8-4             
## [105] evaluate_0.23             readr_2.1.4              
## [107] GenomicFeatures_1.54.1    cli_3.6.1                
## [109] compiler_4.3.2            Rsamtools_2.18.0         
## [111] rlang_1.1.2               crayon_1.5.2             
## [113] rngtools_1.5.2            labeling_0.4.3           
## [115] nor1mix_1.3-0             mclust_6.0.0             
## [117] plyr_1.8.9                stringi_1.7.12           
## [119] viridisLite_0.4.2         BiocParallel_1.36.0      
## [121] munsell_0.5.0             Matrix_1.6-2             
## [123] hms_1.1.3                 sparseMatrixStats_1.14.0 
## [125] bit64_4.0.5               Rhdf5lib_1.24.0          
## [127] KEGGREST_1.42.0           statmod_1.5.0            
## [129] shiny_1.7.5.1             highr_0.10               
## [131] memoise_2.0.1             bslib_0.5.1              
## [133] bit_4.0.5

END of report